
<html lang="en"     class="pb-page"  data-request-id="49470499-77b6-4233-b7d5-84f1e3052d61"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-15;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c00988;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors" /></meta><meta name="dc.Creator" content="Omar  Robles" /></meta><meta name="dc.Creator" content="Jeffrey J.  Jackson" /></meta><meta name="dc.Creator" content="Lisa  Marshall" /></meta><meta name="dc.Creator" content="Oezcan  Talay" /></meta><meta name="dc.Creator" content="David  Chian" /></meta><meta name="dc.Creator" content="Gene  Cutler" /></meta><meta name="dc.Creator" content="Raymond  Diokno" /></meta><meta name="dc.Creator" content="Dennis X.  Hu" /></meta><meta name="dc.Creator" content="Scott  Jacobson" /></meta><meta name="dc.Creator" content="Emily  Karbarz" /></meta><meta name="dc.Creator" content="Paul D.  Kassner" /></meta><meta name="dc.Creator" content="John M.  Ketcham" /></meta><meta name="dc.Creator" content="Jenny  McKinnell" /></meta><meta name="dc.Creator" content="Cesar  Meleza" /></meta><meta name="dc.Creator" content="Maureen K.  Reilly" /></meta><meta name="dc.Creator" content="Erin  Riegler" /></meta><meta name="dc.Creator" content="Hunter P.  Shunatona" /></meta><meta name="dc.Creator" content="Angela  Wadsworth" /></meta><meta name="dc.Creator" content="Ashkaan  Younai" /></meta><meta name="dc.Creator" content="Dirk G.  Brockstedt" /></meta><meta name="dc.Creator" content="David J.  Wustrow" /></meta><meta name="dc.Creator" content="Mikhail  Zibinsky" /></meta><meta name="dc.Description" content="The C–C chemokine receptor 4 (CCR4) is broadly expressed on regulatory T cells (Treg) as well as other circulating and tissue-resident T cells. Treg can be recruited to the tumor microenvironment (..." /></meta><meta name="Description" content="The C–C chemokine receptor 4 (CCR4) is broadly expressed on regulatory T cells (Treg) as well as other circulating and tissue-resident T cells. Treg can be recruited to the tumor microenvironment (..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 15, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00988" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00988" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00988" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00988" /></link>
        
    
    

<title>Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00988" /></meta><meta property="og:title" content="Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0017.jpeg" /></meta><meta property="og:description" content="The C–C chemokine receptor 4 (CCR4) is broadly expressed on regulatory T cells (Treg) as well as other circulating and tissue-resident T cells. Treg can be recruited to the tumor microenvironment (TME) through the C–C chemokines CCL17 and CCL22. Treg accumulation in the TME has been shown to dampen the antitumor immune response and is thought to be an important driver in tumor immune evasion. Preclinical and clinical data suggest that reducing the Treg population in the TME can potentiate the antitumor immune response of checkpoint inhibitors. We have developed small-molecule antagonists of CCR4, featuring a novel piperidinyl-azetidine motif, that inhibit the recruitment of Treg into the TME and elicit antitumor responses as a single agent or in combination with an immune checkpoint blockade. The discovery of these potent, selective, and orally bioavailable CCR4 antagonists, and their activity in in vitro and in vivo models, is described herein." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00988"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00988">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00988&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00988&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00988&amp;href=/doi/10.1021/acs.jmedchem.0c00988" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 8584-8607</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00967" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00955" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Omar Robles</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Omar Robles</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Omar++Robles">Omar Robles</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey J. Jackson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey J. Jackson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+J.++Jackson">Jeffrey J. Jackson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7219-5279" title="Orcid link">http://orcid.org/0000-0002-7219-5279</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisa Marshall</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa Marshall</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Marshall">Lisa Marshall</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Oezcan Talay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Oezcan Talay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Oezcan++Talay">Oezcan Talay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Chian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Chian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Chian">David Chian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gene Cutler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gene Cutler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gene++Cutler">Gene Cutler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Raymond Diokno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raymond Diokno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raymond++Diokno">Raymond Diokno</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dennis X. Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dennis X. Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dennis+X.++Hu">Dennis X. Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott Jacobson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott Jacobson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Jacobson">Scott Jacobson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emily Karbarz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emily Karbarz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emily++Karbarz">Emily Karbarz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul D. Kassner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul D. Kassner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+D.++Kassner">Paul D. Kassner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John M. Ketcham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John M. Ketcham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+M.++Ketcham">John M. Ketcham</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jenny McKinnell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jenny McKinnell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jenny++McKinnell">Jenny McKinnell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cesar Meleza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cesar Meleza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cesar++Meleza">Cesar Meleza</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maureen K. Reilly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maureen K. Reilly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maureen+K.++Reilly">Maureen K. Reilly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erin Riegler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erin Riegler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erin++Riegler">Erin Riegler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hunter P. Shunatona</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hunter P. Shunatona</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hunter+P.++Shunatona">Hunter P. Shunatona</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Angela Wadsworth</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Angela Wadsworth</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Angela++Wadsworth">Angela Wadsworth</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ashkaan Younai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ashkaan Younai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ashkaan++Younai">Ashkaan Younai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dirk G. Brockstedt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dirk G. Brockstedt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dirk+G.++Brockstedt">Dirk G. Brockstedt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David J. Wustrow</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David J. Wustrow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#711506040205031e0631031001055f121e1c"><span class="__cf_email__" data-cfemail="0e6a797b7d7a7c61794e7c6f7e7a206d6163">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+J.++Wustrow">David J. Wustrow</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Mikhail Zibinsky</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mikhail Zibinsky</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3f5245565d56514c54467f4d5e4f4b115c5052"><span class="__cf_email__" data-cfemail="e98493808b80879a8290a99b88999dc78a8684">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mikhail++Zibinsky">Mikhail Zibinsky</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00988&amp;href=/doi/10.1021%2Facs.jmedchem.0c00988" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 8584–8607</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 15, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 June 2020</li><li><span class="item_label"><b>Published</b> online</span>15 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00988" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00988</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8584%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DOmar%2BRobles%252C%2BJeffrey%2BJ.%2BJackson%252C%2BLisa%2BMarshall%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D15%26contentID%3Dacs.jmedchem.0c00988%26title%3DNovel%2BPiperidinyl-Azetidines%2Bas%2BPotent%2Band%2BSelective%2BCCR4%2BAntagonists%2BElicit%2BAntitumor%2BResponse%2Bas%2Ba%2BSingle%2BAgent%2Band%2Bin%2BCombination%2Bwith%2BCheckpoint%2BInhibitors%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8607%26publicationDate%3DAugust%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00988"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1243</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00988" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Omar&quot;,&quot;last_name&quot;:&quot;Robles&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;J. Jackson&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Marshall&quot;},{&quot;first_name&quot;:&quot;Oezcan&quot;,&quot;last_name&quot;:&quot;Talay&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Chian&quot;},{&quot;first_name&quot;:&quot;Gene&quot;,&quot;last_name&quot;:&quot;Cutler&quot;},{&quot;first_name&quot;:&quot;Raymond&quot;,&quot;last_name&quot;:&quot;Diokno&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;X. Hu&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Jacobson&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;Karbarz&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;D. Kassner&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;M. Ketcham&quot;},{&quot;first_name&quot;:&quot;Jenny&quot;,&quot;last_name&quot;:&quot;McKinnell&quot;},{&quot;first_name&quot;:&quot;Cesar&quot;,&quot;last_name&quot;:&quot;Meleza&quot;},{&quot;first_name&quot;:&quot;Maureen&quot;,&quot;last_name&quot;:&quot;K. Reilly&quot;},{&quot;first_name&quot;:&quot;Erin&quot;,&quot;last_name&quot;:&quot;Riegler&quot;},{&quot;first_name&quot;:&quot;Hunter&quot;,&quot;last_name&quot;:&quot;P. Shunatona&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;Wadsworth&quot;},{&quot;first_name&quot;:&quot;Ashkaan&quot;,&quot;last_name&quot;:&quot;Younai&quot;},{&quot;first_name&quot;:&quot;Dirk&quot;,&quot;last_name&quot;:&quot;G. Brockstedt&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;J. Wustrow&quot;},{&quot;first_name&quot;:&quot;Mikhail&quot;,&quot;last_name&quot;:&quot;Zibinsky&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8584-8607&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00988&quot;},&quot;abstract&quot;:&quot;The C–C chemokine receptor 4 (CCR4) is broadly expressed on regulatory T cells (Treg) as well as other circulating and tissue-resident T cells. Treg can be recruited to the tumor microenvironment (TME) through the C–C chemokines CCL17 and CCL22. Treg accumulation in the TME has been shown to dampen the antitumor immune response and is thought to be an important driver in tumor immune evasion. Preclinical and clinical data suggest that reducing the Treg population in the TME can potentiate the antitumor immune response of checkpoint inhibitors. We have developed small-molecule antagonists of CCR4, featuring a novel piperidinyl-azetidine motif, that inhibit the recruitment of Treg into the TME and elicit antitumor responses as a single agent or in combination with an immune checkpoint blockade. The discovery of these potent, selective, and orally bioavailable CCR4 antagonists, and their activity in in vitro and in vivo models, is described herein.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00988&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00988" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00988&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00988" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00988&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00988" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00988&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00988&amp;href=/doi/10.1021/acs.jmedchem.0c00988" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00988" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00988" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00988%26sid%3Dliteratum%253Aachs%26pmid%3D32667798%26genre%3Darticle%26aulast%3DRobles%26date%3D2020%26atitle%3DNovel%2BPiperidinyl-Azetidines%2Bas%2BPotent%2Band%2BSelective%2BCCR4%2BAntagonists%2BElicit%2BAntitumor%2BResponse%2Bas%2Ba%2BSingle%2BAgent%2Band%2Bin%2BCombination%2Bwith%2BCheckpoint%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D15%26spage%3D8584%26epage%3D8607%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292582" title="Calcium">Calcium</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=290669" title="Fluxes">Fluxes</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/jmcmar.2020.63.issue-15/20200813/jmcmar.2020.63.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The C–C chemokine receptor 4 (CCR4) is broadly expressed on regulatory T cells (T<sub>reg</sub>) as well as other circulating and tissue-resident T cells. T<sub>reg</sub> can be recruited to the tumor microenvironment (TME) through the C–C chemokines CCL17 and CCL22. T<sub>reg</sub> accumulation in the TME has been shown to dampen the antitumor immune response and is thought to be an important driver in tumor immune evasion. Preclinical and clinical data suggest that reducing the T<sub>reg</sub> population in the TME can potentiate the antitumor immune response of checkpoint inhibitors. We have developed small-molecule antagonists of CCR4, featuring a novel piperidinyl-azetidine motif, that inhibit the recruitment of T<sub>reg</sub> into the TME and elicit antitumor responses as a single agent or in combination with an immune checkpoint blockade. The discovery of these potent, selective, and orally bioavailable CCR4 antagonists, and their activity in <i>in vitro</i> and <i>in vivo</i> models, is described herein.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In many cancers, recruitment of CD4<sup>+</sup> FOXP3<sup>+</sup> regulatory T cells (T<sub>reg</sub>) into the tumor microenvironment (TME) reduces the antitumor immune response and is thought to be a key driver in tumor immune evasion.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> The accumulation of T<sub>reg</sub> in the TME has been associated with poor patient prognosis in various cancers.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10">(5−10)</a> Preclinical and clinical data suggest that reduction of T<sub>reg</sub> populations in the TME can enhance antitumor immune responses of checkpoint therapy.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a></div><div class="NLM_p">The C–C chemokine receptor 4 (CCR4) is a G protein-coupled receptor (GPCR) highly expressed on T<sub>reg</sub>, in addition to other circulating and tissue-resident T cells, including T helper type 2 (Th2) cells and skin-homing T cells.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> CCR4 is the receptor of the C–C chemokines CCL17 (also known as thymus- and activation-regulated chemokine or TARC) and CCL22 (also called macrophage-derived chemokine or MDC). Gradients of these chemokines direct cell trafficking and homing through chemotaxis.<a onclick="showRef(event, 'ref6 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref6 ref15 ref16 ref17">(6,15−17)</a> More recently, chemokine-like factor 1 (CKLF1) has also been shown to induce chemotaxis via CCR4.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> It is recognized that CCR4 plays a key role in stimulating T<sub>reg</sub> trafficking into the TME of many tumors due to high expression levels of CCL17 and CCL22.<a onclick="showRef(event, 'ref6 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref6 ref20 ref21">(6,20,21)</a></div><div class="NLM_p">Recognizing the important role of CCR4 in cell migration and homing on specific T cell subpopulations has made this receptor an attractive target for therapeutic intervention. Over the past decade, several small-molecule CCR4 antagonists have been reported. These antagonists can be grouped into two classes based on their proposed binding sites.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> Class I antagonists (<b>1</b>–<b>4a</b>,<b>b</b>,<a onclick="showRef(event, 'ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28">(25−28)</a><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which feature a heterocyclic core decorated with a lipophilic substituent and an amine-containing side chain, bind extracellularly at the allosteric antagonist binding site I. Class II antagonists (<b>5</b>–<b>6a</b>,<b>b</b>,<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), containing a heterocyclic core substituted with a sulfonamide side chain and a lipophilic motif, bind intracellularly at the allosteric antagonist binding site II.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative class I and class II CCR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Previously reported CCR4 antagonists were developed targeting a subset of Th2 cells for the treatment of inflammation, allergic disorders, and autoimmune disease.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> Among them, GSK2239633 (<b>5</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), a class II antagonist developed by GlaxoSmithKline, was evaluated in a 2011 Phase I clinical trial in healthy volunteers for the treatment of asthma. Low blood exposure resulted in low target engagement and prevented further clinical development.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> AztraZeneca has also developed a series of CCR4 class II antagonists and have identified AZD-1678 and AZD-2098 as preclinical candidates (<b>6a</b>, <b>6b</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>),<a onclick="showRef(event, 'ref30 ref34'); return false;" href="javascript:void(0);" class="ref ref30 ref34">(30,34)</a> although no clinical development has been reported.</div><div class="NLM_p">The CCR4 receptor has also been targeted with depleting monoclonal antibodies. Mogamulizumab (KW0761), a humanized defucosylated anti-CCR4 depleting antibody developed by Kyowa Hakko Kirin, was approved in Japan in 2012 for the treatment of relapsed/refractory CCR4<sup>+</sup> adult T-cell leukemia/lymphoma (ATCLL) and in 2014 for relapsed/refractory CCR4<sup>+</sup> cutaneous T cell lymphoma (CTCL).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In August of 2018, the FDA approved mogamulizumab to treat two types of CTCL, Sézary disease and mycosis fungoides.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> However, systemic depletion of CCR4 containing cells in healthy tissues appears to lead to serious skin-related side effects,<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> including cases of Stevens–Johnson Syndrome (SJS). This is presumably due to depletion of T<sub>reg</sub> in the skin, leading to drastic changes in the ratio of T effector cells to T<sub>reg</sub> and thus triggering an autoimmune response. Small-molecule reversible inhibition of CCR4-mediated cell migration and homing, without depleting specific subpopulations of T cells, could offer a safer approach. We have demonstrated in a preclinical model in which T<sub>reg</sub> numbers in the skin were not affected, suggesting they are neither depleted nor their migration into healthy skin is prevented by the CCR4 receptor blockade with small-molecule antagonists.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p last">We have recently reported the discovery of novel small-molecule antagonists that inhibit the trafficking of T<sub>reg</sub> into the TME. These class I antagonists featured a novel pyrazolopyrazine core with a unique cyclohexenyl side chain (<b>4a</b>,<b>b</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Although <b>4b</b> inhibited the migration of T<sub>reg</sub> in both <i>in vitro</i> and <i>in vivo</i> models, it suffered from high clearance in rats and also required high doses to achieve significant reduction of T<sub>reg</sub> migration in mouse models. While <b>4b</b> was a suitable tool compound for proof of concept experiments, we wanted to advance our program by discovering a more simplified side chain. These new antagonists should maintain potency and selectivity for CCR4, while also encompassing improved ADME properties required for oral dosing. Our search led us to the discovery of a novel piperidinyl-azetidine motif, which, in combination with our pyrazolopyrazine cores, yielded highly potent, selective, and orally bioavailable antagonists of CCR4. Herein, we highlight the SAR of this novel series as well as their activity in several <i>in vitro</i> and <i>in vivo</i> models.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75557" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75557" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure–Activity Relationships</h3><div class="NLM_p">We have previously reported a pharmacophore map that we built using the structures of published class I CCR4 antagonists (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). This model was further refined using our published SAR in combination with computational studies using a known CCR4 homology model.<a onclick="showRef(event, 'ref28 ref39'); return false;" href="javascript:void(0);" class="ref ref28 ref39">(28,39)</a> In this model, a highly optimized right-hand phenyl group bearing two halogen substituents in positions 2 and 4 is connected to an aromatic core (usually heterocyclic). The core is linked to an amine-containing side chain. The size and spatial orientation of the linker critically dictates positioning of the basic nitrogen, which is key for activity. Using this pharmacophore model, compounds <b>4a</b>,<b>b</b> were designed and demonstrated high potency against CCR4.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> We further applied this model to the design of a simplified side chain with the goal of reducing stereochemical complexity in our antagonists.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Pharmacophore map of previously reported CCR4 antagonists. (B) Current RAPT pharmacophore model. (C) Design of novel piperidinyl-azetidine series using a pharmacophore map for class I CCR4 antagonists: topological and spatial orientation of the basic nitrogen is crucial for maintaining potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We turned our attention to smaller ring systems and were attracted to the simplicity of symmetrically substituted four membered rings. Our previously reported SAR,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> as well as other published data,<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> suggested that the connecting atom from the side chain to the core should be a nitrogen or a sp<sup>2</sup> carbon in order to keep the most favorable spatial orientation. Thus, we set out to explore the nitrogen containing azetidine ring. Our refined pharmacophore map incorporating azetidine as a linker is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B.</div><div class="NLM_p">Using a simple 6–4 ring system in which a piperidine ring is connected to the azetidine, we walked the nitrogen around the piperidine ring to identify the ideal positioning of the basic nitrogen (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). Compound <b>7</b>, with the nitrogen directly connected to the azetidine ring, was found to be inactive in a calcium flux assay. Increasing the distance of the basic nitrogen to the azetidinyl nitrogen, as seen in compound <b>8</b>, resulted in modest but encouraging potency with an IC<sub>50</sub> of 1.37 μM. We moved the basic nitrogen one atom further and tested the 3-(piperidin-3-yl)azetidine motif. We were pleased to find compound <b>9</b> had an IC<sub>50</sub> of 596 nM in the calcium flux assay as a 1:1 mixture of diastereomers. Finally, we prepared the 3-(piperidin-4-yl)azetidine analogue <b>10</b> that had the basic nitrogen furthest from the linker nitrogen and found that this analogue was inactive.</div><div class="NLM_p">Next, we set out to explore the chemical space around the novel 3-(piperidin-3-yl)azetidine side chain. This included the role substitutions on the basic nitrogen, and the absolute stereochemistry of the piperidine ring, would play on potency of these antagonists. We found that polar groups linked by one, two, or three carbons to the piperidinyl nitrogen dramatically improved the potency of these CCR4 antagonists, as exemplified by sulfonamide <b>16</b>, which possessed an IC<sub>50</sub> of 121 nM prepared as a 1:1 mixture of diastereomers from racemic amine <b>11</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). At this point, we decided to separate the diastereomers by chiral preparative HPLC and found that antagonist <b>18</b> bearing the (<i>R</i>) configuration was 5-fold more potent than the corresponding diastereomer <b>17</b> with (<i>S</i>) configuration.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>16</b> and Activities of the Single Diastereomers <b>17</b> and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethenesulfonyl fluoride, DCM; (b) MeOH, NH<sub>4</sub>OH, 70 °C; (c) 4 N HCl in dioxane, DCM; (d) (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine, DMSO, <i>N</i>,<i>N</i>-diisopropylethylamine, 80 °C, 4 h; (d) separation of diastereomers on chiral HPLC.</p></p></figure><div class="NLM_p">The absolute stereochemistry of compound <b>18</b> was unambiguously confirmed by single-crystal X-ray diffraction of a key intermediate (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">Supporting Information</a> for details).</div><div class="NLM_p">These findings prompted an extensive SAR campaign to improve the potency of this series in the primary calcium flux assay, and subsequently, to evaluate the ability of these antagonists to inhibit the migration of cells expressing CCR4 in the presence of a CCL22 gradient. We have previously reported a 96-well medium-throughput chemotaxis (CTX) assay using CCR4-expressing CCRF-CEM cells.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Antagonists that inhibited calcium flux in the double-digit nanomolar range were also run in a physiologically more relevant CTX assay. This platform is considered the gold standard assay for interrogating <i>in vitro</i> cellular migration. Since the assay is run in 100% human serum (HS), the reported potencies reflect the protein binding of the compounds. Although calcium flux allowed us to triage compounds based on their CCR4 affinity, a significant shift in CTX potency was often observed, likely due to plasma protein binding. Importantly, this platform can be extended to other relevant cell types, including primary immune cells (T<sub>reg</sub> and Th2 cells).</div><div class="NLM_p">The results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. As mentioned above, sulfonamide <b>18</b> was highly potent in the calcium flux assay; however, this compound suffered a large shift in the CTX assay. Reversing the terminal sulfonamide was tolerated, and antagonists (<b>19</b> and <b>20</b>) displayed increased potency in the primary calcium flux assay (29 and 31 nM, respectively) with only a 4–5-fold shift in the cell migration assay. 2-Carbon linked sulfone <b>21</b> was equipotent to sulfonamide <b>18</b> and suffered a similar CTX shift. While the 3-carbon linked sulfone <b>22</b> was 3-fold more potent in the calcium flux assay (22 nM), it had a 10-fold shift in the CTX assay. Replacing the sulfonamide functional group with 3-carbon-linked carboxylic acid <b>23</b> displayed similar inhibition in the calcium flux and a similar shift in the CTX assay, as compared to the parent sulfonamide. The 2-carbon-linked carboxylic acid <b>24</b> had a similar potency in the calcium flux assay but was 2-fold more potent in the CTX assay. Interestingly, replacing the C3-methyl in the pyrazolopyrazine core for a C3-cyano pyrazolopyrazine core yielded carboxylic acid <b>25</b> that was 2-fold more potent in the calcium flux assay than the C3-methyl analogue, but with similar CTX potencies. Decreasing the length of the linker by one carbon was tolerated and provided antagonist <b>26</b>, which displayed increased activity in the primary calcium flux assay (36 nM) but also showed a large shift in the CTX assay. Terminal amides were also active CCR4 antagonists as seen in amide <b>27</b>, which was 42 nM in the calcium flux assay and 242 nM in the cell migration assay. Reversed amides <b>28</b> and <b>29</b> were found to be marginally more potent CCR4 antagonists. Amide <b>28</b> had an IC<sub>50</sub> of 6 nM in the calcium flux assay and 40 nM in the CTX assay, while the more lipophilic amide <b>29</b> was slightly less potent. Methyl carbamate <b>30</b> was also highly potent in the calcium flux assay (23 nM) but suffered a 5-fold shift in the chemotaxis assay. Introduction of a small heterocycle was also tolerated. Imidazole <b>31</b>, connected by a 1-carbon linker attached to the C3-cyano pyrazolopyrazine core, possessed a calcium flux potency of 21 nM and CTX potency of 97 nM.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of the Piperidinyl Side Chain</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0015.gif" alt="" id="GRAPHIC-d7e781-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0016.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Assay ran in the absence of serum.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Assay ran in 100% human serum. N.D. is defined as not determined.</p></div></div><div></div></div><div class="NLM_p">Terminal nitriles produced less potent CCR4 antagonists. Antagonist <b>32</b>, bearing a terminal nitrile connected to the piperidine through a one carbon linker, was 1470 nM in the calcium flux assay. Extending the linker by one carbon improved the potency of analogue <b>33</b>, but it had a large shift in the chemotaxis assay. Similarly, introducing a terminal trifluoromethyl with a 2-carbon tether was detrimental for potency, as compound <b>34</b> was 505 nM in the calcium flux assay and its analogue <b>35</b> on the C3-cyano pyrazolopyrazine core had similar activity. Simple alcohols were also studied and yielded highly active CCR4 antagonists. The 3-carbon linked alcohol <b>36</b> was moderately less potent than its 2-carbon analogue <b>37</b>. Antagonist <b>37</b> showed an IC<sub>50</sub> of 24 nM in the inhibition of calcium flux and 74 nM in the chemotaxis assay. Replacing the C3-methyl for a C3-cyano on the core yielded compound <b>38</b>, which was highly potent in both CCR4 functional assays. In the primary calcium flux assay, compound <b>38</b> had an IC<sub>50</sub> of 22 nM and 50 nM in the CTX cell migration assay. We then explored other substitutions at the C3-position of the pyrazolopyrazine core. Placing terminal amides at the C3-position was productive and generated potent CCR4 antagonist <b>39</b>. Compound <b>39</b>, bearing an unsubstituted amide at the C3 position, displayed an IC<sub>50</sub> of 8 nM in the calcium flux assay and 36 nM in the chemotaxis assay. The C3-carboxylic acid substituted pyrazolopyrazine <b>40</b> was found to be inactive. Monomethylated amide <b>41</b> was 3-fold less potent than the unsubstituted analogue <b>39</b> and had a large shift in the migration assay. Finally, adding a second methyl group on the terminal amide <b>42</b> restored potency in the calcium flux assay (9 nM), but this substituted amide suffered from a large shift in the chemotaxis assay.</div><div class="NLM_p">We then evaluated the <i>in vitro</i> metabolic stability and pharmacokinetic properties of several of these potent CCR4 antagonists in human and rat hepatocytes as well as rat <i>in vivo</i> PK (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Sulfonamide <b>19</b> was moderately stable in a human hepatocyte assay with 85% remaining, while, in rat hepatocytes, only 53% remained after incubating for 60 min. The lower rat <i>in vitro</i> metabolic stability of <b>19</b> was also reflected in a rat <i>in vivo</i> PK study, which showed medium clearance and low bioavailability. The reverse amide <b>28</b> displayed good stability in both rat and human hepatocytes. In rat PK, <b>28</b> had relatively low clearance (11 mL/min/kg); however, the bioavailability of this antagonist was only 13%. The <i>in vitro</i> metabolic stability of the 2-carbon linked alcohol <b>37</b> was also assessed and revealed that this antagonist was stable in human hepatocytes (87% remaining) and moderately stable in the rat hepatocyte assay (62% remaining). Consistent with these findings, the rat <i>in vivo</i> PK of compound <b>37</b> was remarkably improved, with moderate clearance (32.3 mL/min/kg) and 61% bioavailability.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Metabolic Stability and Rat <i>In Vivo</i> PK of the Selected CCR4 Antagonist</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="/" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char="/">hepatocytes<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> % rem r/h</th><th class="colsep0 rowsep0" align="center" char=".">rat IV CL (mL/min/kg)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">rat %F<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="/">53/85</td><td class="colsep0 rowsep0" align="char" char=".">41.6</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char="/">68/94</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char="/">62/87</td><td class="colsep0 rowsep0" align="char" char=".">32.3</td><td class="colsep0 rowsep0" align="char" char=".">61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char="/">73/91</td><td class="colsep0 rowsep0" align="char" char=".">47.6</td><td class="colsep0 rowsep0" align="char" char=".">49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="char" char="/">95/95</td><td class="colsep0 rowsep0" align="char" char=".">190.8</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">% remaining after incubating for 60 min.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Dose of 0.5 mg/kg IV.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Dose of 2 mg/kg PO.</p></div></div></div><div class="NLM_p">Compound <b>38</b> had slightly improved metabolic stability in the <i>in vitro</i> rat and human hepatocyte assay as compared to its analogue <b>37</b>. Compound <b>38</b> possessed medium clearance (47.6 mL/min/kg) in a rat <i>in vivo</i> PK experiment and was 49% bioavailable upon oral dosing. Amide <b>39</b> was remarkably stable in both in human and rat hepatocytes (95% and 95% remaining, correspondingly) but had extremely high clearance in a rat <i>in vivo</i> PK study (190.8 mL/min/kg) and was not bioavailable.</div><div class="NLM_p">Compounds <b>37</b> and <b>38</b> were evaluated for inhibition of the five most common isoforms of cytochrome P450 and found that both possessed clean CYP450 profiles (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Furthermore, compounds <b>37</b> and <b>38</b> showed no activity in a CYP450 induction assay. However, in a CYP450 time-dependent inhibition assay (CYP450 TDI) for the 3A4 isoform, there was a 2.6-fold shift in its IC<sub>50</sub> when compound <b>37</b> was incubated in the presence NADPH as compared to when it was incubated in the absence of the cofactor. Compound <b>38</b> did not display a significant shift in its IC<sub>50</sub> when it was incubated in the presence NADPH as compared to incubation in the absence of the cofactor. We speculate that metabolism at the C3-methyl in the pyrazolopyrazine core might be responsible for the CYP450 TDI.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>In Vitro</i> CYP Profile of Compounds <b>37</b> and <b>38</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">cmpd <b>37</b></th><th class="colsep0 rowsep0" align="center">cmpd <b>38</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP450 inhibition (IC<sub>50</sub>) for isoforms 1A2, 2C9, 2C19, 2D6, and 3A4<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>40 μM</td><td class="colsep0 rowsep0" align="left">>40 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP induction<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">negative</td><td class="colsep0 rowsep0" align="left">negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP450 TDI IC<sub>50</sub> shift for isoform 3A4<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2.6-fold</td><td class="colsep0 rowsep0" align="left">1.2-fold</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">Supporting Information</a> for details.</p></div></div></div><div class="NLM_p">On the basis of these results, we further profiled compound <b>38</b> in several <i>in vitro</i> and <i>in vivo</i> experiments. A mouse <i>in vivo</i> PK study revealed that compound <b>38</b> had low clearance (10.2 mL/min/kg), medium volume of distribution (5.2 L/kg), a half-life of 6.9 h, and good bioavailability (%F = 29) that led to high exposure after oral dosing (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Mouse PK, <i>In Vitro</i> iTreg Chemotaxis and Selectivity Profile of Antagonist <b>38</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse <i>in vivo</i> PK</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">10.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (hr)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">6.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO AUC<sub>0–last</sub> (ng hr/mL)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">751</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CTX IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">50/64<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">miTreg CTX IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hiTreg CTX IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">33</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Dose of 0.5 mg/kg IV.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Dose of 2 mg/kg PO.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">CCL17 was used as a chemoattractant</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Assay run in 100% mouse serum.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Assay run in 100% human serum.</p></div></div></div><div class="NLM_p">When CCL17 was used as a chemoattractant instead of CCL22, the CTX IC<sub>50</sub> value was 64 nM. Compound <b>38</b> was also evaluated for its ability to inhibit the CCR4-mediated migration of the more physiologically relevant induced mouse and human regulatory T cells (iT<sub>reg</sub>) in an <i>in vitro</i> chemotaxis assay (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Compound <b>38</b> inhibited the migration of mouse iT<sub>reg</sub> cells with an IC<sub>50</sub> of 39 nM, while the IC<sub>50</sub> in human iT<sub>reg</sub> cells was 33 nM.</div><div class="NLM_p">The selectivity of CCR4 antagonist <b>38</b> against other prevalent chemokine receptors was also assessed, and it was found that compound <b>38</b> was highly selective for CCR4, as it did not inhibit other chemokine receptors from the panel at a concentration of 500 nM (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Selectivity of CCR4 antagonist <b>38</b> at 500 nM against a panel of human chemokine receptors in a β-arrestin recruitment assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <i>In Vivo</i> T<sub>reg</sub> Migration Studies in a Mouse</h3><div class="NLM_p">Having established that antagonist <b>38</b> potently and selectively inhibited the migration of T<sub>reg</sub> cells in <i>in vitro</i> models, we then evaluated the ability of <b>38</b> to inhibit the migration of T<sub>reg</sub> into the TME using a previously reported <i>in vivo</i> murine pancreatic ductal adenocarcinoma model (Pan02).<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> Compound <b>38</b> significantly inhibited the migration of adoptively transferred GFP<sup>+</sup> iT<sub>reg</sub> to the TME in a dose-dependent manner, as compared to the control group (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Importantly, treatment with compound <b>38</b> did not show any significant reduction in the number of GFP<sup>+</sup> or endogenous T<sub>reg</sub> in the spleen, nor other healthy tissues, including the skin and lung.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Treatment with Compound <b>38</b> reduces T<sub>reg</sub> migration into the tumor. (A) Schematic outline of treatment and tumor model that is used in this study. (B) Number of GFP<sup>+</sup> T<sub>reg</sub> in the tumor. For statistical analysis, the two-tailed <i>t</i> test was used.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Antitumor Efficacy of Compound 38 in a Pan02-Ova and Ct26 Tumor Models As a Single Agent and in Combination with Checkpoint Inhibitors</h3><div class="NLM_p">After confirming that CCR4 antagonist <b>38</b> effectively inhibited the migration of regulatory T cells into the TME in an <i>in vivo</i> model, we sought to explore the extent of antitumor efficacy that could be achieved through CCR4 antagonism. To that end, we used a Pan02-OVA tumor model (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">Supporting Information</a>) to examine the antitumor efficacy of antagonist <b>38</b> as a single agent and in combination with an anti-CTLA-4 checkpoint inhibitor with therapeutic dosing of both agents (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Antagonist <b>38</b> significantly reduced the tumor growth as compared to the vehicle control group and was comparable to the group that received the anti-CTLA-4 antibody. Importantly, when CCR4 antagonist <b>38</b> was combined with anti-CTLA-4, a further reduction on the tumor growth was observed.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacy of compound <b>38</b> in a Pan02-OVA model with a 50 mg/kg PO QD dosing regimen. See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">Supporting Information</a> for details. For statistical analysis, the two-tailed <i>t</i> test was used.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, to evaluate synergy with another widely used checkpoint inhibitor, an anti-PD-L1 antibody, we designed a therapeutic combination study in the CT26 mouse model (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">Supporting Information</a>). In this study (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), we observed significant tumor growth inhibition in animals who received combination treatment compared to the single agent treatment groups. This suggests that inhibiting T<sub>reg</sub> migration may enhance an immune-mediated antitumor response by removing the inhibitory effect of T<sub>reg</sub> in TME.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Antitumor efficacy of compound <b>38</b> in a CT26 model with a 50 mg/kg PO QD dosing regimen. See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">Supporting Information</a> for details. For statistical analysis, the two-tailed <i>t</i> test was used.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetic Profiling of Compound <b>38</b> in a Dog and Cynomolgus Monkey</h3><div class="NLM_p last">Considering the promising <i>in vitro</i> and <i>in vivo</i> pharmacology profile of antagonist <b>38</b>, we sought to fully profile its pharmacokinetic properties in higher species (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">Supporting Information</a>). In higher species, the <i>in vivo</i> clearance of compound <b>38</b> was 3-fold lower than predicted by the <i>in vitro</i> assay. In the dog, compound <b>38</b> had low clearance (7.3 mL/min/kg), a half-life of 12.7 h, and was 44% bioavailable. Similarly, in the cynomolgus monkey, compound <b>38</b> had low clearance (3.7 mL/min/kg), a long terminal half-life (10.7 h), and good bioavailability (%<i>F</i> = 41).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthetic Chemistry</h3><div class="NLM_p">CCR4 antagonists <b>9</b> and <b>16</b>–<b>42</b> were synthesized through a straightforward sequence starting with introduction of an alkyl group to amine <b>11</b> (racemic or enantioenriched), followed by deprotection of the Boc group, and completed by nucleophilic aromatic substitution with an appropriately substituted pyrazolopyrazine intermediate <b>15a</b>–<b>d</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In general, the introduction of an alkyl group was achieved via reductive amination, alkylation with an alkyl halide, or Michael addition (General Procedures A–C in <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).</div><div class="NLM_p">Compounds <b>7</b>–<b>10</b> were made via a nucleophilic aromatic substitution reaction between intermediate <b>15a</b> and the corresponding amines, which were either commercially available or accessed via reductive amination as described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>7</b>–<b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-(azetidin-3-yl)piperidine or 1-(azetidin-3-yl)-<i>N</i>,<i>N</i>-dimethylmethanamine, <i>N</i>,<i>N</i>-diisopropylethylamine, DMSO, 80 °C, 12 h; (b) ethyl glyoxylate or acetaldehyde, NaBH(OAc)<sub>3</sub>, 1,2-DCE, rt; (c) HCl, 1,4-dioxane<sub>,</sub>DCM, rt; (d) <i>N</i>,<i>N</i>-diisopropylethylamine, <b>15a</b>, DMF, 80 °C, 12 h.</p></p></figure><div class="NLM_p">Compounds <b>9</b>, <b>19</b>, <b>20</b>, <b>22</b>, <b>24</b>, <b>27</b>, <b>28</b>–<b>31</b>, <b>36</b>, <b>37</b>, and <b>39</b> were synthesized using racemic amine <b>11</b>, and diastereomers were separated by chiral HPLC or SFC. Chiral resolution of racemic <b>11</b> was accomplished by fractional crystallization with <i>R</i>-mandelic acid. X-ray crystallography determined that the piperidinyl stereocenter of <b>11</b> used to prepare the more active diastereomers possessed the <i>R</i> configuration. Stereochemistry of the piperidinyl stereocenter of the more active diastereomers isolated by SFC (compounds <b>19</b>, <b>28</b>, and <b>37</b>) was unambiguously confirmed by the synthesis using enantiopure (<i>R</i>)-<b>11</b> and comparing NMR spectra of the compounds prepared from racemic and enantioenriched <b>11</b>. On this basis, the absolute stereochemistry of the piperidinyl group of the more active isomers obtained by chromatographic separation was assigned as <i>R</i>. Compounds <b>19</b>, <b>21</b>, <b>23</b>, <b>25</b>, <b>26</b>, <b>28</b>, <b>32</b>–<b>35</b>, <b>37</b>, <b>38</b>, and <b>40</b>–<b>42</b> were prepared from resolved (<i>R</i>)-<b>11</b>.</div><div class="NLM_p">Sulfonylated and acylated compounds <b>19</b>, <b>20</b>, and <b>28</b>–<b>30</b> were prepared by reductive amination with 2-(<i>N</i>-phthalimidyl)acetaldehyde aldehyde. Standard liberation of the protected amine with hydrazine hydrate, followed by acylation or sulfonylation with an appropriate reagent, provided access to intermediate <b>48</b>, which was then Boc deprotected and used as is in the nucleophilic aromatic displacement with <b>15a</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Similar to previously described reactions, the yields for the final coupling were moderate to low (15–35%).</div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>19</b>, <b>20</b>, and <b>28</b>–<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaHB(OAC)<sub>3</sub>, 1,2-DCE, rt; (b) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O, EtOH, rt;(c) RSO<sub>2</sub>Cl or RCOCl, DCM, <i>N</i>,<i>N</i>-diisopropylethylamine; (d) HCl, 1,4-dioxane, DCM, rt; (e) <b>15a</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C; (f) separation of diastereomers by Chiral HPLC or SFC.</p><p class="last"><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on the maximum single diastereomer recovery.</p></p></figure><div class="NLM_p">Compounds <b>21</b>, <b>14</b>, <b>15</b>, <b>17</b>, and <b>33</b> were accessed using mild conditions for Michael addition of amine <b>11</b> to the corresponding electrophile in dichloromethane or DMF. These reactions went to complete conversion at room temperature, and the products were used in the subsequent steps without purification (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). In the case of compound <b>36</b>, Michael addition of methyl acrylate to amine <b>11</b> was followed by the reduction of the ester using LiBH<sub>4</sub>. Standard deprotection and S<sub>N</sub>Ar yielded the desired product (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>21</b>, <b>24</b>, <b>25</b>, <b>27</b>, and <b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <span class="smallcaps smallerCapital">l</span>-(+)-mandelic acid, MTBE, 60 °C, 40%; (b) Michael acceptor, DCM, rt; (c) HCl, 1,4-dioxane, DCM, rt; (d) <b>15a</b> or <b>15b</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C.</p><p><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on maximum single diastereomer recovery.</p><p class="last"><span class="fn-label"><sup>c</sup></span>Compound was made from racemic amine and diastereomers were separated by chiral HPLC or SFC.</p></p></figure><figure id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0011.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Piperidinyl-Azetidine CCR4 Antagonist <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl acrylate, DMF, 50 °C, 3 h; (b) LiBH<sub>4</sub>, THF, MeOH, 50 °C, 24 h; (c) HCl, 1,4-dioxane, DCM, rt; (d) <b>15a</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C; (e) separation of diastereomers by chiral HPLC using OZ-H, 20% ethanol/80% heptanes with 0.1% diethylamine.</p><p class="last"><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on the maximum single diastereomer recovery.</p></p></figure><div class="NLM_p">Reductive amination was used to synthesize compounds <b>23</b>, <b>26</b>, <b>31</b>, and <b>36</b>–<b>42</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). Compounds <b>37</b>–<b>42</b> were obtained from the same hydroxyethyl intermediate <b>54</b> (R<sub>1</sub> = CH<sub>2</sub>OTBS, <b>57</b>), which was prepared via reductive amination with TBS-protected hydroxyacetaldehyde. Acidic conditions for Boc removal also simultaneously deprotected the TBS group, and the crude material was used in the S<sub>N</sub>Ar, with intermediate <b>15</b>, to access final compounds <b>37</b> and <b>38</b> (explicit synthesis of this key compound is shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>). Amides <b>40</b>–<b>42</b> were obtained from the intermediate compound <b>55</b> by hydrolysis of the ester on the pyrazolopyrimidine core (compound <b>40</b>) and T3P-mediated coupling with the methylamine (<b>41</b>) or dimethylamine (<b>42</b>).</div><figure id="sch6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0012.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>23</b>, <b>26</b>, <b>31</b>, <b>37</b>–<b>39</b>, and <b>40</b>–<b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <span class="smallcaps smallerCapital">l</span>-(+)-mandelic acid, MTBE, 60 °C, 40%; (b) aldehyde, NaHB(OAc)<sub>3</sub>, 1,2-DCE, rt; (c) HCl, 1,4-dioxane, DCM, rt; (d) <b>15</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C; (e) LiOH, MeOH, water, rt; (f) MeNH<sub>2</sub> or Me<sub>2</sub>NH, T<sub>3</sub>P, EtOAc.</p><p><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on the maximum single diastereomer recovery.</p><p><span class="fn-label"><sup>c</sup></span>The compound was made from racemic amine, and diastereomers were separated by chiral HPLC or SFC.</p><p><span class="fn-label"><sup>d</sup></span>Yield is shown for methyl ester, which was hydrolyzed using LiOH in MeOH/water with 90% yield to afford <b>23</b>.</p><p class="last"><span class="fn-label"><sup>e</sup></span>This compound was prepared using both racemic amine <b>11</b> and enantioenriched (<i>R</i>)-<b>11</b>, confirming stereochemistry of the product.</p></p></figure><div class="NLM_p">Finally, simple alkylation with alkyl bromide along with a catalytic amount of sodium or potassium iodide was used to access intermediate <b>56</b>, which provided access to compounds <b>22</b>, <b>24</b>, <b>25</b>, and <b>32</b> via the same deprotection/coupling sequence (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).</div><figure id="sch7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0013.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>22</b>, <b>32</b>, <b>34</b>, and <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <span class="smallcaps smallerCapital">l</span>-(+)-mandelic acid, MTBE, 60 °C, 40%; (b) R<sub>1</sub>CH<sub>2</sub>X (X = Br or I), acetonitrile or 1,4-dioxane, potassium or sodium carbonate, 75–90 °C, 12 h; (c) HCl, 1,4-dioxane, DCM, rt; (d) <b>15a</b> or <b>15b</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C.</p><p><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on the maximum single diastereomer recovery.</p><p class="last"><span class="fn-label"><sup>c</sup></span>The compound was made from racemic amine, and diastereomers were separated by chiral HPLC or SFC.</p></p></figure><div class="NLM_p">Due to low reactivity of the methyl substituted compound <b>15a</b>, the yields of the aromatic nucleophilic substitution step were underwhelming (8–70%), with most of the examples falling into the 20–30% yield range. Pyrazolopyrazines with electron-withdrawing substituents, such as CN (<b>15b</b>), CO<sub>2</sub>Et (<b>15c</b>), or CONH<sub>2</sub> (<b>15d</b>), provided higher yields in the coupling step with yields ranging from 32 to 99%.<named-content content-type="anchor" rid="sch8" type="simple"></named-content></div><figure id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0014.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compound <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <span class="smallcaps smallerCapital">l</span>-(+)-mandelic acid, MTBE, 60 °C, 40%; (b) NaBH(OAc)<sub>3</sub>, 1,2-DCE, 22 °C, 98%; (c) HCl, 1,4-dioxane, DCM 22 °C, 99%; (d) <b>15b</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DCM, 22 °C, 83%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00436" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00436" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have discovered a series of potent, selective, and orally bioavailable small-molecule CCR4 antagonists containing a novel piperidinyl-azetidine functionality. By inhibiting CCR4-induced chemotaxis, these inhibitors block recruitment of T<sub>reg</sub> to the TME. Compound <b>38</b> displayed good <i>in vitro</i> and <i>in vivo</i> ADME properties. After oral dosing, compound <b>38</b> significantly inhibited the migration of T<sub>reg</sub> into the TME in a Pan02 tumor model in a dose-dependent manner. Importantly, antagonist <b>38</b> did not affect the trafficking of T<sub>reg</sub> to other healthy tissues.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> We also demonstrated significant antitumor efficacy as a single agent in a Pan02-OVA tumor model, comparable to anti-CTLA-4 checkpoint inhibition. Furthermore, the combination of tool compound <b>38</b> with the anti-CTLA-4 and anti-PD-L1 antibodies enhanced the antitumor response. Together, these findings demonstrate the potential of CCR4 inhibition to potentiate standard-of-care immunotherapy checkpoint inhibitors. These studies with tool compound <b>38</b> led to further work culminating in the clinical candidate FLX475 (structure not shown), currently in clinical trials against several cancers both as a single agent and in combination with the approved checkpoint inhibitor pembrolizumab.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Methods for Chemistry</h3><div class="NLM_p last">All commercial reagents and solvents were used as received unless otherwise noted. An inert atmosphere of nitrogen was used for reactions involving the air of moisture-sensitive reagents. Analytical thin-layer chromatography (TLC) was performed on precoated glass-backed plates (silica gel 60F<sub>254</sub>; 2.5 cm × 7.5 cm, 0.25 mm thickness, EMD Millipore 1.15341.0001) visualized using combinations of UV visualization, <i>p</i>-anisaldehyde, potassium permanganate, and iodine staining. Silica gel column chromatography was performed using Teledyne ISCO RediSep Rf normal phase (35–70 μm) silica gel columns on a Teledyne ISCO CombiFlash Rf or CombiFlash Rf+ purification system (detection at 254 nm). Reversed-phase preparative HPLC was carried out using a Gemini-NX-C18 column (10 μm, 250 mm × 30 mm, Phenomenex, Torrance, CA) eluting with a linear gradient from 5 to 100% acetonitrile in water containing 0.1% trifluoroacetic acid over 30 min on a Teledyne ISCO EZ Prep, Teledyne ISCO ACCQPrep HP125, or Agilent 1200 Series purification system. Analytical reversed-phase HPLC was performed using a Gemini-NX-C18 column (5 μm, 250 × 4.6 mm, Phenomenex, Torrance, CA), eluting with acetonitrile in water with 0.1% trifluoroacetic acid on an Agilent 1200 Series purification system (detection at 254 nm). Proton NMR spectra were recorded on a Varian Oxford 400 MHz spectrometer, and carbon NMR spectra were recorded at 100 MHz. Chemical shifts (δ) are reported in parts per million (ppm) and referenced to tetramethylsilane (δ = 0 ppm). Coupling constants (<i>J</i>) are reported in hertz (Hz), and abbreviations for signal coupling are as follows: s = singlet, d = doublet, dd = double doublets, t = triplet, q = quartet, m = multiplet, bs = broad singlet. Analytical LC-MS was performed using a ZORBAX SB-C18 column (1.8 μm, 2.1 × 50 mm, 600 bar, Agilent, Santa Clara, CA), eluting with a linear gradient from 0% to 100% B over 2 min and then 100% B for 3 min (A = 5% acetonitrile in water with 0.1% formic acid, B = 5% water in acetonitrile with 0.1% formic acid, flow rate 0.4 mL/min) using an Agilent 1260 Infinity II LC System (detection at 254 nm) equipped with an Agilent 6120 Quadrupole LC-MS in electrospray ionization mode (ESI+). The purity of all compounds used in bioassays was determined by this method to be >95% pure.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure A for Alkylation of <i>tert</i>-Butyl 3-(Piperidin-3-yl)azetidine-1-carboxylate by Reductive Amination</h3><div class="NLM_p last">Commercially available <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (1.0 equiv) was dissolved in 1,2-dichloroethane (0.2 M), and then the appropriate aldehyde or ketone (1.0–2.0 equiv) was added all at once. The mixture was stirred for 5 min at room temperature, and then sodium triacetoxyborohydride (2.0 equiv) was added. The mixture was stirred at room temperature, and conversion was monitored by LC-MS. Upon completion, the reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the desired product, which was purified by silica gel chromatography, preparative reverse-phase HPLC, or used without further purification.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure B for Alkylation of <i>tert</i>-Butyl 3-(Piperidin-3-yl)azetidine-1-carboxylate</h3><div class="NLM_p last">Commercially available <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (1.0 equiv) was dissolved in the appropriate dry solvent (0.2 M), and an alkyl halide (1 equiv), sodium iodide (0.1 equiv), and sodium carbonate (2 equiv) were added to the solution. Then, the mixture was heated to 75 °C under a nitrogen atmosphere, and the reaction was monitored by LC-MS; upon completion, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3×). The combined organic fractions were dried over sodium sulfate, filtered, and concentrated under reduced pressure; the residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane as an eluent.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure C for Michael Addition with <i>tert</i>-Butyl 3-(Piperidin-3-yl)azetidine-1-carboxylate</h3><div class="NLM_p last">Commercially available <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (1.0 equiv) was dissolved in the appropriate dry solvent (0.2 M) and either (a) a Michael acceptor (1 equiv) was added to the solution at once and the reaction mixture was stirred at room temperature or heated to 50 °C until complete conversion was achieved (monitored by LC-MS); upon completion, the volatiles were removed under reduced pressure, and the residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane as an eluent.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure D for Deprotection of 1-Alkyl <i>tert</i>-Butyl 3-(Piperidin-3-yl)azetidine-1-carboxylate</h3><div class="NLM_p last">1-Alkyl <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> was dissolved in dichloromethane (0.2 M), and then a solution of HCl (3 equiv, 4 M in 1,4-dioxane) or trifluoroacetic acid (5 equiv) was added. The mixture was stirred at room temperature, and the reaction was monitored by LC-MS; upon completion, the volatiles were removed under reduced pressure, and the crude product was used as is without any further purification.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Procedure E for Nucleophilic Aromatic Substitution (S<sub>N</sub>Ar) with 1-Alkyl 3-(Azetidin-3-yl)-piperidine</h3><div class="NLM_p last">1-Alkyl 3-(azetidin-3-yl)-piperidine <b>11</b> (1.1 equiv) and the appropriate heteroaryl chloride (1.0 equiv) were dissolved in dimethylformamide, dimethyl sulfoxide, or dichloromethane, and <i>N</i>,<i>N</i>-diisopropylethylamine (2.0–3.0 equiv) was added. The reaction was heated to 40–100 °C. The reaction was monitored by LC-MS. Upon completion, the mixture was cooled to room temperature and purified by silica gel chromatography or reversed-phase preparative HPLC.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>R</i>)-1-(1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-(3-(piperidin-1-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>7</b>)</h3><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-oxoazetidine-1-carboxylate (1.0 g, 5.84 mmol), piperidine (0.58 mL, 5.84 mmol), and sodium triacetoxyborohydride (3.7 g, 17.52 mmol) in 1,2-dichloroethane (15 mL) at 23 °C for 2 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure, and the residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–5%) and afforded <i>tert</i>-butyl 3-(piperidin-1-yl)azetidine-1-carboxylate (57% yield): LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 241.19, found 241.2.</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl 3-(piperidin-1-yl)azetidine-1-carboxylate (800 mg, 3.33 mmol) was dissolved in dichloromethane (16 mL), and then trifluoroacetic acid (1.27 mL, 16.65 mmol) was added. The mixture was stirred at 23 °C for 12 h and then concentrated under reduced pressure to afford 1-(azetidin-3-yl)piperidine 2,2,2-trifluoroacetate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>17</sub>N<sub>2</sub> [M + H]<sup>+</sup> 141.14, found 141.2.</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. 1-(Azetidin-3-yl)piperidine 2,2,2-trifluoroacetate (185 mg, 0.73 mmol) was dissolved in dimethyl sulfoxide (2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (225 mg, 0.66 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.5 mL, 2.92 mmol) were added. The mixture was heated to 80 °C for 12 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford (<i>R</i>)-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-(3-(piperidin-1-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine 2,2,2-trifluoroacetate (<b>7</b>, 8% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; TFA salt) δ 7.85 (s, 1H), 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.35 (d, <i>J</i> = 8.5 Hz, 1H), 7.27 (dd, <i>J</i> = 8.5, 2.1 Hz,1H), 6.31 (q, <i>J</i> = 7.0 Hz, 1H), 4.56–4.46 (m, 2H), 4.42–4.33 (m, 2H), 4.29–4.20 (m, 1H), 3.72–3.49 (m, 2H), 3.00–2.82 (m, 2H), 2.52 (s, 3H), 2.08–1.95 (m, 3H), 1.87 (d, <i>J</i> = 7.1 Hz, 3H), 1.86–1.65 (m, 2H), 1.63–1.48 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> 445.17, found 445.0.</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>R</i>)-1-(1-(1-(1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)-<i>N</i>,<i>N</i>-dimethylmethanamine (<b>8</b>)</h3><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. Commercially available 1-(azetidin-3-yl)-<i>N</i>,<i>N</i>-dimethylmethanamine dihydrochloride (60 mg, 0.32 mmol) was dissolved in dimethyl sulfoxide (1 mL); then, (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (100 mg, 0.29 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.25 mL, 1.45 mmol) were added. The mixture was heated to 80 °C for 12 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford (<i>R</i>)-1-(1-(1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)-<i>N</i>,<i>N</i>-dimethylmethanamine 2,2,2-trifluoroacetate (<b>8</b>, 19% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; TFA salt) δ 8.14 (bs, 1H), 7.69 (s, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.34 (d, <i>J</i> = 2.1 Hz, 1H), 7.15 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.31 (q, <i>J</i> = 7.1 Hz, 1H), 4.44–4.35 (m, 2H), 3.98–3.89 (m, 2H), 3.42 (d, <i>J</i> = 6.9 Hz, 2H), 3.40–3.30 (m, 1H), 2.89 (s, 6H), 2.57 (s, 3H), 1.88 (d, <i>J</i> = 7.1 Hz, 3H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>25</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> 419.15, found 419.0.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Ethyl 2-(3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)acetate (<b>9</b>)</h3><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (200 mg, 0.83 mmol), ethyl glyoxalate (0.17 mL, 0.83 mmol, 50% in toluene), and sodium triacetoxyborohydride (528 mg, 2.49 mmol) in 1,2-dichloroethane (3 mL) at 23 °C for 12 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure, and the residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–10%) and afforded <i>tert-</i>butyl 3-(1-(2-ethoxy-2-oxoethyl)piperidin-3-yl)azetidine-1-carboxylate (96% yield): LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>31</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 327.23, found 327.2.</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert-</i>Butyl 3-(1-(2-ethoxy-2-oxoethyl)piperidin-3-yl)azetidine-1-carboxylate (261 mg, 0.80 mmol) was dissolved in dichloromethane (4 mL), and then HCl (0.62 mL, 2.49 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 4 h and then concentrated under reduced pressure to afford ethyl 2-(3-(azetidin-3-yl)piperidin-1-yl)acetate hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 227.18, found 227.1.</div></div><div id="sec4_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. Ethyl 2-(3-(azetidin-3-yl)piperidin-1-yl)acetate hydrochloride (210 mg, 0.80 mmol) was dissolved in dimethyl sulfoxide (2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (273 mg, 0.80 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.56 mL, 3.2 mmol) were added. The mixture was heated to 80 °C for 4 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford ethyl 2-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)acetate 2,2,2-trifluoroacetate (<b>9</b>, 11% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; TFA salt) δ 10.43 (bs, 1H), 7.66 (s, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.34 (d, <i>J</i> = 2.2 Hz, 1H), 7.14 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.31 (q, <i>J</i> = 7.0 Hz, 1H), 4.24 (q, <i>J</i> = 7.2 Hz, 2H), 4.22–4.15 (m, 1H), 3.98–3.84 (m, 4H), 3.68–3.53 (m, 2H), 3.21–3.03 (m, 1H), 2.94–2.74 (m, 1H), 2.68–2.58 (m, 1H), 2.56 (s, 3H), 2.43–2.28 (m, 1H), 2.13–1.91 (m, 5H), 1.88 (d, <i>J</i> = 7.1 Hz, 3H), 1.29 (t, <i>J</i> = 7.1 Hz, 3H), 1.22–1.04 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 531.20, found 531.1.</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>R</i>)-1-(1-(2,4-Dichlorophenyl)ethyl)-6-(3-(1-ethylpiperidin-4-yl)azetidin-1-yl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>10</b>)</h3><div id="sec4_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-(piperidin-4-yl)azetidine-1-carboxylate <b>11</b> (200 mg, 0.83 mmol), acetaldehyde (46 μL, 1.66 mmol), and sodium triacetoxyborohydride (353 mg, 1.66 mmol) in 1,2-dichloroethane (4 mL) at 23 °C for 24 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure and afforded <i>tert</i>-butyl 3-(1-ethylpiperidin-4-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>29</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 269.22, found 269.2.</div></div><div id="sec4_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude from step 1 was dissolved in dichloromethane (4 mL), and then HCl (0.62 mL, 2.49 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure to afford 4-(azetidin-3-yl)-1-ethylpiperidine hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>21</sub>N<sub>2</sub> [M + H]<sup>+</sup> 169.17, found 169.2.</div></div><div id="sec4_10_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 4-(azetidin-3-yl)-1-ethylpiperidine hydrochloride from step 2 was dissolved in dimethylformamide (5 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (283 mg, 0.83 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.27 mL, 1.66 mmol) were added. The mixture was heated to 80 °C for 12 h and then cooled to 23 °C and concentrated under reduced pressure. The residue was purified by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford (<i>R</i>)-1-(1-(2,4-dichlorophenyl)ethyl)-6-(3-(1-ethylpiperidin-4-yl)azetidin-1-yl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine 2,2,2-trifluoroacetate (<b>10</b>, 12% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN; TFA salt) δ 7.75 (s, 1H), 7.49 (d, <i>J</i> = 2.2 Hz, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.28 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.27 (q, <i>J</i> = 7.0 Hz, 1H), 4.82 (bs, 1H), 4.27–4.16 (m, 2H), 3.92–3.81 (m, 2H), 3.64–3.50 (m, 1H), 3.49–3.31 (m, 1H), 3.22–2.76 (m, 3H), 2.66–2.53 (m, 1H), 2.47 (s, 3H), 2.03–1.95 (m, 7H), 1.86 (d, <i>J</i> = 7.0 Hz, 3H), 1.66–1.42 (m, 2H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>31</sub>Cl<sub>2</sub>N<sub>6</sub> [M + H]<sup>+</sup> 473.20, found 473.2.</div></div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 2-(3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethane-1-sulfonamide (<b>16</b>)</h3><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_3" aria-label="General Procedure B">General Procedure B</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (200 mg, 0.83 mmol) and ethenesulfonyl fluoride (76 μL, 0.91 mmol) in dichloromethane (2 mL) at 23 °C for 10 min; then the volatiles were removed under reduced pressure, and the residue was dissolved in methanol (2 mL). Then concentrated ammonium hydroxide (1 mL) was added. The mixture was heated to 70 °C for 30 min and then cooled to 23 °C and concentrated under reduced pressure to afford <i>tert</i>-butyl 3-(1-(2-sulfamoylethyl)piperidin-3-yl)azetidine-1-carboxylate <b>13</b>, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 348.20, found 348.1.</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude <i>tert</i>-butyl 3-(1-(2-sulfamoylethyl)piperidin-3-yl)azetidine-1-carboxylate <b>13</b> from step 1 was dissolved in dichloromethane (4 mL), and then HCl (0.62 mL, 2.49 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure to afford 2-(3-(azetidin-3-yl)piperidin-1-yl)ethane-1-sulfonamide hydrochloride <b>14</b>, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 248.14, found 248.2.</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 2-(3-(azetidin-3-yl)piperidin-1-yl)ethane-1-sulfonamide hydrochloride <b>14</b> from step 2 was dissolved in dimethyl sulfoxide (2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (219 mg, 0.64 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.45 mL, 2.56 mmol) were added. The mixture was heated to 80 °C for 4 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford ethyl 2-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)acetate 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomers (<b>16</b>, 15% yield); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 552.17, found 552.2.</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 2-((<i>S</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethane-1-sulfonamide (<b>17</b>)</h3><div class="NLM_p last">The mixture of diastereomers <b>16</b> was basified using a basification column (PL-HCO<sub>3</sub>MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as an eluent and concentrated under reduced pressure. The residue was separated by preparative chiral HPLC using a Chiralpak IF column (Daicel Corporation, West Chester, PA) and 45% isopropanol in heptanes (0.1% diethylamine) as an eluent and afforded 2-((<i>S</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethane-1-sulfonamide (<b>17</b>) as the first eluting diastereomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, free base) δ 7.70 (s, 1H), 7.43 (d, <i>J</i> = 2.1 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 7.24 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.28 (q, <i>J</i> = 7.1 Hz, 1H), 4.25–4.16 (m, 2H), 3.94–3.88 (m, 2H), 3.31 (bs, 1H), 3.28 (bs, 1H), 2.94–2.81 (m, 4H), 2.64–2.51 (m, 1H), 2.49 (s, 3H), 2.12–2.01 (m, 1H), 1.86 (d, <i>J</i> = 7.1 Hz, 3H), 1.84–1.69 (m, 4H), 1.64–1.50 (m, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 2H), 1.01–0.86 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 552.17, found 552.2.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethane-1-sulfonamide (<b>18</b>)</h3><div class="NLM_p last">The mixture of diastereomers <b>16</b> was basified using a basification column (PL-HCO<sub>3</sub>MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as an eluent and concentrated under reduced pressure. The residue was separated by preparative chiral HPLC using a Chiralpak IF column (Daicel Corporation, West Chester, PA) and 45% isopropanol in heptanes (0.1% diethylamine) as an eluent and afforded 2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethane-1-sulfonamide (<b>18</b>) as the second eluting diastereomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, free base) δ 7.70 (s, 1H), 7.43 (d, <i>J</i> = 2.1 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.24 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.28 (q, <i>J</i> = 7.1 Hz, 1H), 4.27–4.14 (m, 2H), 3.97–3.85 (m, 2H), 3.29 (bs, 1H), 3.27 (bs, 1H), 2.95–2.80 (m, 3H), 2.64–2.52 (m, 1H), 2.49 (s, 3H), 2.12–2.01 (m, 1H), 1.86 (d, <i>J</i> = 7.1 Hz, 3H), 1.83–1.70 (m, 5H), 1.65–1.51 (m, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 2H), 1.00–0.86 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 552.17, found 552.2.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-(2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)methanesulfonamide (<b>19</b>)</h3><div id="sec4_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using either <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> or enantioenriched (<i>R</i>)-11 (300 mg, 1.25 mmol), 3-(1,3-dioxoisoindolin-2-yl)propanal <b>46</b> (236 mg, 1.25 mmol, 50% in toluene), and sodium triacetoxyborohydride (529 mg, 2.5 mmol) in 1,2-dichloroethane (5 mL) at 23 °C for 15 min. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (5 mL), and then hydrazine hydrate (0.24 mL, 5.0 mmol) was added. The mixture was stirred at 23 °C for 18 h, and then the mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude <i>tert</i>-butyl 3-[1-(2-aminoethyl)-3-piperidyl]azetidine-1-carboxylate <b>47</b> (120 mg, 0.423 mmol) was dissolved in dichloromethane (2 mL), and then triethylamine (0.18 mL, 1.27 mmol) and methanesulfonyl chloride (39 μL, 0.508 mmol) were added. The mixture was stirred at 23 °C for 30 min, and then the mixture was quenched with aqueous sodium carbonate (10 mL, 1 M) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressured and afforded <i>tert</i>-butyl 3-(1-(2-(methylsulfonamido)ethyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>32</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 362.21, found 362.1.</div></div></div><div id="sec4_15_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Step 2</h3><div class="NLM_p">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude <i>tert</i>-butyl 3-(1-(2-(methylsulfonamido)ethyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in dichloromethane (4 mL), and then HCl (0.50 mL, 2.0 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure to afford <i>N</i>-(2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)methanesulfonamide hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 262.16, found 262.1.</div><div id="sec4_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude <i>N</i>-(2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)methanesulfonamide hydrochloride from step 2 was dissolved in dimethylformamide (1 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (72 mg, 0.21 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.18 mL, 1.05 mmol) were added. The mixture was heated to 80 °C for 4 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford <i>N</i>-(2-(3-(1-(1-((R)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)methanesulfonamide 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomers (if racemic <b>11</b> was used). The title compound was separated from its diastereomer by SFC using an AS-H column (2 × 25 cm) and eluting with 30% ethanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, to give the free base of the title compound as the second eluting isomer and converted to the corresponding HCl salt by dissolution in ethanol, cooling to 0 °C, and the addition of 1 equiv of 0.01 M HCl in ethanol and afforded 13 mg (20% yield) of <i>N</i>-(2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)methanesulfonamide (<b>19</b>): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 7.76 (s, 1H), 7.45 (d, <i>J</i> = 2.1 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.27 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.29 (q, <i>J</i> = 7.1 Hz, 1H), 4.34–4.21 (m, 2H), 4.04–3.96 (m, 2H), 3.82–3.41 (m, 4H), 3.29–3.26 (m, 1H), 3.03 (s, 3H), 3.02–2.92 (m, 2H), 2.76–2.60 (m, 2H), 2.50 (s, 3H), 2.23–2.10 (m, 1H), 2.08–1.89 (m, 3H), 1.87 (d, <i>J</i> = 7.1 Hz, 3H), 1.25–1.18 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 566.19, found 566.0.</div></div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)propane-2-sulfonamide (<b>20</b>)</h3><div class="NLM_p">A mixture of the title compound and its diastereomer was prepared as follows:</div><div id="sec4_16_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (300 mg, 1.25 mmol), 3-(1,3-dioxoisoindolin-2-yl)propanal <b>46</b> (236 mg, 1.25 mmol, 50% in toluene), and sodium triacetoxyborohydride (529 mg, 2.5 mmol) in 1,2-dichloroethane (5 mL) at 23 °C for 15 min. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (5 mL), and then hydrazine hydrate (0.24 mL, 5.0 mmol) was added. The mixture was stirred at 23 °C for 18 h, and then mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude <i>tert</i>-butyl 3-[1-(2-aminoethyl)-3-piperidyl]azetidine-1-carboxylate <b>47</b> (120 mg, 0.423 mmol) was dissolved in dichloromethane (2 mL), and then triethylamine (0.18 mL, 1.27 mmol) and 2-propanesulfonyl chloride (57 μL, 0.508 mmol) were added. The mixture was stirred at 23 °C for 30 min; then the mixture was quenched with aqueous sodium carbonate (10 mL, 1 M) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressured and afforded <i>tert</i>-butyl 3-(1-(2-((1-methylethyl)sulfonamido)ethyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>36</sub>N<sub>3</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 390.24, found 390.1.</div></div><div id="sec4_16_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl 3-(1-(2-((1-methylethyl)sulfonamido)ethyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in dichloromethane (4 mL), and then HCl (0.50 mL, 2.0 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure to afford <i>N</i>-(2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)propane-2-sulfonamide hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 290.19, found 290.1.</div></div><div id="sec4_16_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude <i>N</i>-(2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)methanesulfonamide hydrochloride from step 2 was dissolved in dimethylformamide (1 mL); then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (72 mg, 0.21 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.18 mL, 1.05 mmol) were added. The mixture was heated to 80 °C for 4 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford <i>N</i>-(2-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)propane-2-sulfonamide 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomers. The title compound was separated from its diastereomer by SFC using an AS-H column (2 × 25 cm) and eluting with 25% isopropanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, to give the free base of the title compound as the second eluting isomer and converted to the corresponding HCl salt by dissolution in ethanol, cooling to 0 °C, and the addition of 1 equiv of 0.01 M HCl in ethanol and afforded 23 mg of <i>N</i>-(2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)propane-2-sulfonamide (<b>20</b>, 35% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 7.74 (s, 1H), 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.26 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.29 (q, <i>J</i> = 7.1 Hz, 1H), 4.33–4.22 (m, 2H), 4.04–3.96 (m, 2H), 3.77–3.70 (m, 1H), 3.68–3.59 (m, 1H), 3.56–3.45 (m, 2H), 3.37–3.32 (m, 1H), 3.27–3.23 (m, 2H), 3.01–2.91 (m, 2H), 2.74–2.62 (m, 2H), 2.50 (s, 3H), 2.19–2.10 (m, 1H), 2.08–1.88 (m, 2H), 1.86 (d, <i>J</i> = 7.1 Hz, 3H), 1.37 (d, <i>J</i> = 6.8 Hz, 3H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H), 1.24–1.18 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>38</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 594.22, found 594.0.</div></div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-(3-((<i>R</i>)-1-(2-(methylsulfonyl)ethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>21</b>)</h3><div id="sec4_17_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_4" aria-label="General Procedure C">General Procedure C</a> using <i>tert</i>-butyl (<i>R</i>)-3-(piperidin-3-yl)azetidine-1-carboxylate (<i>R</i>)-<b>11</b> (1.15 g, 4.79 mmol) and methyl vinyl sulfone (0.42 mL, 4.79 mmol) in dichloromethane (24 mL) at 23 °C for 30 min; then the volatiles were removed under reduced pressure to afford <i>tert</i>-butyl (<i>R</i>)-3-(1-(2-(methylsulfonyl)ethyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>31</sub>N<sub>2</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 347.20, found 347.1.</div></div><div id="sec4_17_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude <i>tert</i>-butyl (<i>R</i>)-3-(1-(2-(methylsulfonyl)ethyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in dichloromethane (24 mL), and then HCl (5.95 mL, 23.8 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 30 min and then concentrated under reduced pressure to afford (<i>R</i>)-3-(azetidin-3-yl)-1-(2-(methylsulfonyl)ethyl)piperidine hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 247.15, found 247.1.</div></div><div id="sec4_17_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude (<i>R</i>)-3-(azetidin-3-yl)-1-(2-(methylsulfonyl)ethyl)piperidine hydrochloride (137 mg, 0.483 mmol) from step 2 was dissolved in dimethylformamide (2 mL); then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (150 mg, 0.439 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.23 mL, 1.32 mmol) were added. The mixture was heated to 80 °C for 2 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 209 mg of 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-(3-((<i>R</i>)-1-(2-(methylsulfonyl)ethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>21</b>, 81% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.71 (s, 1H), 7.39 (d, <i>J</i> = 8.5 Hz, 1H), 7.35 (d, <i>J</i> = 2.2 Hz, 1H), 7.16 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.32 (q, <i>J</i> = 7.0 Hz, 1H), 4.24 (q, <i>J</i> = 8.7 Hz, 2H), 4.00–3.88 (m, 2H), 3.74–3.60 (m, 3H), 3.61–3.51 (m, 2H), 3.03 (s, 3H), 2.87–2.69 (m, 1H), 2.56 (s, 3H), 2.50 (d, <i>J</i> = 17.2 Hz, 1H), 2.31–2.18 (m, 1H), 2.07–1.91 (m, 5H), 1.89 (d, <i>J</i> = 7.1 Hz, 3H), 1.27–1.05 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 551.18, found 551.0.</div></div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-(3-((<i>R</i>)-1-(3-(methylsulfonyl)propyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>22</b>)</h3><div class="NLM_p">A mixture of the title compound and its diastereomer was prepared as follows:</div><div id="sec4_18_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_3" aria-label="General Procedure B">General Procedure B</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (775 mg, 3.22 mmol), 1-bromo-3-methylsulfonyl-propane (648 mg, 3.22 mmol), sodium iodide (48 mg, 0.3200 mmol), and sodium carbonate (683 mg, 6.45 mmol) in 1,4-dioxane (10 mL) at 75 °C for 12 h. The reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (3 × 30 mL), and the combined organic fractions were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–10%) and afforded <i>tert</i>-butyl 3-(1-(3-(methylsulfonyl)propyl)piperidin-3-yl)azetidine-1-carboxylate (780 mg) as a colorless oil: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>33</sub>N<sub>2</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 361.22, found 361.1.</div></div><div id="sec4_18_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl 3-(1-(3-(methylsulfonyl)propyl)piperidin-3-yl)azetidine-1-carboxylate (760 mg, 2.11 mmol) from step 1 was dissolved in methanol (1 mL), and then HCl (2 mL, 8 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 60 min and then concentrated under reduced pressure to afford 3-(azetidin-3-yl)-1-(3-(methylsulfonyl)propyl)piperidine hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 261.16, found 261.1.</div></div><div id="sec4_18_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 3-(azetidin-3-yl)-1-(3-(methylsulfonyl)propyl)piperidine hydrochloride (250 mg, 0.75 mmol) from step 2 was dissolved in dimethylformamide (2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (256 mg, 0.75 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.65 mL, 3.75 mmol) were added. The mixture was heated to 80 °C for 2 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-(3-(1-(3-(methylsulfonyl)propyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomer. The title compound was separated from its diastereomer by SFC using an IC column (2 × 25 cm) and eluting with 40% ethanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, to give the free base of the title compound as the second eluting isomer and converted to the corresponding HCl salt by dissolution in ethanol, cooling to 0 °C, and the addition of 1 equiv of 0.01 M HCl in ethanol and afforded 56 mg 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-(3-((<i>R</i>)-1-(3-(methylsulfonyl)propyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>22</b>, 25% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, HCl salt) δ 7.74 (s, 1H), 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 7.26 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.29 (q, <i>J</i> = 7.0 Hz, 1H), 4.32–4.21 (m, 2H), 3.97 (dd, <i>J</i> = 9.0, 5.7 Hz, 2H), 3.50–3.37 (m, 2H), 3.25 (t, <i>J</i> = 7.4 Hz, 2H), 3.20–3.10 (m, 2H), 3.03 (s, 3H), 2.83–2.51 (m, 3H), 2.50 (s, 3H), 2.32–2.17 (m, 2H), 2.13–1.90 (m, 3H), 1.86 (d, <i>J</i> = 7.1 Hz, 3H), 1.83–1.67 (m, 1H), 1.25–1.11 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>35</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 565.19, found 565.0.</div></div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 4-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)butanoic Acid (<b>23</b>)</h3><div id="sec4_19_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl (<i>R</i>)-3-(piperidin-3-yl)azetidine-1-carboxylate (<i>R</i>)-11 (200 mg, 0.83 mmol) and methyl 4-oxobutanoate (96 mg, 0.83 mmol) in 1,2-dichloroethane (5 mL) at 23 °C for 1 h. Upon completion, the reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the desired product, which was purified by silica gel chromatography using 0–5% methanol/dichloromethane. Then the solvent was removed under reduced pressure to afford 234 mg (83%) of <i>tert</i>-butyl (<i>R</i>)-3-(1-(4-methoxy-4-oxobutyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>32</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 341.24, found 341.15.</div></div><div id="sec4_19_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>, where 234 mg (0.69 mmol) of <i>tert</i>-butyl (<i>R</i>)-3-(1-(4-methoxy-4-oxobutyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in dichloromethane (5 mL), and then HCl (5 mL, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 30 min and then concentrated under reduced pressure to afford 190 mg of methyl (<i>R</i>)-4-(3-(azetidin-3-yl)piperidin-1-yl)butanoate hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>[M + H]<sup>+</sup> 241.19, found 241.14.</div></div><div id="sec4_19_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude (<i>R</i>)-4-(3-(azetidin-3-yl)piperidin-1-yl)butanoate hydrochloride (85 mg, 0.31 mmol) from step 2 was dissolved in anhydrous dimethyl sulfoxide (2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (106 mg, 0.31 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.22 mL, 1.24 mmol) were added. The mixture was heated to 80 °C for 16 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford methyl 4-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)butanoic acid (84 mg, 50% yield).</div></div><div id="sec4_19_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Step 4</h4><div class="NLM_p last">Methyl 4-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)butanoic acid (84 mg, 0.15 mmol) was dissolved in 2 mL of methanol, and lithium hydroxide solution in water (18 mg, 0.75 mmol in 0.5 mL of water) was added. The mixture was stirred for 16 h at 23 °C, and then all solvent was removed <i>in vacuo</i> to dryness. A mixture of 2 mL of acetonitrile and 1 mL of 3 M HCl was added to the residue, and the solution was directly injected on reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min. 4-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)butanoic acid (<b>23</b>) was obtained in 90% yield (71 mg): <sup>1</sup>H NMR (400 MHz, acetonitrile-<i>d</i><sub>3</sub>, TFA salt) δ 8.03 (bs, 1H), 7.73 (s, 1H), 7.47 (d, 1H, <i>J</i> = 2.2 Hz), 7.41 (d, 1H, <i>J</i> = 8.5 Hz), 7.26 (dd, 1H, <i>J</i> = 2.2 Hz, <i>J</i> = 8.5 Hz), 6.25 (q, 1H, <i>J</i> = 7.1 Hz), 4.19 (td, 2H, <i>J</i> = 8.5 Hz, <i>J</i> = 15.4 Hz), 3.90 (dt, 2H, <i>J</i> = 5.7 Hz, <i>J</i> = 9.3 Hz), 3.50 (dd, 2H, <i>J</i> = 12.4 Hz, <i>J</i> = 24.1 Hz), 3.12–3.04 (m, 2H), 2.84–2.72 (m, 1H), 2.66–2.49 (m, 2H), 2.45 (s, 3H), 2.44 (t, 2H, <i>J</i> = 6.8 Hz), 2.16–2.04 (m, 1H), 2.03–1.68 (m, 8H), 1.13 (dq, 1H, <i>J</i> = 4.0 Hz, <i>J</i> = 12.9 Hz) ppm; LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 531.20, found 531.1.</div></div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 3-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propanoic Acid (<b>24</b>)</h3><div class="NLM_p">A mixture of the title compound and its diastereomer was prepared as follows:</div><div id="sec4_20_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_4" aria-label="General Procedure C">General Procedure C</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (420 mg, 1.75 mmol) and <i>tert</i>-butyl acrylate (0.77 mL, 5.25 mmol) in dimethylformamide (2 mL) at 50 °C for 3 h; then the volatiles were removed under reduced pressure to afford <i>tert</i>-butyl 3-(1-(3-(<i>tert</i>-butoxy)-3-oxopropyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>37</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 369.28, found 369.2.</div></div><div id="sec4_20_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude <i>tert</i>-butyl 3-(1-(3-(<i>tert</i>-butoxy)-3-oxopropyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in dichloromethane (5 mL), and then HCl (6 mL, 24 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 3 h and then concentrated under reduced pressure to afford 3-(3-(azetidin-3-yl)piperidin-1-yl)propanoic acid hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 213.16, found 213.2.</div></div><div id="sec4_20_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 3-(3-(azetidin-3-yl)piperidin-1-yl)propanoic acid hydrochloride from step 2 was dissolved in dimethyl sulfoxide (4 mL); then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (526 mg, 1.54 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (1.1 mL, 6.16 mmol) were added. The mixture was heated to 80 °C for 12 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 3-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propanoic acid 2,2,2-trifluoroacetate as a 1:1 mixture The title compound was separated from its diastereomer by SFC using an AD-H column (2 cm × 25 cm) and eluting with 40% isopropanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, to afford 159 mg of 3-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propanoic acid (<b>24</b>, 40% yield) as the first eluting isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; free base) δ 7.73 (s, 1H), 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 7.25 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.28 (q, <i>J</i> = 7.1 Hz, 1H), 4.25 (q, <i>J</i> = 9.0 Hz, 2H), 4.01–3.91 (m, 2H), 3.42–3.33 (m, 2H), 3.20–3.09 (m, 2H), 2.76–2.60 (m, 2H), 2.53 (t, <i>J</i> = 6.9 Hz, 2H), 2.49 (s, 3H), 2.11–1.98 (m, 1H), 1.99–1.88 (m, 3H), 1.86 (d, <i>J</i> = 7.1 Hz, 3H), 1.81–1.66 (m, 1H), 1.24–1.09 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>31</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 517.19, found 517.1.</div></div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 3-((<i>R</i>)-3-(1-(3-Cyano-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propanoic Acid (<b>25</b>)</h3><div id="sec4_21_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_4" aria-label="General Procedure C">General Procedure C</a> using <i>tert</i>-butyl 3-[(3<i>R</i>)-3-piperidyl]azetidine-1-carboxylate (<i>R</i>)-<b>11</b> (3 g, 7.64 mmol) and ethyl acrylate (2.5 mL, 22.9 mmol) in dimethylformamide (10 mL) at 65 °C for 3 h; then the volatiles were removed under reduced pressure to afford <i>tert</i>-butyl 3-[(3<i>R</i>)-1-(3-ethoxy-3-oxo-propyl)-3-piperidyl]azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>33</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 341.24, found 341.1.</div></div><div id="sec4_21_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl 3-[(3<i>R</i>)-1-(3-ethoxy-3-oxo-propyl)-3-piperidyl]azetidine-1-carboxylate (200 mg, 0.587 mmol) from step 1 was dissolved in methanol (3 mL), and then HCl (5 mL, 20 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 3 h and then concentrated under reduced pressure. The residue was dissolved in a mixture of THF/water/ethanol (3:1:1, 5 mL), then lithium hydroxide was added (94 mg, 4.11 mmol), and the mixture was stirred at 23 °C for 24 h and then acidified to pH 4 with HCl (4 N in 1,4-dioxane). The volatiles were removed under reduced pressure to afford 3-[(3<i>R</i>)-3-(azetidin-3-yl)-1-piperidyl]propanoic acid hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 213.16, found 213.2.</div></div><div id="sec4_21_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 3-[(3<i>R</i>)-3-(azetidin-3-yl)-1-piperidyl]propanoic acid hydrochloride from step 2 was dissolved in dimethyl sulfoxide (1.5 mL); then 6-chloro-1-[(1<i>R</i>)-1-(2,4-dichlorophenyl)ethyl]pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile <b>15b</b> (207 mg, 0.587 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.307 mL, 1.76 mmol) were added. The mixture was heated to 50 °C for 12 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 169 mg of 3-((<i>R</i>)-3-(1-(3-cyano-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propanoic acid (<b>25</b>, 32% yield): <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>, TFA salt) δ 11.39 (bs, 1H), 8.00 (s, 1H), 7.51 (d, <i>J</i> = 2.1 Hz, 1H), 7.49 (d, <i>J</i> = 8.5 Hz, 1H), 7.38 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.46 (q, <i>J</i> = 7.0 Hz, 1H), 4.49–4.26 (m, 2H), 4.22–4.10 (m, 2H), 3.84–3.63 (m, 2H), 3.56–3.40 (m, 2H), 3.12–2.94 (m, 2H), 2.90–2.69 (m, 2H), 2.49–2.29 (m, 1H), 2.04–1.94 (m, 4H), 1.92 (d, <i>J</i> = 7.1 Hz, 3H), 1.29 (s, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>28</sub>C<sub>l2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 528.17, found 528.0.</div></div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 2-((<i>R</i>)-3-(1-(3-Cyano-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)acetic Acid (<b>26</b>)</h3><div id="sec4_22_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-[(3<i>R</i>)-3-piperidyl]azetidine-1-carboxylate (<i>R</i>)-<b>11</b> (1.72 g, 7.16 mmol), ethyl glyoxalate (1.35 mL, 8.59 mmol, 50% in toluene), and sodium triacetoxyborohydride (3.79 g, 17.9 mmol) in 1,2-dichloroethane (35 mL) at 23 °C for 1 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure and afforded <i>tert</i>-butyl (<i>R</i>)-3-(1-(2-ethoxy-2-oxoethyl)piperidin-3-yl)azetidine-1-carboxylate (99% yield). The crude was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>31</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 327.23, found 327.2.</div></div><div id="sec4_22_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl (<i>R</i>)-3-(1-(2-ethoxy-2-oxoethyl)piperidin-3-yl)azetidine-1-carboxylate (200 mg, 0.613 mmol) from step 1 was dissolved in dichloromethane (3 mL), and then HCl (0.76 mL, 3.06 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 4 h and then concentrated under reduced pressure. The residue was dissolved in a mixture of 1,4-dioxane/water (3:1, 4 mL), then lithium hydroxide was added (44 mg, 1.84 mmol), and the mixture was stirred at 50 °C for 1 h and then acidified to pH 4 with HCl (4 N in 1,4-dioxane). The volatiles were removed under reduced pressure to afford (<i>R</i>)-2-(3-(azetidin-3-yl)piperidin-1-yl)acetic acid hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 199.14, found 199.1.</div></div><div id="sec4_22_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. (<i>R</i>)-2-(3-(Azetidin-3-yl)piperidin-1-yl)acetic acid hydrochloride (129 mg, 0.55 mmol) was dissolved in dichloromethane (2.6 mL), and then 6-chloro-1-[(1<i>R</i>)-1-(2,4-dichlorophenyl)ethyl]pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile <b>15b</b> (178 mg, 0.51 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.26 mL, 1.52 mmol) were added. The mixture was stirred at 23 °C for 2 h and then concentrated under reduced pressure. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 2-((<i>R</i>)-3-(1-(3-cyano-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)acetic acid (<b>26</b>, 99% yield). The title compound was converted to the corresponding besylate salt by dissolution in dichloromethane, cooling to 0 °C, and the addition of 1 equiv of benzenesulfonic acid in dichloromethane followed by concentration under reduced pressure: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, besylate salt) δ 7.95 (s, 1H), 7.87–7.80 (m, 2H), 7.48 (d, <i>J</i> = 2.1 Hz, 1H), 7.44–7.39 (m, 3H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.32 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.46 (q, <i>J</i> = 7.0 Hz, 1H), 4.40–4.19 (m, 2H), 4.04 (s, 2H), 4.03–3.95 (m, 2H), 3.76–3.50 (m, 2H), 3.10–2.94 (m, 1H), 2.90–2.75 (m, 1H), 2.75–2.61 (m, 1H), 2.30–2.13 (m, 1H), 2.08–1.93 (m, 2H), 1.91 (d, <i>J</i> = 7.0 Hz, 3H), 1.88–1.78 (m, 1H), 1.33–1.09 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 514.15, found 514.0.</div></div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 3-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propanamide (<b>27</b>)</h3><div class="NLM_p">A mixture of the title compound and its diastereomer was prepared as follows:</div><div id="sec4_23_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_4" aria-label="General Procedure C">General Procedure C</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (200 mg, 0.83 mmol) and <i>tert</i>-butyl acrylamide (148 mg, 2.08 mmol) in dimethylformamide (1 mL) at 50 °C for 3 h; then the volatiles were removed under reduced pressure, and the residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–20%) and afforded <i>tert</i>-butyl 3-(1-(3-amino-3-oxopropyl)piperidin-3-yl)azetidine-1-carboxylate (96% yiled); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 312.23, found 312.2.</div></div><div id="sec4_23_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl 3-(1-(3-amino-3-oxopropyl)piperidin-3-yl)azetidine-1-carboxylate (249 mg, 0.8 mmol) from step 1 was dissolved in dichloromethane (4 mL), and then trifluoroacetic acid (1 mL, 13.07 mmol) was added. The mixture was stirred at 23 °C for 8 h and then concentrated under reduced pressure to afford 3-(3-(azetidin-3-yl)piperidin-1-yl)propanamide 2,2,2-trifluoroacetate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>22</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 212.18, found 212.2.</div></div><div id="sec4_23_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 3-(3-(azetidin-3-yl)piperidin-1-yl)propanamide 2,2,2-trifluoroacetate from step 2 was dissolved in dimethyl sulfoxide (2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (273 mg, 0.80 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.56 mL, 3.2 mmol) were added. The mixture was heated to 80 °C for 12 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 3-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propanamide 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomers. The mixture of diastereomers was basified using a basification column (PL-HCO3MP SPE, 500 mg per 5 mL tube, Agilent) using dichloromethane and methanol (4:1) as an eluent and concentrated under reduced pressure. The residue was separated by preparative chiral HPLC using a Chiralpak ID column (Daicel Corporation, West Chester, PA) and 20% ethanol in heptanes (0.1% diethylamine) as an eluent and afforded 42 mg of 3-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propenamide (<b>27</b>,20% yield) as the second eluting isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; free base) δ 8.09 (bs, 1H), 7.64 (s, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 1H), 7.34 (d, <i>J</i> = 2.1 Hz, 1H), 7.12 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.31 (q, <i>J</i> = 7.1 Hz, 1H), 5.54 (bs, 1H), 4.25–4.11 (m, 2H), 3.91–3.77 (m, 2H), 2.89 (t, <i>J</i> = 12.3 Hz, 2H), 2.68–2.56 (m, 3H), 2.56 (s, 3H), 2.46–2.37 (m, 2H), 2.08–1.95 (m, 1H), 1.88 (d, <i>J</i> = 7.1 Hz, 3H), 1.86–1.65 (m, 4H), 1.63–1.49 (m, 1H), 1.03–0.85 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 516.20, found 516.0.</div></div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> <i>N</i>-(2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)acetamide (<b>28</b>)</h3><div id="sec4_24_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> or enantioenriched (<i>R</i>)-<b>11</b> (300 mg, 1.25 mmol), 3-(1,3-dioxoisoindolin-2-yl)propanal (236 mg, 1.25 mmol, 50% in toluene), and sodium triacetoxyborohydride (529 mg, 2.5 mmol) in 1,2-dichloroethane (5 mL) at 23 °C for 15 min. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (5 mL), and then hydrazine hydrate (0.24 mL, 5.0 mmol) was added. The mixture was stirred at 23 °C for 18 h, and then the mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude <i>tert</i>-butyl 3-[1-(2-aminoethyl)-3-piperidyl]azetidine-1-carboxylate (120 mg, 0.423 mmol) was dissolved in dichloromethane (2 mL), and then triethylamine (0.18 mL, 1.27 mmol) and acetyl chloride (36 μL, 0.508 mmol) were added. The mixture was stirred at 23 °C for 30 min and then quenched with aqueous sodium carbonate (10 mL, 1 M) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressured and afforded <i>tert</i>-butyl 3-(1-(2-acetamidoethyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 326.24, found 326.2.</div></div><div id="sec4_24_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude <i>tert</i>-butyl 3-(1-(2-acetamidoethyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in dichloromethane (4 mL), and then HCl (0.50 mL, 2.0 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure to afford <i>N</i>-(2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)acetamide hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>24</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 226.19, found 226.1.</div></div><div id="sec4_24_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude <i>N</i>-(2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)acetamide hydrochloride from step 2 was dissolved in dimethylformamide (1 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (72 mg, 0.21 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.18 mL, 1.05 mmol) were added. The mixture was heated to 80 °C for 4 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford <i>N</i>-(2-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)acetamide 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomers (if racemic <b>11</b> was used). The title compound was separated from its diastereomer by SFC using an AD-H column (2 × 25 cm) and eluting with 25% ethanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, to give the free base of the title compound as the first eluting isomer and converted to the corresponding HCl salt by dissolution in ethanol, cooling to 0 °C, and the addition of 1 equiv of 0.01 M HCl in ethanol and afforded 11 mg of <i>N</i>-(2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)acetamide (<b>28</b>, 19% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 7.75 (s, 1H), 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 7.26 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.29 (q, <i>J</i> = 7.1 Hz, 1H), 4.27 (q, <i>J</i> = 9.0 Hz, 2H), 4.06–3.94 (m, 2H), 3.79–3.61 (m, 2H), 3.58–3.48 (m, 1H), 3.25 (t, <i>J</i> = 5.8 Hz, 2H), 2.99–2.86 (m, 1H), 2.72–2.62 (m, 2H), 2.50 (s, 3H), 2.15–1.85 (m, 4H), 1.99 (s, 3H), 1.86 (d, <i>J</i> = 7.1 Hz, 3H), 1.85–1.77 (m, 1H), 1.27–1.19 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 530.22, found 530.1.</div></div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> <i>N</i>-(2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)isobutyramide (<b>29</b>)</h3><div class="NLM_p">A mixture of the title compound and its diastereomer was prepared as follows:</div><div id="sec4_25_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (300 mg, 1.25 mmol), 3-(1,3-dioxoisoindolin-2-yl)propanal (236 mg, 1.25 mmol, 50% in toluene), and sodium triacetoxyborohydride (529 mg, 2.5 mmol) in 1,2-dichloroethane (5 mL) at 23 °C for 15 min. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (5 mL), and then hydrazine hydrate (0.24 mL, 5.0 mmol) was added. The mixture was stirred at 23 °C for 18 h, and then mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude <i>tert</i>-butyl 3-[1-(2-aminoethyl)-3-piperidyl]azetidine-1-carboxylate (120 mg, 0.423 mmol) was dissolved in dimethylformamide (2 mL), and then triethylamine (0.18 mL, 1.27 mmol), isobutyric acid (46 μL, 0.508 mmol), and HATU (193 mg, 0.508 mmol) were added. The mixture was stirred at 23 °C for 30 min, quenched with aqueous sodium carbonate (10 mL, 1 M), and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressured and afforded <i>tert</i>-butyl 3-(1-(2-isobutyramidoethyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>36</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 354.28, found 354.2.</div></div><div id="sec4_25_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude <i>tert</i>-butyl 3-(1-(2-isobutyramidoethyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in dichloromethane (4 mL), and then HCl (0.50 mL, 2.0 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure to afford <i>N</i>-(2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)isobutyramide hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>28</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 254.22, found 254.1.</div></div><div id="sec4_25_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude <i>N</i>-(2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)isobutyramide hydrochloride from step 2 was dissolved in dimethylformamide (1 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (72 mg, 0.21 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.18 mL, 1.05 mmol) were added. The mixture was heated to 80 °C for 4 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford <i>N</i>-(2-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)isobutyramide 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomers. The title compound was separated from its diastereomer by SFC using an AD-H column (2 × 25 cm) and eluting with 25% ethanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, to give the free base of the title compound as the first eluting isomer and converted to the corresponding HCl salt by dissolution in ethanol, cooling to 0 °C, and the addition of 1 equiv of 0.01 M HCl in ethanol and afforded 12 mg (20% yield) of <i>N</i>-(2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)isobutyramide (<b>29</b>): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 7.75 (s, 1H), 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 1H), 7.25 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.29 (q, <i>J</i> = 7.1 Hz, 1H), 4.33–4.21 (m, 2H), 4.05–3.92 (m, 2H), 3.73–3.55 (m, 4H), 3.28–3.20 (m, 2H), 3.01–2.87 (m, 1H), 2.76–2.62 (m, 2H), 2.50 (s, 3H), 2.22–1.88 (m, 5H), 1.86 (d, <i>J</i> = 7.1 Hz, 3H), 1.32–1.18 (m, 1H), 1.13 (d, <i>J</i> = 6.9 Hz, 6H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>38</sub>Cl<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 558.25, found 558.1.</div></div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Methyl (2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)carbamate (<b>30</b>)</h3><div class="NLM_p">A mixture of the title compound and its diastereomer was prepared as follows:</div><div id="sec4_26_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (300 mg, 1.25 mmol), 3-(1,3-dioxoisoindolin-2-yl)propanal (236 mg, 1.25 mmol, 50% in toluene), and sodium triacetoxyborohydride (529 mg, 2.5 mmol) in 1,2-dichloroethane (5 mL) at 23 °C for 15 min. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (5 mL), and then hydrazine hydrate (0.24 mL, 5.0 mmol) was added. The mixture was stirred at 23 °C for 18 h, and then the mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude <i>tert</i>-butyl 3-[1-(2-aminoethyl)-3-piperidyl]azetidine-1-carboxylate (120 mg, 0.423 mmol) was dissolved in dichloromethane (2 mL), and then triethylamine (0.18 mL, 1.27 mmol) and methyl chloroformate (39 μL, 0.508 mmol) were added. The mixture was stirred at 23 °C for 30 min, then quenched with aqueous sodium carbonate (10 mL, 1 M), and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressured and afforded <i>tert</i>-butyl 3-(1-(2-((methoxycarbonyl)amino)ethyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>32</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 342.24, found 342.1.</div></div><div id="sec4_26_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude <i>tert</i>-butyl 3-(1-(2-((methoxycarbonyl)amino)ethyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in dichloromethane (4 mL), and then HCl (0.50 mL, 2.0 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 1 h and then concentrated under reduced pressure to afford methyl (2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)carbamate hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 242.19, found 242.2.</div></div><div id="sec4_26_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude methyl (2-(3-(azetidin-3-yl)piperidin-1-yl)ethyl)carbamate hydrochloride from step 2 was dissolved in dimethylformamide (1 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (72 mg, 0.21 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.18 mL, 1.05 mmol) were added. The mixture was heated to 80 °C for 4 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford methyl (2-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)carbamate 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomers. The title compound was separated from its diastereomer by SFC using an AD-H column (2 × 25 cm) and eluting with 35% isopropanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, to give the free base of the title compound as the first eluting isomer and converted to the corresponding HCl salt by dissolution in ethanol, cooling to 0 °C, and the addition of 1 equiv of 0.01 M HCl in ethanol and afforded 9 mg of methyl (2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethyl)carbamate(<b>30</b>, 55% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 7.74 (s, 1H), 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 7.25 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.29 (q, <i>J</i> = 7.1 Hz, 1H), 4.33–4.22 (m, 2H), 4.03–3.94 (m, 2H), 3.67 (s, 3H), 3.64–3.42 (m, 2H), 3.19 (d, <i>J</i> = 11.5 Hz, 3H), 2.86 (s, 1H), 2.72–2.55 (m, 2H), 2.50 (s, 3H), 2.16–1.90 (m, 4H), 1.86 (d, <i>J</i> = 7.1 Hz, 3H), 1.85–1.75 (m, 1H), 1.34–1.20 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 546.22, found 546.1.</div></div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 6-(3-((<i>R</i>)-1-((1<i>H</i>-Imidazol-5-yl)methyl)piperidin-3-yl)azetidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>31</b>)</h3><div class="NLM_p">A mixture of the title compound and its diastereomer was prepared as follows:</div><div id="sec4_27_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (200 mg, 0.83 mmol), 1<i>H</i>-imidazole-5-carbaldehyde (120 mg, 1.25 mmol), and sodium triacetoxyborohydride (265 mg, 1.25 mmol) in 1,2-dichloroethane (2 mL) at 23 °C for 1 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure and afforded <i>tert</i>-butyl 3-(1-((1<i>H</i>-imidazol-5-yl)methyl)piperidin-3-yl)azetidine-1-carboxylate. The crude was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 321.23, found 321.1.</div></div><div id="sec4_27_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude <i>tert</i>-butyl 3-(1-((1<i>H</i>-imidazol-5-yl)methyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in methanol (1 mL), and then HCl (2 mL, 4 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 4 h and then concentrated under reduced pressure to afford 1-((1<i>H</i>-imidazol-5-yl)methyl)-3-(azetidin-3-yl)piperidine dihydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>21</sub>N<sub>4</sub> [M + H]<sup>+</sup> 221.1, found 221.1.</div></div><div id="sec4_27_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. 1-((1<i>H</i>-Imidazol-5-yl)methyl)-3-(azetidin-3-yl)piperidine dihydrochloride (243 mg, 0.83 mmol) was dissolved in dichloromethane (2 mL), and then 6-chloro-1-[(1<i>R</i>)-1-(2,4-dichlorophenyl)ethyl]pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile <b>15b</b> (293 mg, 0.83 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.5 mL, 2.91 mmol) were added. The mixture was stirred at 23 °C for 2 h and then concentrated under reduced pressure. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 6-(3-(1-((1<i>H</i>-imidazol-5-yl)methyl)piperidin-3-yl)azetidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomers. The title compound was separated from its diastereomer by SFC using an AD-H column (2 × 25 cm) and eluting with 30% isopropanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, to give 76 mg of 6-(3-((<i>R</i>)-1-((1<i>H</i>-imidazol-5-yl)methyl)piperidin-3-yl)azetidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>31</b>, 35% yield) as the second eluting isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD, Free base) δ 7.93 (s, 1H), 7.63 (d, <i>J</i> = 1.2 Hz, 1H), 7.48 (d, <i>J</i> = 2.1 Hz, 1H), 7.38 (d, <i>J</i> = 8.5 Hz, 1H), 7.31 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 7.00 (s, 1H), 6.45 (q, <i>J</i> = 7.0 Hz, 1H), 4.31–4.17 (m, 2H), 4.00–3.84 (m, 2H), 3.57 (s, 2H), 2.96–2.84 (m, 2H), 2.66–2.53 (m, 1H), 2.11–2.01 (m, 1H), 1.90 (d, <i>J</i> = 7.0 Hz, 3H), 1.86–1.69 (m, 4H), 1.65–1.51 (m, 1H), 0.96–0.83 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>9</sub> [M + H]<sup>+</sup> 536.18, found 536.0.</div></div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> 6-(3-((<i>R</i>)-1-(Cyanomethyl)piperidin-3-yl)azetidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>32</b>)</h3><div id="sec4_28_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_3" aria-label="General Procedure B">General Procedure B</a> using <i>tert</i>-butyl (R)-3-(piperidin-3-yl)azetidine-1-carboxylate (<i>R</i>)-<b>11</b> (275 mg, 1.14 mmol), 2-bromoacetonitrile (192 mg, 1.6 mmol), potassium iodide (4 mg, 0.02 mmol), and potassium carbonate (316 mg, 2.29 mmol) in acetonitrile (4.4 mL) at 90 °C for 12 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3×); the combined organic fractions were dried over sodium sulfate, filtered, and concentrated under reduced pressure, and <i>tert</i>-butyl (<i>R</i>)-3-(1-(cyanomethyl)piperidin-3-yl)azetidine-1-carboxylate was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 280.20, found 280.2.</div></div><div id="sec4_28_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl (<i>R</i>)-3-(1-(cyanomethyl)piperidin-3-yl)azetidine-1-carboxylate (300 mg, 1.07 mmol) from step 1 was dissolved in dichloromethane (10 mL), and then HCl (2 mL, 8 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 3 h and then concentrated under reduced pressure to afford (<i>R</i>)-2-(3-(azetidin-3-yl)piperidin-1-yl)acetonitrile hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>17</sub>N<sub>3</sub> [M + H]<sup>+</sup> 180.15, found 180.2.</div></div><div id="sec4_28_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude (<i>R</i>)-2-(3-(azetidin-3-yl)piperidin-1-yl)acetonitrile hydrochloride from step 2 was dissolved in dichloromethane (1.2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile <b>15b</b> (120 mg, 0.34 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.30 mL, 1.70 mmol) were added. The mixture was stirred at 23 °C for 12 h. The reaction was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate solution. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure, and the residue was purified by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 97 mg of 6-(3-((<i>R</i>)-1-(cyanomethyl)piperidin-3-yl)azetidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile 2,2,2-trifluoroacetate (<b>32</b>, 59% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; TFA salt) δ 7.95 (s, 1H), 7.48 (d, <i>J</i> = 2.1 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.31 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.45 (q, <i>J</i> = 7.0 Hz, 1H), 4.36–4.24 (m, 2H), 4.04–3.95 (m, 4H), 3.15 (d, <i>J</i> = 11.3 Hz, 2H), 2.76–2.66 (m, 1H), 2.67–2.58 (m, 1H), 2.35 (t, <i>J</i> = 11.0 Hz, 1H), 2.05–1.97 (m, 2H), 1.95–1.84 (m, 1H), 1.90 (d, <i>J</i> = 7.0 Hz, 3H), 1.79–1.62 (m, 1H), 1.16–0.98 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>8</sub> [M + H]<sup>+</sup> 495.16, found 495.2.</div></div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> 6-(3-((<i>R</i>)-1-(2-Cyanoethyl)piperidin-3-yl)azetidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>33</b>)</h3><div id="sec4_29_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_4" aria-label="General Procedure C">General Procedure C</a> using <i>tert</i>-butyl (<i>R</i>)-3-(piperidin-3-yl)azetidine-1-carboxylate (<i>R</i>)-<b>11</b> (115 mg, 0.48 mmol) and acrylonitrile (0.03 mL, 0.48 mmol) in dichloromethane (2 mL) at 23 °C for 16 h; then the volatiles were removed under reduced pressure, and the <i>tert</i>-butyl (<i>R</i>)-3-(1-(2-cyanoethyl)piperidin-3-yl)azetidine-1-carboxylate was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>27</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 294.22, found 294.2.</div></div><div id="sec4_29_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl (<i>R</i>)-3-(1-(2-cyanoethyl)piperidin-3-yl)azetidine-1-carboxylate (130 mg, 0.44 mmol) from step 1 was dissolved in dichloromethane (2 mL), and then HCl (1 mL, 4 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 2 h and then concentrated under reduced pressure to afford (<i>R</i>)-3-(3-(azetidin-3-yl)piperidin-1-yl)propanenitrile hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>19</sub>N<sub>3</sub> [M + H]<sup>+</sup> 194.17, found 194.2.</div></div><div id="sec4_29_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude (<i>R</i>)-3-(3-(azetidin-3-yl)piperidin-1-yl)propanenitrile hydrochloride from step 2 was dissolved in dichloromethane (1.2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile <b>15b</b> (80 mg, 0.23 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.20 mL, 1.13 mmol) were added. The mixture was stirred at 23 °C for 12 h. The reaction was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate solution. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–10%) to afford 73 mg of 6-(3-((<i>R</i>)-1-(2-cyanoethyl)piperidin-3-yl)azetidin-1-yl)-1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>33</b>, 63% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; BsOH Salt) δ 8.20 (s, 1H), 8.12–8.04 (m, 2H), 7.74 (d, <i>J</i> = 2.1 Hz, 1H), 7.66–7.60 (m, 4H), 7.57 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.71 (q, <i>J</i> = 7.1 Hz, 1H), 4.64–4.48 (m, 2H), 4.36–4.20 (m, 2H), 3.97–3.82 (m, 2H), 3.78 (t, <i>J</i> = 7.2 Hz, 2H), 3.35 (t, <i>J</i> = 7.2 Hz, 2H), 3.30–3.19 (m, 2H), 3.02 (t, <i>J</i> = 12.0 Hz, 1H), 2.98–2.86 (m, 1H), 2.46–2.27 (m, 2H), 2.16 (d, <i>J</i> = 7.1 Hz, 3H), 2.25–2.02 (m, 1H), 1.59–1.38 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>8</sub> [M + H]<sup>+</sup> 509.17, found 509.2.</div></div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-6-(3-((<i>R</i>)-1-(3,3,3-trifluoropropyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>34</b>)</h3><div id="sec4_30_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_3" aria-label="General Procedure B">General Procedure B</a> using <i>tert</i>-butyl (<i>R</i>)-3-(piperidin-3-yl)azetidine-1-carboxylate (<i>R</i>)-<b>11</b> (1.1 g, 4.58 mmol) and 3-iodo-1,1,1-trifluoropropane (0.64 mL, 5.49 mmol), potassium iodide (15 mg, 0.02 mmol), and potassium carbonate (1.27 g, 9.15 mmol) in acetonitrile (22 mL) at 80 °C for 12 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3×); the combined organic fractions were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was dissolved in dichloromethane and filtered through a silica gel plug using 50% ethyl acetate in hexanes and concentrated, yielding <i>tert</i>-butyl (<i>R</i>)-3-(1-(3,3,3-trifluoropropyl)piperidin-3-yl)azetidine-1-carboxylate (90% yield), which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>27</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 337.21, found 337.2.</div></div><div id="sec4_30_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl (<i>R</i>)-3-(1-(3,3,3-trifluoropropyl)piperidin-3-yl)azetidine-1-carboxylate (1.40 g, 4.16 mmol) from step 1 was dissolved in dichloromethane (28 mL), and then HCl (5.2 mL, 20.8 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 5 h and then concentrated under reduced pressure to afford (<i>R</i>)-3-(azetidin-3-yl)-1-(3,3,3-trifluoropropyl)piperidine hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>19</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 237.16, found 237.2.</div></div><div id="sec4_30_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude (<i>R</i>)-3-(azetidin-3-yl)-1-(3,3,3-trifluoropropyl)piperidine hydrochloride (96 mg, 0.35 mmol) from step 2 was dissolved in dichloromethane (1.4 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (100 mg, 0.29 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.15 mL, 0.88 mmol) were added. The mixture was stirred at 23 °C for 4 h. The reaction was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate solution. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of ethyl acetate in hexanes (0 to 75%) to afford 15 mg of 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-6-(3-((<i>R</i>)-1-(3,3,3-trifluoropropyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine (<b>34</b>, 10% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; free base) δ 7.64 (s, 1H), 7.38 (d, <i>J</i> = 8.5 Hz, 1H), 7.35 (d, <i>J</i> = 2.2 Hz, 1H), 7.14 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.31 (q, <i>J</i> = 7.1 Hz, 1H), 4.19 (td, <i>J</i> = 8.4, 4.2 Hz, 2H), 3.90–3.82 (m, 2H), 2.87–2.72 (m, 2H), 2.64–2.57 (m, 2H), 2.57, s, 3H), 2.39–2.23 (m, 2H), 2.06 = 1.94 (m, 1H), 1.89 (d, <i>J</i> = 7.1 Hz, 3H), 1.86–1.65 (m, 5H), 1.63–1.50 (m, 1H), 0.99–0.82 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>29</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>6</sub> [M + H]<sup>+</sup> 541.19, found 541.2.</div></div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(3,3,3-trifluoropropyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>35</b>)</h3><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. (<i>R</i>)-3-(Azetidin-3-yl)-1-(3,3,3-trifluoropropyl)piperidine 56 (R<sub>1</sub> = CH<sub>2</sub>CF<sub>3</sub>) hydrochloride (93 mg, 0.34 mmol) was dissolved in dichloromethane (1.4 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile <b>15b</b> (100 mg, 0.28 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.15 mL, 0.88 mmol) were added. The mixture was stirred at 23 °C for 12 h. The reaction was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate solution. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–10%) to afford 115 mg of 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(3,3,3-trifluoropropyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (35, 78% yield): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; free base) δ 7.81 (s, 1H), 7.37 (d, <i>J</i> = 2.1 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 7.19 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.45 (q, <i>J</i> = 7.1 Hz, 1H), 4.30–4.18 (m, 2H), 3.96–3.85 (m, 2H), 2.84–2.72 (m, 2H), 2.71–2.51 (m, 2H), 2.39–2.20 (m, 2H), 2.06–1.97 (m, 1H), 1.89 (d, <i>J</i> = 7.1 Hz, 3H), 1.87–1.67 (m, 5H), 1.65–1.46 (m, 1H), 1.00–0.80 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>26</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>7</sub> [M + H]<sup>+</sup> 552.17, found 552.2.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> 3-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propan-1-ol (<b>36</b>)</h3><div class="NLM_p">A mixture of the title compound and its diastereomer was prepared as follows:</div><div id="sec4_32_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Step 1</h4><div class="NLM_p last">The alkylation was performed according to <a class="ref internalNav" href="#sec4_3" aria-label="General Procedure B">General Procedure B</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (350 mg, 1.46 mmol) and methyl acrylate (0.4 mL, 4.38 mmol) in dimethylformamide (3 mL) at 50 °C for 3 h, and then the volatiles were removed under reduced pressure. The residue was dissolved in tetrahydrofuran (10 mL), and then lithium borohydride (128 mg, 5.84 mmol) and methanol (280 μL, 8.76 mmol) were added. The mixture was stirred at 50 °C for 24 h, quenched with aqueous ammonium chloride (10 mL, 1 M), and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressured. The residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–10%) and <i>tert</i>-butyl 3-(1-(3-hydroxypropyl)piperidin-3-yl)azetidine-1-carboxylate (44% yield): LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>31</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 299.23, found 299.2.</div></div><div id="sec4_32_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl 3-(1-(3-hydroxypropyl)piperidin-3-yl)azetidine-1-carboxylate (190 mg, 0.64 mmol) from step 1 was dissolved in dichloromethane (5 mL), and then HCl (2 mL, 8 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 30 min and then concentrated under reduced pressure to afford 3-(3-(azetidin-3-yl)piperidin-1-yl)propan-1-ol hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>23</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 199.18, found 199.2.</div></div><div id="sec4_32_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 3-(3-(azetidin-3-yl)piperidin-1-yl)propan-1-ol hydrochloride from step 2 was dissolved in dimethyl sulfoxide (4 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (189 mg, 0.55 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.38 mL, 2.20 mmol) were added. The mixture was heated to 80 °C for 12 h and then cooled to 23 °C. The mixture was purified directly by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 3-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propan-1-ol 2,2,2-trifluoroacetate as a 1:1 mixture of diastereomers. The title compound was separated from its diastereomer by preparative chiral HPLC using a CHIRALCEL OZ-H column (Daicel Corporation, West Chester, PA) and 20% ethanol in heptanes (0.1% diethylamine) as an eluent and afforded 69 mg of 3-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)propan-1-ol (<b>36</b>, 50% yield) as the first eluting isomer: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; free base) δ 7.64 (s, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 7.34 (d, <i>J</i> = 2.1 Hz, 1H), 7.13 (dd, <i>J</i> = 8.6, 2.2 Hz, 1H), 6.31 (q, <i>J</i> = 7.1 Hz, 1H), 4.19 (t, <i>J</i> = 8.4 Hz, 2H), 3.91 (dd, <i>J</i> = 8.6, 5.9 Hz, 1H), 3.85 (dd, <i>J</i> = 8.5, 5.9 Hz, 1H), 3.80 (t, <i>J</i> = 5.2 Hz, 2H), 3.07–2.90 (m, 3H), 2.62 (t, <i>J</i> = 5.6 Hz, 2H), 2.56 (s, 3H), 2.55–2.51 (m, 1H), 2.08–1.93 (m, 1H), 1.89 (d, <i>J</i> = 7.1 Hz, 3H), 1.87–1.66 (m, 5H), 1.65–1.50 (m, 1H), 1.02–0.86 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 503.21, found 503.0.</div></div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> 2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol (<b>37</b>)</h3><div id="sec4_33_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> or enantioenriched (<i>R</i>)-<b>11</b> (200 mg, 0.83 mmol), 2-((<i>tert</i>-butyldimethylsilyl)oxy)acetaldehyde (145 mg, 0.83 mmol), and sodium triacetoxyborohydride (352 mg, 1.66 mmol) in 1,2-dichloroethane (5 mL) at 23 °C for 2 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure, and the residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–10%) and afforded <i>tert</i>-butyl 3-(1-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethyl)piperidin-3-yl)azetidine-1-carboxylate (88% yield): LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>43</sub>N<sub>2</sub>O<sub>3</sub>Si [M + H]<sup>+</sup> 399.30, found 399.2.</div></div><div id="sec4_33_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl 3-(1-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethyl)piperidin-3-yl)azetidine-1-carboxylate (290 mg, 0.73 mmol) from step 1 was dissolved in dichloromethane (5 mL), and then HCl (3 mL, 12 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 90 min and then concentrated under reduced pressure to afford 2-(3-(azetidin-3-yl)piperidin-1-yl)ethan-1-ol hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>21</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 185.17, found 185.2.</div></div><div id="sec4_33_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 2-(3-(azetidin-3-yl)piperidin-1-yl)ethan-1-ol hydrochloride from step 2 was dissolved in dimethylformamide (2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine <b>15a</b> (137 mg, 0.40 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.36 mL, 2.05 mmol) were added. The mixture was heated to 80 °C for 3 h and then cooled to 23 °C and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–20%) and afforded 2-(3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol as a 1:1 mixture of diastereomers (if racemic <b>11</b> was used). The title compound was separated from its diastereomer by SFC using an AD-H column (2 × 25 cm) and eluting with 40% isopropanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, and afforded 68 mg of 2-((<i>R</i>)-3-(1-(1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol(<b>37</b>, 70% yield) as the first eluting isomer.: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>; free base) δ 7.64 (s, 1H), 7.38 (d, <i>J</i> = 8.5 Hz, 1H), 7.35 (d, <i>J</i> = 2.1 Hz, 1H), 7.14 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.32 (q, <i>J</i> = 7.1 Hz, 1H), 4.23–4.14 (m, 2H), 3.92–3.83 (m, 2H), 3.67–3.58 (m, 2H), 2.87 (t, <i>J</i> = 10.5 Hz, 2H), 2.66–2.58 (m, 1H), 2.57 (s, 3H), 2.34–2.21 (m, 2H), 2.09 (t, <i>J</i> = 11.2 Hz, 1H), 1.89 (d, <i>J</i> = 7.1 Hz, 3H), 1.87–1.69 (m, 4H), 1.69–1.53 (m, 1H), 1.03–0.89 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>31</sub>Cl<sub>2</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 489.19, found 489.1.</div></div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-<i>N</i>-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>38</b>)</h3><div id="sec4_34_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl (<i>R</i>)-3-(piperidin-3-yl)azetidine-1-carboxylate (<i>R</i>)-11 (8.25 g, 34.3 mmol), 2-((<i>tert</i>-butyldimethylsilyl)oxy)acetaldehyde (5.98 g, 34.3 mmol), and sodium triacetoxyborohydride (18.17 g, 85.75 mmol) in 1,2-dichloroethane (172 mL) at 23 °C for 2 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure and afforded <i>tert</i>-butyl (<i>R</i>)-3-(1-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>43</sub>N<sub>2</sub>O<sub>3</sub>Si [M + H]<sup>+</sup> 399.30, found 399.2.</div></div><div id="sec4_34_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. The crude <i>tert</i>-butyl (<i>R</i>)-3-(1-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethyl)piperidin-3-yl)azetidine-1-carboxylate from step 1 was dissolved in dichloromethane (68.6 mL), and then HCl (42.88 mL, 171.5 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 2 h and then concentrated under reduced pressure to afford (<i>R</i>)-2-(3-(azetidin-3-yl)piperidin-1-yl)ethan-1-ol hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>21</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 185.17, found 185.2.</div></div><div id="sec4_34_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. (<i>R</i>)-2-(3-(Azetidin-3-yl)piperidin-1-yl)ethan-1-ol hydrochloride (7.57 g, 34.3 mmol) from step 2 was dissolved dichloromethane (62 mL); then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-<i>N</i>-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile <b>15b</b> (<b>43</b>, 11 g, 31.2 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (16 mL, 93.6 mmol) were added. The mixture was stirred at 23 °C for 2 h, diluted with dichloromethane (100 mL), and washed with a saturated aqueous solution of sodium carbonate (100 mL). The aqueous fraction was extracted with dichloromethane; the combined organic fractions were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–20%) and afforded 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-<i>N</i>-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carbonitrile (<b>38</b>, 83% yield) and converted to the corresponding HCl salt by dissolution in ethanol, cooling to 0 °C, and the addition of 1 equiv of 0.01 M HCl in ethanol: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; HCl salt) δ 7.97 (s, 1H), 7.49 (d, <i>J</i> = 2.1 Hz, 1H), 7.38 (d, <i>J</i> = 8.5 Hz, 1H), 7.32 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.46 (q, <i>J</i> = 7.1 Hz, 1H), 4.40–4.27 (m, 2H), 4.06 (dd, <i>J</i> = 9.2, 5.7 Hz, 2H), 3.93 (t, <i>J</i> = 5.2 Hz, 2H), 3.71–3.61 (m, 2H), 3.30–3.25 (m, 2H), 3.02–2.91 (m, 1H), 2.79–2.65 (m, 2H), 2.26–2.14 (m, 1H), 2.10–1.95 (m, 2H), 1.92 (d, <i>J</i> = 7.1 Hz, 3H), 1.90–1.80 (m, 1H), 1.31–1.20 (m, 1H). <sup>13</sup>C NMR (101 MHz; CD<sub>3</sub>OD; HCl salt) δ 153.7, 143.0, 137.0, 134.1, 133.1, 133.0, 129.0, 128.9, 127.5, 125.1, 117.4, 112.2, 66.7, 59.1, 55.0, 54.9, 53.3, 53.1, 52.7, 38.0, 32.9, 24.7, 22.3, 18.6. LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 500.17, found 500.0.</div></div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide (<b>39</b>)</h3><div class="NLM_p">A mixture of the title compound and its diastereomer was prepared as follows:</div><div id="sec4_35_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl 3-(piperidin-3-yl)azetidine-1-carboxylate <b>11</b> (200 mg, 0.83 mmol), 2-((<i>tert</i>-butyldimethylsilyl)oxy)acetaldehyde (145 mg, 0.83 mmol), and sodium triacetoxyborohydride (352 mg, 1.66 mmol) in 1,2-dichloroethane (5 mL) at 23 °C for 2 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure, and the residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–10%) and afforded <i>tert</i>-butyl 3-(1-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethyl)piperidin-3-yl)azetidine-1-carboxylate (88% yield): LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>43</sub>N<sub>2</sub>O<sub>3</sub>Si [M + H]<sup>+</sup> 399.30, found 399.2.</div></div><div id="sec4_35_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl 3-(1-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethyl)piperidin-3-yl)azetidine-1-carboxylate (290 mg, 0.73 mmol) from step 1 was dissolved in dichloromethane (5 mL), and then HCl (3 mL, 12 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 90 min and then concentrated under reduced pressure to afford 2-(3-(azetidin-3-yl)piperidin-1-yl)ethan-1-ol hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>21</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 185.17, found 185.2.</div></div><div id="sec4_35_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 2-(3-(azetidin-3-yl)piperidin-1-yl)ethan-1-ol hydrochloride from step 2 was dissolved in dimethylformamide (2 mL), and then (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a><b>15d</b> (148 mg, 0.40 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.36 mL, 2.05 mmol) were added. The mixture was heated to 80 °C for 3 h, cooled to 23 °C, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–20%) and afforded 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-(1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide as a 1:1 mixture of diastereomers. The title compound was separated from its diastereomer by SFC using an AD-H column (2 × 25 cm) and eluting with 40% ethanol (0.1% diethylamine) in CO<sub>2</sub>, 100 bar, and afforded 65 mg of 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide (<b>39</b>, 63% yield) as the first eluting isomer: <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; free base) δ 7.88 (s, 1H), 7.46 (d, <i>J</i> = 2.1 Hz, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.27 (dd, <i>J</i> = 8.0, 2.1 Hz, 1H), 6.44 (q, <i>J</i> = 7.0 Hz, 1H), 4.24 (q, <i>J</i> = 9.0 Hz, 2H), 3.99–3.88 (m, 2H), 3.71 (t, <i>J</i> = 6.0 Hz, 2H), 3.04–2.92 (m, 2H), 2.67–2.54 (m, 3H), 2.18–2.06 (m, 1H), 1.93 (d, <i>J</i> = 7.1 Hz, 3H), 1.90–1.71 (m, 4H), 1.70–1.54 (m, 1H), 1.02–0.83 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 518.18, found 518.1.</div></div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylic Acid (<b>40</b>)</h3><div id="sec4_36_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> Step 1</h4><div class="NLM_p last">The reductive amination was performed according to <a class="ref internalNav" href="#sec4_2" aria-label="General Procedure A">General Procedure A</a> using <i>tert</i>-butyl (<i>R</i>)-3-(piperidin-3-yl)azetidine-1-carboxylate (<i>R</i>)-<b>11</b> (5.6 g, 23.3 mmol), 2-((<i>tert</i>-butyldimethylsilyl)oxy)acetaldehyde (5.42 g, 28.0 mmol), and sodium triacetoxyborohydride (12.3 g, 58.3 mmol) in 1,2-dichloroethane (116 mL) at 23 °C for 2 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure and afforded <i>tert</i>-butyl (<i>R</i>)-3-(1-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethyl)piperidin-3-yl)azetidine-1-carboxylate, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>43</sub>N<sub>2</sub>O<sub>3</sub>Si [M + H]<sup>+</sup> 399.30, found 399.2.</div></div><div id="sec4_36_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> Step 2</h4><div class="NLM_p last">Boc deprotection was performed according to <a class="ref internalNav" href="#sec4_5" aria-label="General Procedure D">General Procedure D</a>. <i>tert</i>-Butyl (<i>R</i>)-3-(1-(2-((<i>tert</i>-butyldimethylsilyl)oxy)ethyl)piperidin-3-yl)azetidine-1-carboxylate (1.0 g, 2.51 mmol) from step 1 was dissolved in dichloromethane (5 mL), and then HCl (3.14 mL, 12.5 mmol, 4 N in 1,4-dioxane) was added. The mixture was stirred at 23 °C for 90 min and then concentrated under reduced pressure to afford (<i>R</i>)-2-(3-(azetidin-3-yl)piperidin-1-yl)ethan-1-ol hydrochloride, which was used in the next step without further purification: LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>21</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 185.17, found 185.2.</div></div><div id="sec4_36_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> Step 3</h4><div class="NLM_p last">The S<sub>N</sub>Ar reaction was performed according to <a class="ref internalNav" href="#sec4_6" aria-label="General Procedure E">General Procedure E</a>. The crude 2-(3-(azetidin-3-yl)piperidin-1-yl)ethan-1-ol hydrochloride from step 2 was dissolved in dichloromethane (8.3 mL), and then ethyl (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a><b>15c</b> (500 mg, 1.3 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (1.1 mL, 6.3 mmol) were added. The mixture was stirred at 23 °C for 4 h and then concentrated under reduced pressure. The residue was purified by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford ethyl 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate trifluoroacetate (<b>55</b>, 80% yield); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>31</sub>Cl<sub>2</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 547.20, found 547.2.</div></div><div id="sec4_36_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> Step 4</h4><div class="NLM_p last">Lithium hydroxide monohydrate (210 mg, 5.0 mmol) was added to a solution of ethyl 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylate (548 mg, 1.0 mmol) in THF (2 mL) and water (2.0 mL). The reaction was heated at 50 °C for 2 h. After cooling to room temperature, the mixture was concentrated, and the residue was purified by reversed-phase preparative HPLC (Gemini-NX, 10 μm, 250 mm × 30 mm, C18 column, Phenomenex, Torrance, CA), eluent = 0–100% acetonitrile in water, both eluents containing 0.1% TFA, gradient elution over 30 min to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylic acid (<b>40</b>, 70% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; free base) δ 7.94 (s, 1H), 7.48 (d, 1H, <i>J</i> = 2.1 Hz), 7.40 (d, 1H, <i>J</i> = 8.2 Hz), 7.29 (dd, 1H, <i>J</i> = 2.1 Hz, <i>J</i> = 8.5 Hz), 6.48 (q, 1H, <i>J</i> = 7.0 Hz), 2.48–4.26 (m, 2H), 4.07–3.97 (m, 2H), 3.93–3.88 (m, 2H), 3.70–3.67 (m, 2H), 3.30–3.23 (m, 2H), 2.98–2.88 (m, 1H), 2.75–2.65 (m, 2H), 2.20–1.80 (m, 7H), 1.31–1.18 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup> 519.16, found 519.1.</div></div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-<i>N</i>-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide (<b>41</b>)</h3><div class="NLM_p last">A solution of propylphosphonic anhydride (0.93 mL, 0.16 mmol, 50 wt % in ethyl acetate) was added to a mixture of 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylic acid <b>40</b> (68 mg, 0.13 mmol) and methylamine (325 mL, 0.65 mmol, 2 M in THF) in ethyl acetate (1 mL) and dimethylformamide (0.5 mL). The reaction mixture was stirred at 50 °C for 16 h, quenched with 2 mL of a 1:1 mixture of water and brine, and then extracted with ethyl acetate. The organic layer was dried with sodium sulfate, filtered, and concentrated, and the residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–20%) to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-<i>N</i>-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide (41, 40% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; free base) δ 7.85 (s, 1H), 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.25 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 6.42 (q, <i>J</i> = 7.0 Hz, 1H), 4.23 (q, <i>J</i> = 8.8 Hz, 2H), 3.99–3.87 (m, 2H), 3.73 (t, <i>J</i> = 5.9 Hz, 2H), 3.10–3.03 (m, 2H), 3.01 (s, 3H), 2.68 (t, <i>J</i> = 5.9 Hz, 2H), 2.65–2.54 (m, 1H), 2.27–2.16 (m, 1H), 1.92 (d, <i>J</i> = 7.1 Hz, 3H), 1.90–1.73 (m, 4H), 1.73–1.58 (m, 1H), 1.05–0.91 (m, 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>32</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 532.20, found 532.2.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> 1-((<i>R</i>)-1-(2,4-Dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-<i>N</i>,<i>N</i>-dimethyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide (<b>42</b>)</h3><div class="NLM_p last">A solution of propylphosphonic anhydride (0.93 mL, 0.16 mmol, 50 wt % in ethyl acetate) was added to a mixture of 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxylic acid <b>40</b> (68 mg, 0.13 mmol) and dimethylamine (325 mL, 0.65 mmol, 2 M in THF) in ethyl acetate (1 mL) and dimethylformamide (0.5 mL). The reaction mixture was stirred at 50 °C for 16 h, quenched with 2 mL of a 1:1 mixture of water and brine, and then extracted with ethyl acetate. The organic layer was dried with sodium sulfate, filtered, and concentrated, and the residue was purified by silica gel chromatography using a gradient of methanol in dichloromethane (0–20%) to afford 1-((<i>R</i>)-1-(2,4-dichlorophenyl)ethyl)-6-(3-((<i>R</i>)-1-(2-hydroxyethyl)piperidin-3-yl)azetidin-1-yl)-<i>N</i>,<i>N</i>-dimethyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine-3-carboxamide (<b>42</b>, 20% yield): <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD; free base) δ 7.87 (s, 1H), 7.47 (d, 1H, <i>J</i> = 2.1 Hz), 7.43 (d, 1H, <i>J</i> = 8.5 Hz), 7.28 (dd, 1H, <i>J</i> = 8.5, 2.1 Hz), 6.42 (1H, q, <i>J</i> = 7.1 Hz), 4.32–4.22 (m, 2H), 4.03–3.93 (m, 2H), 3.76 (t, 2H, <i>J</i> = 5.8 Hz), 3.18 (s, 6H), 3.11–3.17 (m, 2H), 2.82–2.74 (m, 2H), 2.68–2.58 (m, 1H), 2.38–2.28 (m, 1H), 2.12–1.78 (m, 8H), 1.76–1.63 (m, 1H), 1.09–0.97 (m 1H); LRMS-ESI<sup>+</sup><i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>Cl<sub>2</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 546.21, found 546.2.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> Chiral Resolution of <i>tert</i>-Butyl (<i>R</i>)-3-(Piperidin-3-yl)azetidine-1-carboxylate ((<i>R</i>)-<b>11</b>)</h3><div class="NLM_p last"><i>tert</i>-Butyl 3-(3-piperidyl)azetidine-1-carboxylate (77.0 g, 320 mmol) <b>11</b> was dissolved in <i>tert</i>-butyl methyl ether (1700 mL) in a 5 L three-necked flask equipped with a mechanical stirrer and a water condenser. When the mixture was stirred at reflux, <span class="smallcaps smallerCapital">l</span>-(+)-mandelic acid (24.38 g, 160 mmol) was added. The resulting mixture stirred at reflux for 15 min and then cooled to 23 °C over 12 h. The white solid was collected by filtration and rinsed with <i>tert</i>-butyl methyl ether (500 mL). The white solid was resuspended in <i>tert</i>-butyl methyl ether (1700 mL) and stirred at reflux for 30 min. The solid was collected by filtration and washed with <i>tert</i>-butyl methyl ether (500 mL). The process was repeated once more to afford a white solid (62.8 g, 95% ee by chiral HPLC on a Chiralpak IC-3 column, 4.6 mm × 250 mm, 3 uM, eluting with 50% heptane, 50% isopropanol at 1 mL/min, detecting at 210 nM, <i>t</i><sub>R</sub> = 8.8–9 min). The white solid was further purified by recrystallization from chloroform/<i>tert</i>-butyl methyl ether (900 mL/900 mL). The salt was dissolved in chloroform (900 mL) and warmed to a slight boil, and then <i>tert</i>-butyl methyl ether (900 mL) was slowly added. It was a clear solution when it was hot. The solution was cooled to 23 °C over 12 h, and crystals appeared. The crystals were isolated by filtration and further dried under a high vacuum for 4 h to afford 64.9 g (>99% ee) of the mandelate salt with 1 equiv of chloroform as confirmed by <sup>1</sup>H NMR (in CD<sub>3</sub>OD) and by X-ray crystallography of a suitable single crystal (Cambridge Crystallographic Data Centre Deposition Number 1991309). The salt was free based by dissolving in dichloromethane (0.5 M) and washing with aqueous sodium hydroxide (1 M, 2 equiv). The organic fraction was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford <i>tert</i>-butyl (<i>R</i>)-3-(piperidin-3-yl)azetidine-1-carboxylate (<i>R</i>)-<b>11</b>, which was used in the next step without further purification.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> Calcium Flux Assay</h3><div class="NLM_p last">Chem-5 hCCR4 cells (EMD Millipore, HTS009C) were cultured under standard conditions and frozen in 1 mL per vial aliquots of 10 × 10<sup>6</sup> cells/mL. The day prior to testing, a vial was thawed rapidly and pipetted into 9 mL of media (DMEM + 10% FBS + 1% Pen-Strep +1% <span class="smallcaps smallerCapital">l</span>-glutamine). Cells were harvested by centrifugation and resuspended in 25 mL of fresh culture medium. An aliquot (25 μL) of the cell suspension was seeded into 384-well plates (Corning CellBind Plates, cat no. 4579) resulting in a cell density of 10 000 cells per well. The plates were centrifuged at 300<i>g</i> for 10 s and incubated overnight at 37 °C and 5% CO<sub>2</sub>. The next day, the media was removed, and 25 μL of serum free media (DMEM + 1% Pen-Strep +1% <span class="smallcaps smallerCapital">l</span>-glutamine) was added. The cells were incubated for an additional 2 h, and 25 μL of assay buffer (Hank’s balanced salt solution +20 mM HEPES, pH 7.4) containing FLIPR Calcium 6 dye (Molecular Devices, no. R8191) and probenecid (2.5 mM, Life Technologies, P36400) was added to each well and incubated at 37 °C and 5% CO<sub>2</sub> for 2 h. The plate was normalized to 0.5% DMSO per well using an HP D300e and incubated at 37 °C and 5% CO<sub>2</sub> for 1 h. Human CCL22 (Peprotech, no. 300-36A) was diluted to 500 nM (5× final concentration) with chemokine buffer (HBSS, 20 mM HEPES, 0.1% BSA) and serially diluted 1:2, 16 points with the 16th point containing no ligand. The 16-point hCCL22 serial dilutions were transferred to a 384-well polypropylene plate (Corning Polypropylene Plates, cat no. Corning 3657). The assay plates and polypropylene plate containing working solutions of hCCL22 were transferred to a FlexStation3 plate reader (Molecular Devices) at 37 °C for 5 min. Fluorescence recordings (485 nm excitation/525 nm emission) were performed at 2.5 s intervals. After 16 s, 12.5 μL of hCCL22 solution was added to each well, and reads were continuously performed for 45 at 2.5 s intervals. The minimum fluorescence (<i>F</i><sub>min</sub>) was calculated by averaging the reads prior to ligand addition, and the change in fluorescence (Δ<i>F</i>) was calculated by subtracting the <i>F</i><sub>min</sub> from the average of the reads following ligand addition. The response Δ<i>F</i>/<i>F</i><sub>min</sub> was plotted as a function of the hCCL22 concentration starting at 100 nM, and the IC<sub>50</sub> and IC<sub>80</sub> values are derived by nonlinear regression analysis using a 4-parameter fit in PRISM software. Values presented are the average of <i>n</i> = 2 or more determinations, where the value of each determination is within 3-fold difference of each other.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> Chemotaxis (CTX) Assay</h3><div class="NLM_p last">The assay was performed using the ChemoTX (NeuroProbe; cat no. 106-5) migration system with a 5 μm pore size polycarbonate trach-etch (PCTE) membrane. CCRF-CEM (ATCC, cat no. CCL-119), <i>in vitro</i> generated mouse iT<sub>reg</sub>, or <i>in vitro</i> generated human iT<sub>reg</sub> cells were suspended in human serum at 2 million cells/mL. The test compound was added to the cell/serum mixture at a final DMSO concentration of 0.25% (v/v), using an HP D300e digital dispenser followed by a 30 min compound preincubation period. Separately, recombinant human CCL22 (Peprotech; no. 300-36A), recombinant human CCL17 (Peprotech; no. 300-30), or mouse CCL22 (Peprotech; no. 250-23) was diluted to 0.9 nM in 1× HBSS with 0.1% BSA, and an aliquot (29 μL) of this ligand solution was placed in the lower wells of the ChemoTX plate. The PCTE membrane was placed onto the plate, and 50 μL of the cell/compound mixture was transferred onto each well of the membrane. The chemotaxis plate was incubated at 37 °C, 100% humidity, and 5% CO<sub>2</sub> for 60 min, after which the polycarbonate membranes were removed, and 15 μL of the ATP-binding agent CellTiter-Glo (Promega; G7571) was added to the lower wells. The amount of luminescence, corresponding to the number of migrated cells, was measured using an EnVision plate reader (PerkinElmer; Waltham, MA). The number of migrated cells in the presence of the ligand alone was set to 100% migration, and the numbers of migrated cells in the presence of ligands were expressed as the corresponding percentage. The results were analyzed by fitting the experimental curves (% migrated cells vs compound concentration) by nonlinear regression using a four-parameter fit using the GraphPad PRISM software. Values presented are the average of <i>n</i> = 2 or more determinations, where the value of each determination is within 3-fold difference of each other.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i140"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00988" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66732" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66732" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00988?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00988</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Assay conditions; hepatocyte stability assay; <i>in vitro</i> CYP450 assay; <i>in vivo</i> pharmacology studies, X-ray structure of the synthetic intermediate of <b>38</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_002.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf">jm0c00988_si_001.pdf (699.81 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_002.xlsx">jm0c00988_si_002.xlsx (17.84 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00988" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David J. Wustrow</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e78390929493958890a795869793c984888a"><span class="__cf_email__" data-cfemail="016576747275736e7641736071752f626e6c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mikhail Zibinsky</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#adc0d7c4cfc4c3dec6d4eddfccddd983cec2c0"><span class="__cf_email__" data-cfemail="e88592818a81869b8391a89a89989cc68b8785">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Omar Robles</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey J. Jackson</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7219-5279" title="Orcid link">http://orcid.org/0000-0002-7219-5279</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Marshall</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oezcan Talay</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Chian</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gene Cutler</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raymond Diokno</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis X. Hu</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Jacobson</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily Karbarz</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul D. Kassner</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John M. Ketcham</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jenny McKinnell</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cesar Meleza</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maureen K. Reilly</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erin Riegler</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hunter P. Shunatona</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela Wadsworth</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashkaan Younai</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dirk G. Brockstedt</span> - <span class="hlFld-Affiliation affiliation">RAPT Therapeutics, 561 Eccles Avenue, South
San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors of this manuscript are/were employees of RAPT Therapeutics.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i141">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76537" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76537" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank all current and former RAPT Therapeutics employees for their commitment and endless support to our CCR4 program.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">CCR4</td><td class="NLM_def"><p class="first last">CC chemokine receptor 4</p></td></tr><tr><td class="NLM_term">CCL17</td><td class="NLM_def"><p class="first last">CC chemokine ligand 17</p></td></tr><tr><td class="NLM_term">CCL22</td><td class="NLM_def"><p class="first last">CC chemokine ligand 22</p></td></tr><tr><td class="NLM_term">T<sub>reg</sub></td><td class="NLM_def"><p class="first last">regulatory T cells</p></td></tr><tr><td class="NLM_term">IO</td><td class="NLM_def"><p class="first last">immuno-oncology</p></td></tr><tr><td class="NLM_term">T<sub>eff</sub></td><td class="NLM_def"><p class="first last">effector T cells</p></td></tr><tr><td class="NLM_term">TME</td><td class="NLM_def"><p class="first last">tumor microenvironment</p></td></tr><tr><td class="NLM_term">Th2</td><td class="NLM_def"><p class="first last">T helper type 2 cell</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">CTCL</td><td class="NLM_def"><p class="first last">Cutaneous T-Cell Lymphoma</p></td></tr><tr><td class="NLM_term">ADCC</td><td class="NLM_def"><p class="first last">antibody-dependent cell-mediated cytotoxicity</p></td></tr><tr><td class="NLM_term">CTX</td><td class="NLM_def"><p class="first last">chemotaxis</p></td></tr><tr><td class="NLM_term">CTLA-4</td><td class="NLM_def"><p class="first last">cytotoxic T-lymphocyte-associated protein 4</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i143">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span>; <span class="NLM_string-name">Jaffee, E.</span>; <span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Immune Evasion by Tumors</span>. In  <i>Advances in Immunology</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">United States</span>, <span class="NLM_year">2006</span>; Vol.  <span class="NLM_volume">90</span>, pp  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">81</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=51-81&author=C.+G.+Drake&author=E.+Jaffee&author=D.+M.+Pardoll&title=Advances+in+Immunology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DC.%2BG.%26atitle%3DMechanisms%2520of%2520Immune%2520Evasion%2520by%2520Tumors%26btitle%3DAdvances%2520in%2520Immunology%26pub%3DAcademic%2520Press%26date%3D2006%26volume%3D90%26spage%3D51%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hadrup, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thor Straten, P.</span></span> <span> </span><span class="NLM_article-title">Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment</span>. <i>Cancer Microenviron.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1007/s12307-012-0127-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1007%2Fs12307-012-0127-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=23242673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOlur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=123-133&author=S.+Hadrupauthor=M.+Doniaauthor=P.+Thor+Straten&title=Effector+CD4+and+CD8+T+Cells+and+Their+Role+in+the+Tumor+Microenvironment&doi=10.1007%2Fs12307-012-0127-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment</span></div><div class="casAuthors">Hadrup, Sine; Donia, Marco; thor Straten, Per</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Microenvironment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-133</span>CODEN:
                <span class="NLM_cas:coden">CMAICW</span>;
        ISSN:<span class="NLM_cas:issn">1875-2284</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  T cells in tumors-the so-called tumor infiltrating lymphocytes (TIL) have been studied intensively over the past years.  Compelling evidence point to a clin. relevance for high nos. of T cells at the tumor site with CD8 memory T cells as a key denominator for overall survival (OS) in patients with colo-rectal cancer (CRC), and also for others solid cancers.  These data goes hand in hand with studies of clonality of TIL showing the T cells among TIL are expanded clonally, and also that tumor specific T cells of CD4 as well as CD8 type are enriched at the tumor site.  The tumor microenvironment is hostile to T cell function e.g., due to expression of enzymes that depletes the amino acids tryptophan and arginine, high concn. of tumor secreted lactate, and presence innate cells or regulatory T cells both with suppressive activity.  Analyses of the specificity of TILs in melanoma demonstrate that quite few known antigens are in fact recognized by these cultures underscoring patient unique and/or mutated antigens may represent important target for recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO_PUIt1Wyz7Vg90H21EOLACvtfcHk0liBipFM12I9wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOlur%252FL&md5=eab48cec4355dedc34341179927989d4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs12307-012-0127-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12307-012-0127-6%26sid%3Dliteratum%253Aachs%26aulast%3DHadrup%26aufirst%3DS.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DThor%2BStraten%26aufirst%3DP.%26atitle%3DEffector%2520CD4%2520and%2520CD8%2520T%2520Cells%2520and%2520Their%2520Role%2520in%2520the%2520Tumor%2520Microenvironment%26jtitle%3DCancer%2520Microenviron.%26date%3D2013%26volume%3D6%26spage%3D123%26epage%3D133%26doi%3D10.1007%2Fs12307-012-0127-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3335</span>– <span class="NLM_lpage">3337</span>, <span class="refDoi"> DOI: 10.1172/JCI83871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1172%2FJCI83871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=26325031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A280%3ADC%252BC287otVersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3335-3337&author=Y.+Yang&title=Cancer+Immunotherapy%3A+Harnessing+the+Immune+System+to+Battle+Cancer&doi=10.1172%2FJCI83871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy: harnessing the immune system to battle cancer</span></div><div class="casAuthors">Yang Yiping</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3335-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immunotherapy.  These successes also underscore the importance of understanding basic tumor immunology for successful clinical translation in treating patients with cancer.  The Reviews in this Review Series focus on current developments in cancer immunotherapy, highlight recent advances in our understanding of basic aspects of tumor immunology, and suggest how these insights can lead to the development of new immunotherapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCDsEQcCnxNc25P7XSLhESfW6udTcc2eZr_M_C6fO5mbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287otVersw%253D%253D&md5=5a53437eb397adb28804ede24b04c8cf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1172%2FJCI83871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI83871%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26atitle%3DCancer%2520Immunotherapy%253A%2520Harnessing%2520the%2520Immune%2520System%2520to%2520Battle%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D3335%26epage%3D3337%26doi%3D10.1172%2FJCI83871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu-Lieskovan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">707</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.cell.2017.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=28187290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1ygtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=707-723&author=P.+Sharmaauthor=S.+Hu-Lieskovanauthor=J.+A.+Wargoauthor=A.+Ribas&title=Primary%2C+Adaptive%2C+and+Acquired+Resistance+to+Cancer+Immunotherapy&doi=10.1016%2Fj.cell.2017.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy</span></div><div class="casAuthors">Sharma, Padmanee; Hu-Lieskovan, Siwen; Wargo, Jennifer A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">707-723</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies.  Broadening the clin. applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy.  The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion.  As the mol. mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clin. outcomes for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcdZs4zsnQGrVg90H21EOLACvtfcHk0liBipFM12I9wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1ygtb4%253D&md5=5a2d0ec3d2d0d438f2e9ede5053ed1aa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DHu-Lieskovan%26aufirst%3DS.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DPrimary%252C%2520Adaptive%252C%2520and%2520Acquired%2520Resistance%2520to%2520Cancer%2520Immunotherapy%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D707%26epage%3D723%26doi%3D10.1016%2Fj.cell.2017.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdemon-Hogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conejo-Garcia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryczek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span> <span> </span><span class="NLM_article-title">Specific Recruitment of Regulatory T cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1038/nm1093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1038%2Fnm1093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=15322536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=942-949&author=T.+J.+Curielauthor=G.+Coukosauthor=L.+Zouauthor=X.+Alvarezauthor=P.+Chengauthor=P.+Mottramauthor=M.+Evdemon-Hoganauthor=J.+R.+Conejo-Garciaauthor=L.+Zhangauthor=M.+Burowauthor=Y.+Zhuauthor=S.+Weiauthor=I.+Kryczekauthor=B.+Danielauthor=A.+Gordonauthor=L.+Myersauthor=A.+Lacknerauthor=M.+L.+Disisauthor=K.+L.+Knutsonauthor=L.+Chenauthor=W.+Zou&title=Specific+Recruitment+of+Regulatory+T+cells+in+Ovarian+Carcinoma+Fosters+Immune+Privilege+and+Predicts+Reduced+Survival&doi=10.1038%2Fnm1093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span></div><div class="casAuthors">Curiel, Tyler J.; Coukos, George; Zou, Linhua; Alvarez, Xavier; Cheng, Pui; Mottram, Peter; Evdemon-Hogan, Melina; Conejo-Garcia, Jose R.; Zhang, Lin; Burow, Matthew; Zhu, Yun; Wei, Shuang; Kryczek, Ilona; Daniel, Ben; Gordon, Alan; Myers, Leann; Lackner, Andrew; Disis, Mary L.; Knutson, Keith L.; Chen, Lieping; Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">942-949</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Regulatory T (Treg) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells.  Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-assocd. antigen-reactive lymphocytes mediated by Treg cells; however, definitive evidence that Treg cells have an immunopathol. role in human cancer is lacking.  Here the authors show, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor Treg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo.  The authors also show that tumor Treg cells are assocd. with a high death hazard and reduced survival.  Human Treg cells preferentially move to and accumulate in tumors and ascites, but rarely enter draining lymph nodes in later cancer stages.  Tumor cells and microenvironmental macrophages produce the chemokine CCL22, which mediates trafficking of Treg cells to the tumor.  This specific recruitment of Treg cells represents a mechanism by which tumors may foster immune privilege.  Thus, blocking Treg cell migration or function may help to defeat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUuPjm7zZim7Vg90H21EOLACvtfcHk0lgqHOC4jJl69Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D&md5=eaf598e6096d6e92381c1b26f4b2fe91</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm1093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1093%26sid%3Dliteratum%253Aachs%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DAlvarez%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DP.%26aulast%3DMottram%26aufirst%3DP.%26aulast%3DEvdemon-Hogan%26aufirst%3DM.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBurow%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DKryczek%26aufirst%3DI.%26aulast%3DDaniel%26aufirst%3DB.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DMyers%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DA.%26aulast%3DDisis%26aufirst%3DM.%2BL.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DW.%26atitle%3DSpecific%2520Recruitment%2520of%2520Regulatory%2520T%2520cells%2520in%2520Ovarian%2520Carcinoma%2520Fosters%2520Immune%2520Privilege%2520and%2520Predicts%2520Reduced%2520Survival%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D942%26epage%3D949%26doi%3D10.1038%2Fnm1093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treilleux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendriss-Vermare, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard-Leon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arfi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biota, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffin, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqual, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray-Coquard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puisieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménétrier-Caux, C.</span></span> <span> </span><span class="NLM_article-title">Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2000</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1158%2F0008-5472.CAN-08-2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=19244125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFSrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2000&author=M.+Gobertauthor=I.+Treilleuxauthor=N.+Bendriss-Vermareauthor=T.+Bachelotauthor=S.+Goddard-Leonauthor=V.+Arfiauthor=C.+Biotaauthor=A.+C.+Doffinauthor=I.+Durandauthor=D.+Oliveauthor=S.+Perezauthor=N.+Pasqualauthor=C.+Faureauthor=I.+Ray-Coquardauthor=A.+Puisieuxauthor=C.+Cauxauthor=J.-Y.+Blayauthor=C.+M%C3%A9n%C3%A9trier-Caux&title=Regulatory+T+Cells+Recruited+through+CCL22%2FCCR4+Are+Selectively+Activated+in+Lymphoid+Infiltrates+Surrounding+Primary+Breast+Tumors+and+Lead+to+an+Adverse+Clinical+Outcome&doi=10.1158%2F0008-5472.CAN-08-2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome</span></div><div class="casAuthors">Gobert, Michael; Treilleux, Isabelle; Bendriss-Vermare, Nathalie; Bachelot, Thomas; Goddard-Leon, Sophie; Arfi, Vanessa; Biota, Cathy; Doffin, Anne Claire; Durand, Isabelle; Olive, Daniel; Perez, Solene; Pasqual, Nicolas; Faure, Christelle; Ray-Coquard, Isabelle; Puisieux, Alain; Caux, Christophe; Blay, Jean-Yves; Menetrier-Caux, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immunohistochem. anal. of FOXP3 in primary breast tumors showed that a high no. of tumor-infiltrating regulatory T cells (Ti-Treg) within lymphoid infiltrates surrounding the tumor was predictive of relapse and death, in contrast to those present within the tumor bed.  Ex vivo anal. showed that these tumor-infiltrating FOXP3+ T cells are typical Treg based on their CD4+CD25highCD127lowFOXP3+ phenotype, their anergic state on in vitro stimulation, and their suppressive functions.  These Ti-Treg could be selectively recruited through CCR4 as illustrated by (a) selective blood Treg CCR4 expression and migration to CCR4 ligands, (b) CCR4 down-regulation on Ti-Treg, and (c) correlation between Ti-Treg in lymphoid infiltrates and intratumoral CCL22 expression.  Importantly, in contrast to other T cells, Ti-Treg are selectively activated locally and proliferate in situ, showing T-cell receptor engagement and suggesting specific recognition of tumor-assocd. antigens (TAA).  Immunohistochem. stainings for ICOS, Ki67, and DC-LAMP show that Ti-Treg were close to mature DC-LAMP+ dendritic cells (DC) in lymphoid infiltrates but not in tumor bed and were activated and proliferating.  Furthermore, proximity between Ti-Treg, CD3+, and CD8+ T cells was documented within lymphoid infiltrates.  Altogether, these results show that Treg are selectively recruited within lymphoid infiltrates and activated by mature DC likely through TAA presentation, resulting in the prevention of effector T-cell activation, immune escape, and ultimately tumor progression.  This study sheds new light on Treg physiol. and validates CCR4/CCL22 and ICOS as therapeutic targets in breast tumors, which represent a major health problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqhKbsz9ynO7Vg90H21EOLACvtfcHk0ljJoQGfbjfxRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFSrtbg%253D&md5=452bc4cee9c3cba90cfce6cf6dd4994d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2360%26sid%3Dliteratum%253Aachs%26aulast%3DGobert%26aufirst%3DM.%26aulast%3DTreilleux%26aufirst%3DI.%26aulast%3DBendriss-Vermare%26aufirst%3DN.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DGoddard-Leon%26aufirst%3DS.%26aulast%3DArfi%26aufirst%3DV.%26aulast%3DBiota%26aufirst%3DC.%26aulast%3DDoffin%26aufirst%3DA.%2BC.%26aulast%3DDurand%26aufirst%3DI.%26aulast%3DOlive%26aufirst%3DD.%26aulast%3DPerez%26aufirst%3DS.%26aulast%3DPasqual%26aufirst%3DN.%26aulast%3DFaure%26aufirst%3DC.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DM%25C3%25A9n%25C3%25A9trier-Caux%26aufirst%3DC.%26atitle%3DRegulatory%2520T%2520Cells%2520Recruited%2520through%2520CCL22%252FCCR4%2520Are%2520Selectively%2520Activated%2520in%2520Lymphoid%2520Infiltrates%2520Surrounding%2520Primary%2520Breast%2520Tumors%2520and%2520Lead%2520to%2520an%2520Adverse%2520Clinical%2520Outcome%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D2000%26doi%3D10.1158%2F0008-5472.CAN-08-2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Betts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Shanawany, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scurr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallimore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godkin, A.</span></span> <span> </span><span class="NLM_article-title">Suppression of Tumour-Specific CD4+ T Cells by Regulatory T Cells is Associated with Progression of Human Colorectal Cancer</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2011-300970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1136%2Fgutjnl-2011-300970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=22207629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kks7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=1163-1171&author=G.+Bettsauthor=E.+Jonesauthor=S.+Junaidauthor=T.+El-Shanawanyauthor=M.+Scurrauthor=P.+Mizenauthor=M.+Kumarauthor=S.+Jonesauthor=B.+Reesauthor=G.+Williamsauthor=A.+Gallimoreauthor=A.+Godkin&title=Suppression+of+Tumour-Specific+CD4%2B+T+Cells+by+Regulatory+T+Cells+is+Associated+with+Progression+of+Human+Colorectal+Cancer&doi=10.1136%2Fgutjnl-2011-300970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer</span></div><div class="casAuthors">Betts, Gareth; Jones, Emma; Junaid, Syed; El-Shanawany, Tariq; Scurr, Martin; Mizen, Paul; Kumar, Mayur; Jones, Sion; Rees, Brian; Williams, Geraint; Gallimore, Awen; Godkin, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1163-1171</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background There is indirect evidence that T cell responses can control the metastatic spread of colorectal cancer (CRC).  However, an enrichment of CD4+Foxp3+ regulatory T cells (Tregs) has also been documented.  Objective To evaluate whether CRC promotes Treg activity and how this influences anti-tumor immune responses and disease progression.  Methods A longitudinal study of Treg activity on a cohort of patients was performed before and after tumor resection.  Specific CD4+ T cell responses were also measured to the tumor assocd. antigens carcinoembryonic antigen (CEA) and 5T4.  Results Tregs from 62 preoperative CRC patients expressed a highly significant increase in levels of Foxp3 compared to healthy age-matched controls (p=0.007), which returned to normal after surgery (p=0.0075).  CD4+ T cell responses to one or both of the tumor assocd. antigens, CEA and 5T4, were obsd. in approx. two-thirds of patients and one third of these responses were suppressed by Tregs.  Strikingly, in all patients with tumor recurrence at 12 mo, significant preoperative suppression was obsd. of tumor-specific (p=0.003) but not control CD4+ T cell responses.  Conclusion These findings demonstrate that the presence of CRC drives the activity of Tregs and accompanying suppression of CD4+ T cell responses to tumor-assocd. antigens.  Suppression is assocd. with recurrence of tumor at 12 mo, implying that Tregs contribute to disease progression.  These findings offer a rationale for the manipulation of Tregs for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR3mvhw4Z1rrVg90H21EOLACvtfcHk0ljJoQGfbjfxRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kks7jM&md5=3ccff67cce65c23da40d1f8da2765397</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2011-300970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2011-300970%26sid%3Dliteratum%253Aachs%26aulast%3DBetts%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DJunaid%26aufirst%3DS.%26aulast%3DEl-Shanawany%26aufirst%3DT.%26aulast%3DScurr%26aufirst%3DM.%26aulast%3DMizen%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DRees%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DGallimore%26aufirst%3DA.%26aulast%3DGodkin%26aufirst%3DA.%26atitle%3DSuppression%2520of%2520Tumour-Specific%2520CD4%252B%2520T%2520Cells%2520by%2520Regulatory%2520T%2520Cells%2520is%2520Associated%2520with%2520Progression%2520of%2520Human%2520Colorectal%2520Cancer%26jtitle%3DGut%26date%3D2012%26volume%3D61%26spage%3D1163%26epage%3D1171%26doi%3D10.1136%2Fgutjnl-2011-300970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">An Increased Abundance of Tumor-Infiltrating Regulatory T Cells Is Correlated with the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e91551</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0091551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1371%2Fjournal.pone.0091551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=24637664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWntb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=Y.+Tangauthor=X.+Xuauthor=S.+Guoauthor=C.+Zhangauthor=Y.+Tangauthor=Y.+Tianauthor=B.+Niauthor=B.+Luauthor=H.+Wang&title=An+Increased+Abundance+of+Tumor-Infiltrating+Regulatory+T+Cells+Is+Correlated+with+the+Progression+and+Prognosis+of+Pancreatic+Ductal+Adenocarcinoma&doi=10.1371%2Fjournal.pone.0091551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Tang, Yichen; Xu, Xuejun; Guo, Shixiang; Zhang, Chaobin; Tang, Yan; Tian, Yi; Ni, Bing; Lu, Binfeng; Wang, Huaizhi</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e91551/1-e91551/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">CD4+CD25+Foxp3+ regulatory T cells (Tregs) can inhibit cytotoxic responses.  Though several studies have analyzed Treg frequency in the peripheral blood mononuclear cells (PBMCs) of pancreatic ductal adenocarcinoma (PDA) patients using flow cytometry (FCM), few studies have examd. how intratumoral Tregs might contribute to immunosuppression in the tumor microenvironment.  Thus, the potential role of intratumoral Tregs in PDA patients remains to be elucidated.  In this study, we found that the percentages of Tregs, CD4+ T cells and CD8+ T cells were all increased significantly in tumor tissue compared to control pancreatic tissue, as assessed via FCM, whereas the percentages of these cell types in PBMCs did not differ between PDA patients and healthy volunteers.  The percentages of CD8+ T cells in tumors were significantly lower than in PDA patient PBMCs.  In addn., the relative nos. of CD4+CD25+Foxp3+ Tregs and CD8+ T cells were neg. correlated in the tissue of PDA patients, and the abundance of Tregs was significantly correlated with tumor differentiation.  Addnl., Foxp3+ T cells were obsd. more frequently in juxtatumoral stroma (immediately adjacent to the tumor epithelial cells).  Patients showing an increased prevalence of Foxp3+ T cells had a poorer prognosis, which was an independent factor for patient survival.  These results suggest that Tregs may promote PDA progression by inhibiting the antitumor immunity of CD8+ T cells at local intratumoral sites.  Moreover, a high proportion of Tregs in tumor tissues may reflect suppressed antitumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOhRQW2-sWLLVg90H21EOLACvtfcHk0ljJoQGfbjfxRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWntb%252FL&md5=8577403b41758396004556664fbc7ad9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0091551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0091551%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DAn%2520Increased%2520Abundance%2520of%2520Tumor-Infiltrating%2520Regulatory%2520T%2520Cells%2520Is%2520Correlated%2520with%2520the%2520Progression%2520and%2520Prognosis%2520of%2520Pancreatic%2520Ductal%2520Adenocarcinoma%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0091551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracci, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsuang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemels, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrensch, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiencke, J. K.</span></span> <span> </span><span class="NLM_article-title">Serum Macrophage-Derived Chemokine/CCL22 Levels are Associated with Glioma Risk, CD4 T Cell Lymphopenia and Survival Time</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">826</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1002/ijc.29441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1002%2Fijc.29441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25604093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVajtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=826-836&author=M.+Zhouauthor=P.+M.+Bracciauthor=L.+S.+McCoyauthor=G.+Hsuangauthor=J.+L.+Wiemelsauthor=T.+Riceauthor=S.+Zhengauthor=K.+T.+Kelseyauthor=M.+R.+Wrenschauthor=J.+K.+Wiencke&title=Serum+Macrophage-Derived+Chemokine%2FCCL22+Levels+are+Associated+with+Glioma+Risk%2C+CD4+T+Cell+Lymphopenia+and+Survival+Time&doi=10.1002%2Fijc.29441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time</span></div><div class="casAuthors">Zhou, Mi; Bracci, Paige M.; McCoy, Lucie S.; Hsuang, George; Wiemels, Joseph L.; Rice, Terri; Zheng, Shichun; Kelsey, Karl T.; Wrensch, Margaret R.; Wiencke, John K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">826-836</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Defects in antigen presenting cell function have been implicated in glioma immunosuppression.  We measured peripheral CCL22, a dendritic cell/macrophage derived T cell trafficking chemokine, in sera from 1,208 glioma cases and 976 controls to assess whether it might provide a biomarker of glioma risk, survival and immune dysfunction.  Cluster models were used to examine the relationship between CCL22 and glioma risk.  Patient survival was assessed using Cox regression models.  We also examd. the relationship between CCL22 levels and CD4 cell counts, as well as allergy history and IgE levels.  CCL22 levels were significantly lower among glioma cases compared with controls (Mean ± SEM: 1.23 ± 0.03 ng/mL in cases vs. 1.60 ± 0.03 ng/mL in controls, p < 0.0001) and this difference remained significant even after controlling for other covariates in the cluster models (highest quartile vs. lowest Odds Ratio = 0.21, p < 0.0001).  CD4 cell counts were pos. correlated with CCL22 in glioma cases (Spearman r2 = 0.51, p < 0.01) and were significantly lower in cases compared with controls.  Higher CCL22 levels were assocd. with longer survival in all cases combined and in GBM cases (hazard ratioallcases = 0.81; 95% CI: 0.72-0.91, p = 0.0003).  CCL22 levels were not assocd. with IgE level or self-reported allergies.  Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histol., grade and IDH mutation status.  CCL22 should be considered a marker of immune status with potential prognostic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7bCfHIddb-LVg90H21EOLACvtfcHk0ljA4yNcDRYHOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVajtb4%253D&md5=8ea50f9c73cca78b7c6f250a302cc7af</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fijc.29441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29441%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DBracci%26aufirst%3DP.%2BM.%26aulast%3DMcCoy%26aufirst%3DL.%2BS.%26aulast%3DHsuang%26aufirst%3DG.%26aulast%3DWiemels%26aufirst%3DJ.%2BL.%26aulast%3DRice%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DKelsey%26aufirst%3DK.%2BT.%26aulast%3DWrensch%26aufirst%3DM.%2BR.%26aulast%3DWiencke%26aufirst%3DJ.%2BK.%26atitle%3DSerum%2520Macrophage-Derived%2520Chemokine%252FCCL22%2520Levels%2520are%2520Associated%2520with%2520Glioma%2520Risk%252C%2520CD4%2520T%2520Cell%2520Lymphopenia%2520and%2520Survival%2520Time%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D826%26epage%3D836%26doi%3D10.1002%2Fijc.29441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motohashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span> <span> </span><span class="NLM_article-title">CD45RA-Foxp3high Regulatory T Cells Have a Negative Impact on the Clinical Outcome of Head and Neck Squamous Cell Carcinoma</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1275</span>– <span class="NLM_lpage">1285</span>, <span class="refDoi"> DOI: 10.1007/s00262-017-2021-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1007%2Fs00262-017-2021-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=28551813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovFChs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1275-1285&author=F.+Iharaauthor=D.+Sakuraiauthor=A.+Horinakaauthor=Y.+Makitaauthor=A.+Fujikawaauthor=T.+Sakuraiauthor=K.+Yamasakiauthor=N.+Kuniiauthor=S.+Motohashiauthor=T.+Nakayamaauthor=Y.+Okamoto&title=CD45RA-Foxp3high+Regulatory+T+Cells+Have+a+Negative+Impact+on+the+Clinical+Outcome+of+Head+and+Neck+Squamous+Cell+Carcinoma&doi=10.1007%2Fs00262-017-2021-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">CD45RA-Foxp3high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma</span></div><div class="casAuthors">Ihara, Fumie; Sakurai, Daiju; Horinaka, Atsushi; Makita, Yuji; Fujikawa, Akira; Sakurai, Toshioki; Yamasaki, Kazuki; Kunii, Naoki; Motohashi, Shinichiro; Nakayama, Toshinori; Okamoto, Yoshitaka</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1275-1285</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A recent study reported Tregs could be divided into functional subsets based on the expression of CD45RA and Foxp3.  Method: The frequency of circulating Treg subsets was analyzed in patients with HNSCC and compared with the frequency in patients with benign tumors.  The assocn. of Treg subsets with the frequency of lymphocyte subsets, status of progression, clin. course, and prognosis were also examd.  Results: The frequency of CD4+Foxp3+ Tregs was comparable between HNSCC patients and age-matched benign tumor patients; however, CD45RA-Foxp3high Tregs were significantly increased in HNSCC patients, in particular those with advanced stage tumors.  The high frequency of CD45RA-Foxp3high Tregs correlated with a poor prognosis and the low frequency of CD45RA-Foxp3high Tregs before treatment showed a better clin. outcome, even in patients with advanced stage tumors.  CD45RA-Foxp3high Treg nos. were decreased after intensive treatments; however, Treg nos. recovered in the early stages of recurrent cases, even before the clin. manifestation.  Conclusion: CD45RA-Foxp3high Tregs are assocd. with the clin. course of HNSCC and might be a new target for treatment and an early marker of tumor recurrence in HNSCC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5iaIxQuliSrVg90H21EOLACvtfcHk0ljA4yNcDRYHOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovFChs70%253D&md5=2709893b5ed3506fafe07a1ddd1f38de</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00262-017-2021-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-017-2021-z%26sid%3Dliteratum%253Aachs%26aulast%3DIhara%26aufirst%3DF.%26aulast%3DSakurai%26aufirst%3DD.%26aulast%3DHorinaka%26aufirst%3DA.%26aulast%3DMakita%26aufirst%3DY.%26aulast%3DFujikawa%26aufirst%3DA.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DYamasaki%26aufirst%3DK.%26aulast%3DKunii%26aufirst%3DN.%26aulast%3DMotohashi%26aufirst%3DS.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DY.%26atitle%3DCD45RA-Foxp3high%2520Regulatory%2520T%2520Cells%2520Have%2520a%2520Negative%2520Impact%2520on%2520the%2520Clinical%2520Outcome%2520of%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2017%26volume%3D66%26spage%3D1275%26epage%3D1285%26doi%3D10.1007%2Fs00262-017-2021-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, S.</span></span> <span> </span><span class="NLM_article-title">Induction of Tumor Immunity by Removing CD25+ and CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">5211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10553041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADyaK1MXntlKktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1999&pages=5211&author=J.+Shimizuauthor=S.+Yamazakiauthor=S.+Sakaguchi&title=Induction+of+Tumor+Immunity+by+Removing+CD25%2B+and+CD4%2B+T+Cells%3A+A+Common+Basis+Between+Tumor+Immunity+and+Autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity</span></div><div class="casAuthors">Shimizu, Jun; Yamazaki, Sayuri; Sakaguchi, Shimon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5211-5218</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">This study shows that removal of a T cell subpopulation can evoke effective tumor immunity in otherwise non-responding animals.  Elimination of CD25-expressing T cells, which constitute 5-10% of peripheral CD4+ T cells in normal naive mice, elicited potent immune responses to syngeneic tumors in vivo and eradicated them.  The responses were mediated by tumor-specific CD8+ CTLs and tumor-nonspecific CD4-8- cytotoxic cells akin to NK cells.  Furthermore, in vitro culture of CD25+4+ T cell-depleted splenic cell suspensions prepd. from tumor-unsensitized normal mice led to spontaneous generation of similar CD4-8- cytotoxic cells capable of killing a broad spectrum of tumors; reconstitution of CD25+4+ T cells inhibited the generation.  In this culture, self-reactive CD25-4+ T cells responding to self peptides/class II MHC complexes on APCs spontaneously proliferated upon removal of CD25+4+ T cells, secreting large amts. of IL-2.  The IL-2 thus produced appeared to be responsible for the generation of CD4-8- NK cells as lymphokine-activated killer cells, because direct addn. of an equiv. amt. of IL-2 to the culture of CD4-8- cells generated similar lymphokine-activated killer/NK cells, whereas coculture of normal CD4-8- cells with CD25-4+ T cells from IL-2-deficient mice did not.  Thus, removal of immunoregulatory CD25+4+ T cells can abrogate immunol. unresponsiveness to syngeneic tumors in vivo and in vitro, leading to spontaneous development of tumor-specific effector cells as well as tumor-nonspecific ones.  This novel way of evoking tumor immunity would help to devise effective immunotherapy for cancer in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo1kVJ1ReNzrVg90H21EOLACvtfcHk0ljA4yNcDRYHOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntlKktbw%253D&md5=5fb4e8865ea721166eb4c6599ab08e0a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DJ.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DInduction%2520of%2520Tumor%2520Immunity%2520by%2520Removing%2520CD25%252B%2520and%2520CD4%252B%2520T%2520Cells%253A%2520A%2520Common%2520Basis%2520Between%2520Tumor%2520Immunity%2520and%2520Autoimmunity%26jtitle%3DJ.%2520Immunol.%26date%3D1999%26volume%3D163%26spage%3D5211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassett, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Macedo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin-Breneman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broaddus, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenwald, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glitza, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vence, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaria, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overwijk, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blando, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span> <span> </span><span class="NLM_article-title">Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">827</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1158%2F2159-8290.CD-15-1545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=27301722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12mtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=827&author=P.-L.+Chenauthor=W.+Rohauthor=A.+Reubenauthor=Z.+A.+Cooperauthor=C.+N.+Spencerauthor=P.+A.+Prietoauthor=J.+P.+Millerauthor=R.+L.+Bassettauthor=V.+Gopalakrishnanauthor=K.+Waniauthor=M.+P.+De+Macedoauthor=J.+L.+Austin-Brenemanauthor=H.+Jiangauthor=Q.+Changauthor=S.+M.+Reddyauthor=W.-S.+Chenauthor=M.+T.+Tetzlaffauthor=R.+J.+Broaddusauthor=M.+A.+Daviesauthor=J.+E.+Gershenwaldauthor=L.+Hayduauthor=A.+J.+Lazarauthor=S.+P.+Patelauthor=P.+Hwuauthor=W.-J.+Hwuauthor=A.+Diabauthor=I.+C.+Glitzaauthor=S.+E.+Woodmanauthor=L.+M.+Venceauthor=I.+I.+Wistubaauthor=R.+N.+Amariaauthor=L.+N.+Kwongauthor=V.+Prietoauthor=R.+E.+Davisauthor=W.+Maauthor=W.+W.+Overwijkauthor=A.+H.+Sharpeauthor=J.+Huauthor=P.+A.+Futrealauthor=J.+Blandoauthor=P.+Sharmaauthor=J.+P.+Allisonauthor=L.+Chinauthor=J.+A.+Wargo&title=Analysis+of+Immune+Signatures+in+Longitudinal+Tumor+Samples+Yields+Insight+into+Biomarkers+of+Response+and+Mechanisms+of+Resistance+to+Immune+Checkpoint+Blockade&doi=10.1158%2F2159-8290.CD-15-1545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade</span></div><div class="casAuthors">Chen, Pei-Ling; Roh, Whijae; Reuben, Alexandre; Cooper, Zachary A.; Spencer, Christine N.; Prieto, Peter A.; Miller, John P.; Bassett, Roland L.; Gopalakrishnan, Vancheswaran; Wani, Khalida; Petaccia De Macedo, Mariana; Austin-Breneman, Jacob L.; Jiang, Hong; Chang, Qing; Reddy, Sangeetha M.; Chen, Wei-Shen; Tetzlaff, Michael T.; Broaddus, Russell J.; Davies, Michael A.; Gershenwald, Jeffrey E.; Haydu, Lauren; Lazar, Alexander J.; Patel, Sapna P.; Hwu, Patrick; Hwu, Wen-Jen; Diab, Adi; Glitza, Isabella C.; Woodman, Scott E.; Vence, Luis M.; Wistuba, Ignacio I.; Amaria, Rodabe N.; Kwong, Lawrence N.; Prieto, Victor; Davis, R. Eric; Ma, Wencai; Overwijk, Willem W.; Sharpe, Arlene H.; Hu, Jianhua; Futreal, P. Andrew; Blando, Jorge; Sharma, Padmanee; Allison, James P.; Chin, Lynda; Wargo, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">827-837</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal.  Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and other cancers, but robust biomarkers have not been identified.  We studied a cohort of patients with metastatic melanoma initially treated with cytotoxic T-lymphocyte-assocd. antigen-4 (CTLA4) blockade (n = 53) followed by programmed death-1 (PD-1) blockade at progression (n = 46), and analyzed immune signatures in longitudinal tissue samples collected at multiple time points during therapy.  In this study, we demonstrate that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade.  Importantly, potential mechanisms of therapeutic resistance to immune checkpoint blockade were also identified.  Significance: These studies demonstrate that adaptive immune signatures in early on-treatment tumor biopsies are predictive of response to checkpoint blockade and yield insight into mechanisms of therapeutic resistance.  These concepts have far-reaching implications in this age of precision medicine and should be explored in immune checkpoint blockade treatment across cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4yheFcpbQs7Vg90H21EOLACvtfcHk0lh19vP3W-yFAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12mtbbP&md5=e8cae5ccf55f9fe4f217044708c1cb32</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1545%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.-L.%26aulast%3DRoh%26aufirst%3DW.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DSpencer%26aufirst%3DC.%2BN.%26aulast%3DPrieto%26aufirst%3DP.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BP.%26aulast%3DBassett%26aufirst%3DR.%2BL.%26aulast%3DGopalakrishnan%26aufirst%3DV.%26aulast%3DWani%26aufirst%3DK.%26aulast%3DDe%2BMacedo%26aufirst%3DM.%2BP.%26aulast%3DAustin-Breneman%26aufirst%3DJ.%2BL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DReddy%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DW.-S.%26aulast%3DTetzlaff%26aufirst%3DM.%2BT.%26aulast%3DBroaddus%26aufirst%3DR.%2BJ.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DHaydu%26aufirst%3DL.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DS.%2BP.%26aulast%3DHwu%26aufirst%3DP.%26aulast%3DHwu%26aufirst%3DW.-J.%26aulast%3DDiab%26aufirst%3DA.%26aulast%3DGlitza%26aufirst%3DI.%2BC.%26aulast%3DWoodman%26aufirst%3DS.%2BE.%26aulast%3DVence%26aufirst%3DL.%2BM.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DAmaria%26aufirst%3DR.%2BN.%26aulast%3DKwong%26aufirst%3DL.%2BN.%26aulast%3DPrieto%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DOverwijk%26aufirst%3DW.%2BW.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DBlando%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26atitle%3DAnalysis%2520of%2520Immune%2520Signatures%2520in%2520Longitudinal%2520Tumor%2520Samples%2520Yields%2520Insight%2520into%2520Biomarkers%2520of%2520Response%2520and%2520Mechanisms%2520of%2520Resistance%2520to%2520Immune%2520Checkpoint%2520Blockade%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D827%26doi%3D10.1158%2F2159-8290.CD-15-1545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berlato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioppa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montfort, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jangani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulbe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemann, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powles, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quezada, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkwill, F. R.</span></span> <span> </span><span class="NLM_article-title">A CCR4 Antagonist Reverses the Tumor-Promoting Microenvironment of Renal Cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1172/JCI82976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1172%2FJCI82976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=28134623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A280%3ADC%252BC1c3gsVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=801-813&author=C.+Berlatoauthor=M.+N.+Khanauthor=T.+Schioppaauthor=R.+Thompsonauthor=E.+Maniatiauthor=A.+Montfortauthor=M.+Janganiauthor=M.+Canosaauthor=H.+Kulbeauthor=U.+B.+Hagemannauthor=A.+R.+Duncanauthor=L.+Fletcherauthor=R.+W.+Wilkinsonauthor=T.+Powlesauthor=S.+A.+Quezadaauthor=F.+R.+Balkwill&title=A+CCR4+Antagonist+Reverses+the+Tumor-Promoting+Microenvironment+of+Renal+Cancer&doi=10.1172%2FJCI82976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer</span></div><div class="casAuthors">Berlato Chiara; Khan Moddasar N; Schioppa Tiziana; Thompson Richard; Maniati Eleni; Montfort Anne; Jangani Maryam; Canosa Monica; Kulbe Hagen; Hagemann Urs B; Duncan Alexander R; Fletcher Laura; Wilkinson Robert W; Powles Thomas; Quezada Sergio A; Balkwill Frances R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">801-813</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Elevated expression of the chemokine receptor CCR4 in tumors is associated with poor prognosis in several cancers.  Here, we have determined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed abnormal levels of CCR4 ligands in RCC patient plasma.  An antagonistic anti-CCR4 antibody had antitumor activity in the RENCA mouse model of RCC.  CCR4 inhibition did not reduce the proportion of infiltrating leukocytes in the tumor microenvironment but altered the phenotype of myeloid cells, increased NK cell and Th1 cytokine levels, and reduced immature myeloid cell infiltrate and blood chemokine levels.  In spite of prominent changes in the myeloid compartment, the anti-CCR4 antibody did not affect RENCA tumors in T cell-deficient mice, and treatment with an anti-class II MHC antibody abrogated its antitumor activity.  We concluded that the effects of the anti-CCR4 antibody required the adaptive immune system and CD4+ T cells.  Moreover, CCL17-induced IFN-γ production was reduced when Th1-polarized normal CD4+ T cells were exposed to the CCR4 ligand, evidencing the involvement of CCR4 in Th1/Th2 regulation.  The anti-CCR4 antibody, alone or in combination with other immune modulators, is a potential treatment approach to human solid cancers with high levels of CCR4-expressing tumor-infiltrating leukocytes and abnormal plasma CCR4 ligand levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoQFKAF-OvBn6CEoQgWY10fW6udTcc2eaAcBqaB1CtWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3gsVGnsA%253D%253D&md5=031641076ef19ed1e1ca081e2ac069b8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1172%2FJCI82976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI82976%26sid%3Dliteratum%253Aachs%26aulast%3DBerlato%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DM.%2BN.%26aulast%3DSchioppa%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DManiati%26aufirst%3DE.%26aulast%3DMontfort%26aufirst%3DA.%26aulast%3DJangani%26aufirst%3DM.%26aulast%3DCanosa%26aufirst%3DM.%26aulast%3DKulbe%26aufirst%3DH.%26aulast%3DHagemann%26aufirst%3DU.%2BB.%26aulast%3DDuncan%26aufirst%3DA.%2BR.%26aulast%3DFletcher%26aufirst%3DL.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DPowles%26aufirst%3DT.%26aulast%3DQuezada%26aufirst%3DS.%2BA.%26aulast%3DBalkwill%26aufirst%3DF.%2BR.%26atitle%3DA%2520CCR4%2520Antagonist%2520Reverses%2520the%2520Tumor-Promoting%2520Microenvironment%2520of%2520Renal%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D801%26epage%3D813%26doi%3D10.1172%2FJCI82976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">CCR4 as a Novel Molecular Target for Immunotherapy of Cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2006.00307.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1111%2Fj.1349-7006.2006.00307.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=16952304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFemtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=1139-1146&author=T.+Ishidaauthor=R.+Ueda&title=CCR4+as+a+Novel+Molecular+Target+for+Immunotherapy+of+Cancer&doi=10.1111%2Fj.1349-7006.2006.00307.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CCR4 as a novel molecular target for immunotherapy of cancer</span></div><div class="casAuthors">Ishida, Takashi; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1139-1146</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukocyte trafficking, which is critically regulated by chemokines and their receptors, shares many of the characteristics of tumor cell infiltration and metastasis.  Expression of CC chemokine receptor 4 (CCR4) by tumor cells is assocd. with skin involvement, but CCR4 also has an important role in normal and tumor immunity.  In a subset of patients with CCR4+ T-cell leukemia/lymphoma, the tumor cells themselves function as regulatory T (Treg) cells, contributing to tumor survival in the face of host antitumor immune responses.  In other types of cancers, the chemokines TARC/CCL17 and MDC/CCL22, specific ligands for CCR4 that are produced by tumor cells and the tumor microenvironment, attract CCR4+ Treg cells to the tumor, where they create a favorable environment for tumor escape from host immune responses.  A novel humanized anti-CCR4 monoclonal antibody (mAb) has been developed, the Fc region of which is defucosylated to enhance antibody-dependent cellular cytotoxicity by increasing its binding affinity to Fc receptor on effector cells.  We are now conducting a phase I clin. trial of this anti-CCR4 mAb in patients with CCR4+ T-cell leukemia/lymphoma in Japan (clin. trials gov. identifier: NCT00355472).  Anti-CCR4 mAb could be an ideal treatment modality for many different cancers, not only to directly kill the CCR4+ tumor cells, but also to overcome the suppressive effect of CCR4+ Treg cells on the host immune response to tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSaM9sSn_TJbVg90H21EOLACvtfcHk0lh19vP3W-yFAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFemtbjJ&md5=1ae7461548ceb9b10873b891551e4d9e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2006.00307.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2006.00307.x%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DCCR4%2520as%2520a%2520Novel%2520Molecular%2520Target%2520for%2520Immunotherapy%2520of%2520Cancer%26jtitle%3DCancer%2520Sci.%26date%3D2006%26volume%3D97%26spage%3D1139%26epage%3D1146%26doi%3D10.1111%2Fj.1349-7006.2006.00307.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshie, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, K.</span></span> <span> </span><span class="NLM_article-title">CCR4 and its Ligands: From Bench to Bedside</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxu079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1093%2Fintimm%2Fdxu079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25087232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFejtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=11-20&author=O.+Yoshieauthor=K.+Matsushima&title=CCR4+and+its+Ligands%3A+From+Bench+to+Bedside&doi=10.1093%2Fintimm%2Fdxu079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">CCR4 and its ligands: from bench to bedside</span></div><div class="casAuthors">Yoshie, Osamu; Matsushima, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-20</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Chemokines and chemokine receptors orchestrate cell migration and homing in the body.  Humans have at least 44 chemokines that are further classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C and CX3C.  All the known chemokine receptors are seven transmembrane-type receptors.  Humans have 18 chemotactic and 5 atypical non-chemotactic (recycling or scavenging) receptors.  CC chemokine receptor 4 (CCR4) is the receptor for two CC chemokine ligands (CCLs)-CCL17 (also called thymus- and activation-regulated chemokine) and CCL22 (macrophage-derived chemokine).  Among the various T-cell subsets, CCR4 is predominantly expressed by Th2 cells, cutaneous lymphocyte antigen-pos. skin-homing T cells and Treg cells.  Thus, CCR4 attracts much attention for its possible clin. applications in diseases involving these T-cell subsets.  Furthermore, CCR4 is often highly expressed by mature T-cell neoplasms such as adult T-cell leukemia/lymphoma (ATL) and cutaneous T-cell lymphomas (CTCLs).  This article is a brief overview of basic and clin. research on CCR4 and its ligands, which has eventually led to the development of a humanized defucosylated anti-CCR4 antibody "Mogamulizumab" for treatment of relapsed/refractory ATL and CTCLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSHH-JLAL3JbVg90H21EOLACvtfcHk0ljCEc8NTKmzOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFejtb0%253D&md5=1361a07097b9ea62f8c04f78638f5460</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxu079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxu079%26sid%3Dliteratum%253Aachs%26aulast%3DYoshie%26aufirst%3DO.%26aulast%3DMatsushima%26aufirst%3DK.%26atitle%3DCCR4%2520and%2520its%2520Ligands%253A%2520From%2520Bench%2520to%2520Bedside%26jtitle%3DInt.%2520Immunol.%26date%3D2015%26volume%3D27%26spage%3D11%26epage%3D20%26doi%3D10.1093%2Fintimm%2Fdxu079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiedemann, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knott, M. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haubner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesseler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kühnemuth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layritz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormanns, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anz, D.</span></span> <span> </span><span class="NLM_article-title">Cancer Cell-Derived IL-1α Induces CCL22 and the Recruitment of Regulatory T Cells</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1175794</span> <span class="refDoi"> DOI: 10.1080/2162402X.2016.1175794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1080%2F2162402X.2016.1175794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=27757295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSgur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=G.+M.+Wiedemannauthor=M.+M.+L.+Knottauthor=V.+K.+Vetterauthor=M.+Rappauthor=S.+Haubnerauthor=J.+Fesselerauthor=B.+K%C3%BChnemuthauthor=P.+Layritzauthor=R.+Thalerauthor=S.+Krugerauthor=S.+Ormannsauthor=D.+Mayrauthor=S.+Endresauthor=D.+Anz&title=Cancer+Cell-Derived+IL-1%CE%B1+Induces+CCL22+and+the+Recruitment+of+Regulatory+T+Cells&doi=10.1080%2F2162402X.2016.1175794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells</span></div><div class="casAuthors">Wiedemann, Gabriela Maria; Knott, Max Martin Ludwig; Vetter, Viola Katharina; Rapp, Moritz; Haubner, Sascha; Fesseler, Julia; Kuehnemuth, Benjamin; Layritz, Patrick; Thaler, Raffael; Kruger, Stephan; Ormanns, Steffen; Mayr, Doris; Endres, Stefan; Anz, David</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e1175794/1-e1175794/11</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">In cancer patients, immunosuppression through regulatory T cells (Treg) is a crucial component of tumor immune evasion and contributes to disease progression.  Tumor-infiltrating Treg in particular suppress local effector T cell responses and are assocd. with poor prognosis in tumors such as human pancreatic cancer or hepatocellular carcinoma (HCC).  The chemokine CCL22 is known to recruit Treg into the tumor tissue and many types of human tumors are known to express high levels of CCL22.  The mechanisms leading to intratumoral secretion of CCL22 are so far unknown.  We demonstrate here that intratumoral CCL22 is induced in tumor-infiltrating immune cells through cancer cell-derived interleukin-1 (IL-1α).  In pancreatic cancer and HCC, CCL22 is produced by intratumoral dendritic cells, while the cancer cells themselves do not secrete CCL22 in vitro and in vivo.  Incubation of human peripheral blood mononuclear cells (PBMC) or murine splenocytes with tumor cells or tumor cell supernatants strongly induced CCL22 secretion in vitro.  Tumor cell supernatants contained IL-1 and CCL22 induction in PBMC could be specifically prevented by the IL-1 receptor antagonist anakinra or by transfection of tumor cell lines with IL-1 siRNA, leading to a suppression of Treg migration.  In conclusion, we identify here tumor cell-derived IL-1α as a major inducer of the Treg attracting chemokine CCL22 in human cancer cells.  Therapeutic blockade of the IL-1 pathway could represent a promising strategy to inhibit tumor-induced immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpslhagMdrESbVg90H21EOLACvtfcHk0ljCEc8NTKmzOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSgur7E&md5=75aaa060cfc445e8af5afe9d60018a88</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1175794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1175794%26sid%3Dliteratum%253Aachs%26aulast%3DWiedemann%26aufirst%3DG.%2BM.%26aulast%3DKnott%26aufirst%3DM.%2BM.%2BL.%26aulast%3DVetter%26aufirst%3DV.%2BK.%26aulast%3DRapp%26aufirst%3DM.%26aulast%3DHaubner%26aufirst%3DS.%26aulast%3DFesseler%26aufirst%3DJ.%26aulast%3DK%25C3%25BChnemuth%26aufirst%3DB.%26aulast%3DLayritz%26aufirst%3DP.%26aulast%3DThaler%26aufirst%3DR.%26aulast%3DKruger%26aufirst%3DS.%26aulast%3DOrmanns%26aufirst%3DS.%26aulast%3DMayr%26aufirst%3DD.%26aulast%3DEndres%26aufirst%3DS.%26aulast%3DAnz%26aufirst%3DD.%26atitle%3DCancer%2520Cell-Derived%2520IL-1%25CE%25B1%2520Induces%2520CCL22%2520and%2520the%2520Recruitment%2520of%2520Regulatory%2520T%2520Cells%26jtitle%3DOncoImmunology%26date%3D2016%26volume%3D5%26doi%3D10.1080%2F2162402X.2016.1175794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiba, S.</span></span> <span> </span><span class="NLM_article-title">Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.3389%2Ffonc.2018.00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=29410946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvotl2jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=3&author=T.+Fujimuraauthor=Y.+Kambayashiauthor=Y.+Fujisawaauthor=T.+Hidakaauthor=S.+Aiba&title=Tumor-Associated+Macrophages%3A+Therapeutic+Targets+for+Skin+Cancer&doi=10.3389%2Ffonc.2018.00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer</span></div><div class="casAuthors">Fujimura Taku; Kambayashi Yumi; Hidaka Takanori; Aiba Setsuya; Fujisawa Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) are significant components of the microenvironment of solid tumors in the majority of cancers.  TAMs sequentially develop from monocytes into functional macrophages.  In each differentiation stage, TAMs obtain various immunosuppressive functions to maintain the tumor microenvironment (e.g., expression of immune checkpoint molecules, production of Treg-related chemokines and cytokines, production of arginase I).  Although the main population of TAMs is immunosuppressive M2 macrophages, TAMs can be modulated into M1-type macrophages in each differential stage, leading to the suppression of tumor growth.  Because the administration of certain drugs or stromal factors can stimulate TAMs to produce specific chemokines, leading to the recruitment of various tumor-infiltrating lymphocytes, TAMs can serve as targets for cancer immunotherapy.  In this review, we discuss the differentiation, activation, and immunosuppressive function of TAMs, as well as their benefits in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd4fdOtIBLJdbHMBt0mMIXfW6udTcc2eaeCFa_By1UULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvotl2jsQ%253D%253D&md5=9ef4239912db99e8c706e1cbc2c11cef</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00003%26sid%3Dliteratum%253Aachs%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DKambayashi%26aufirst%3DY.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DHidaka%26aufirst%3DT.%26aulast%3DAiba%26aufirst%3DS.%26atitle%3DTumor-Associated%2520Macrophages%253A%2520Therapeutic%2520Targets%2520for%2520Skin%2520Cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26spage%3D3%26doi%3D10.3389%2Ffonc.2018.00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span> <span> </span><span class="NLM_article-title">Molecular Cloning and Characterization of Chemokine-Like Factor 1 (CKLF1), a Novel Human Cytokine with Unique Structure and Potential Chemotactic Activity</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">127</span>, <span class="refDoi"> DOI: 10.1042/0264-6021:3570127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1042%2Fbj3570127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=11415443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Ojtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2001&pages=127&author=W.+Hanauthor=Y.+Louauthor=J.+Tangauthor=Y.+Zhangauthor=Y.+Chenauthor=Y.+Liauthor=W.+Guauthor=J.+Huangauthor=L.+Guiauthor=Y.+Tangauthor=F.+Liauthor=Q.+Songauthor=C.+Diauthor=L.+Wangauthor=Q.+Shiauthor=R.+Sunauthor=D.+Xiaauthor=M.+Ruiauthor=J.+Tangauthor=D.+Ma&title=Molecular+Cloning+and+Characterization+of+Chemokine-Like+Factor+1+%28CKLF1%29%2C+a+Novel+Human+Cytokine+with+Unique+Structure+and+Potential+Chemotactic+Activity&doi=10.1042%2F0264-6021%3A3570127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity</span></div><div class="casAuthors">Han, Wenling; Lou, Yaxin; Tang, Junmin; Zhang, Yingmei; Chen, Yingyu; Li, Ying; Gu, Weifeng; Huang, Jiaqiang; Gui, Liming; Tang, Yan; Li, Feng; Song, Quansheng; Di, Chunhui; Wang, Lu; Shi, Qun; Sun, Ronghua; Xia, Donglan; Rui, Min; Tang, Jian; Ma, Dalong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Cytokines are small proteins that have an essential role in the immune and inflammatory responses.  The repertoire of cytokines is becoming diverse and expanding.  Here the authors report the identification and characterization of a novel cytokine designated as chemokine-like factor 1 (CKLF1).  The full-length cDNA of CKLF1 is 530 bp long and a single open reading frame encoding 99 amino acid residues.  CKLF1 bears no significant similarity to any other known cytokine in its amino acid sequence.  Expression of CKLF1 can be partly inhibited by interleukin 10 in PHA-stimulated U937 cells.  Recombinant CKLF1 is a potent chemoattractant for neutrophils, monocytes and lymphocytes; moreover, it can stimulate the proliferation of murine skeletal muscle cells.  These results suggest that CKLF1 might have important roles in inflammation and in the regeneration of skeletal muscle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKBchdzE5wabVg90H21EOLACvtfcHk0lhGqSaPKRZNZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Ojtbk%253D&md5=574d3966f7b27285d697d0c6953f2f60</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1042%2Fbj3570127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3570127%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DGui%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DDi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DD.%26aulast%3DRui%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DD.%26atitle%3DMolecular%2520Cloning%2520and%2520Characterization%2520of%2520Chemokine-Like%2520Factor%25201%2520%2528CKLF1%2529%252C%2520a%2520Novel%2520Human%2520Cytokine%2520with%2520Unique%2520Structure%2520and%2520Potential%2520Chemotactic%2520Activity%26jtitle%3DBiochem.%2520J.%26date%3D2001%26volume%3D357%26spage%3D127%26doi%3D10.1042%2F0264-6021%3A3570127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span> <span> </span><span class="NLM_article-title">Chemokine-Like Factor 1 is a Functional Ligand for CC Chemokine Receptor 4 (CCR4)</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">614</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2005.05.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.lfs.2005.05.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=16137713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWqu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2006&pages=614-621&author=Y.+Wangauthor=Y.+Zhangauthor=X.+Yangauthor=W.+Hanauthor=Y.+Liuauthor=Q.+Xuauthor=R.+Zhaoauthor=C.+Diauthor=Q.+Songauthor=D.+Ma&title=Chemokine-Like+Factor+1+is+a+Functional+Ligand+for+CC+Chemokine+Receptor+4+%28CCR4%29&doi=10.1016%2Fj.lfs.2005.05.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4)</span></div><div class="casAuthors">Wang, Ying; Zhang, Yingmei; Yang, Xue; Han, Wenling; Liu, Yanan; Xu, Qianmei; Zhao, Rui; Di, Chunhui; Song, Quansheng; Ma, Dalong</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">614-621</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chemokine-like factor 1 (CKLF1) exhibits chemotactic effects on leukocytes.  Its amino acid sequence shares similarity with those of TARC/CCL17 and MDC/CCL22, the cognate ligands for CCR4.  The chemotactic effects of CKLF1 for CCR4-transfected cells could be desensitized by TARC/CCL17 and markedly inhibited by PTX.  CKLF1 induced a calcium flux in CCR4-transfected cells and fully desensitized a subsequent response to TARC/CCL17, and TARC/CCL17 could partly desensitize the response to CKLF1.  CKLF1 caused significant receptor internalization in pCCR4-EGFP transfected cells.  Taken together, CKLF1 is a novel functional ligand for CCR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAqlHhhw3zS7Vg90H21EOLACvtfcHk0lhGqSaPKRZNZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWqu7bJ&md5=f33cc1856d52df0d6e8985ff413035f5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2005.05.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2005.05.070%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DDi%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DD.%26atitle%3DChemokine-Like%2520Factor%25201%2520is%2520a%2520Functional%2520Ligand%2520for%2520CC%2520Chemokine%2520Receptor%25204%2520%2528CCR4%2529%26jtitle%3DLife%2520Sci.%26date%3D2006%26volume%3D78%26spage%3D614%26epage%3D621%26doi%3D10.1016%2Fj.lfs.2005.05.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinenaite, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munir Ahmad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Met, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westergaard, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klausen, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svane, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. H.</span></span> <span> </span><span class="NLM_article-title">CCL22-specific T Cells: Modulating the Immunosuppressive Tumor Microenvironment</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1238541</span> <span class="refDoi"> DOI: 10.1080/2162402X.2016.1238541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1080%2F2162402X.2016.1238541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=27999757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2msb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=E.+Martinenaiteauthor=S.+Munir+Ahmadauthor=M.+Hansenauthor=%C3%96.+Metauthor=M.+W.+Westergaardauthor=S.+K.+Larsenauthor=T.+W.+Klausenauthor=M.+Doniaauthor=I.+M.+Svaneauthor=M.+H.+Andersen&title=CCL22-specific+T+Cells%3A+Modulating+the+Immunosuppressive+Tumor+Microenvironment&doi=10.1080%2F2162402X.2016.1238541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment</span></div><div class="casAuthors">Martinenaite, Evelina; Munir Ahmad, Shamaila; Hansen, Morten; Met, Ozcan; Westergaard, Marie Wulff; Larsen, Stine Kiaer; Klausen, Tobias Wirenfeldt; Donia, Marco; Svane, Inge Marie; Andersen, Mads Hald</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e1238541/1-e1238541/10</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Tumor cells and tumor-infiltrating macrophages produce the chemokine CCL22, which attracts regulatory T cells (Tregs) into the tumor microenvironment, decreasing anticancer immunity.  Here, we investigated the possibility of targeting CCL22-expressing cells by activating specific T cells.  We analyzed the CCL22 protein signal sequence, identifying a human leukocyte antigen A2- (HLA-A2-) restricted peptide epitope, which we then used to stimulate peripheral blood mononuclear cells (PMBCs) to expand populations of CCL22-specific T cells in vitro.  T cells recognizing an epitope derived from the signal-peptide of CCL22 will recognize CCL22-expressing cells even though CCL22 is secreted out of the cell.  CCL22-specific T cells recognized and killed CCL22-expressing cancer cells.  Furthermore, CCL22-specific T cells lysed acute monocytic leukemia cells in a CCL22 expression-dependent manner.  Using the Enzyme-Linked ImmunoSPOT assay, we examd. peripheral blood mononuclear cells from HLA-A2+ cancer patients and healthy volunteers for reactivity against the CCL22-derived T-cell epitope.  This revealed spontaneous T-cell responses against the CCL22-derived epitope in cancer patients and in healthy donors.  Finally, we performed tetramer enrichment/depletion expts. to examine the impact of HLA-A2-restricted CCL22-specific T cells on CCL22 levels among PMBCs.  The addn. or activation of CCL22-specific T cells decreased the CCL22 level in the microenvironment.  Activating CCL22-specific T cells (e.g., by vaccination) may directly target cancer cells and tumor-assocd. macrophages, thereby modulating Treg recruitment into the tumor environment and augmenting anticancer immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9WDcRz5OxnbVg90H21EOLACvtfcHk0lhGqSaPKRZNZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2msb7P&md5=543da99773be1ac52e9b600fee286639</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1238541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1238541%26sid%3Dliteratum%253Aachs%26aulast%3DMartinenaite%26aufirst%3DE.%26aulast%3DMunir%2BAhmad%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DMet%26aufirst%3D%25C3%2596.%26aulast%3DWestergaard%26aufirst%3DM.%2BW.%26aulast%3DLarsen%26aufirst%3DS.%2BK.%26aulast%3DKlausen%26aufirst%3DT.%2BW.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DSvane%26aufirst%3DI.%2BM.%26aulast%3DAndersen%26aufirst%3DM.%2BH.%26atitle%3DCCL22-specific%2520T%2520Cells%253A%2520Modulating%2520the%2520Immunosuppressive%2520Tumor%2520Microenvironment%26jtitle%3DOncoImmunology%26date%3D2016%26volume%3D5%26doi%3D10.1080%2F2162402X.2016.1238541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komabayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishibe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkuri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harabuchi, Y.</span></span> <span> </span><span class="NLM_article-title">CCL17 and CCL22/CCR4 Signaling is a Strong Candidate for Novel Targeted Therapy Against Nasal Natural Killer/T-Cell Lymphoma</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1007/s00262-015-1675-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1007%2Fs00262-015-1675-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25754123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1Omsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=697-705&author=T.+Kumaiauthor=T.+Nagatoauthor=H.+Kobayashiauthor=Y.+Komabayashiauthor=S.+Uedaauthor=K.+Kishibeauthor=T.+Ohkuriauthor=M.+Takaharaauthor=E.+Celisauthor=Y.+Harabuchi&title=CCL17+and+CCL22%2FCCR4+Signaling+is+a+Strong+Candidate+for+Novel+Targeted+Therapy+Against+Nasal+Natural+Killer%2FT-Cell+Lymphoma&doi=10.1007%2Fs00262-015-1675-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma</span></div><div class="casAuthors">Kumai, Takumi; Nagato, Toshihiro; Kobayashi, Hiroya; Komabayashi, Yuki; Ueda, Seigo; Kishibe, Kan; Ohkuri, Takayuki; Takahara, Miki; Celis, Esteban; Harabuchi, Yasuaki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">697-705</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Nasal natural killer/T-cell lymphoma (NNKTL) is assocd. with Epstein-Barr virus and has a poor prognosis because of local invasion and/or multiple dissemination.  Various chemokines play a role in tumor proliferation and invasion, and chemokine receptors including the C-C chemokine receptor 4 (CCR4) are recognized as potential targets for treating hematol. malignancies.  The aim of the present study was to det. whether specific chemokines are produced by NNKTL.  We compared chemokine expression patterns in culture supernatants of NNKTL cell lines with those of other lymphoma or leukemia cell lines using chemokine protein array and ELISA.  Chemokine (C-C motif) ligand (CCL) 17 and CCL22 were highly produced by NNKTL cell lines as compared to the other cell lines.  In addn., CCL17 and CCL22 were readily obsd. in the sera of NNKTL patients.  The levels of these chemokines were significantly higher in patients than in healthy controls.  Furthermore, we detected the expression of CCR4 (the receptor for CCL17 and CCL22) on the surface of NNKTL cell lines and in tissues of NNKTL patients.  Anti-CCR4 monoclonal antibody (mAb) efficiently induced antibody-dependent cellular cytotoxicity mediated by natural killer cells against NNKTL cell lines.  Our results suggest that CCL17 and CCL22 may be important factors in the development of NNKTL and open up the possibility of immunotherapy of this lymphoma using anti-CCR4 mAb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg0g-aCyoytLVg90H21EOLACvtfcHk0ljkuicINT6_PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1Omsrk%253D&md5=8d437143dd821e1f2785236b556c1bdd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs00262-015-1675-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-015-1675-7%26sid%3Dliteratum%253Aachs%26aulast%3DKumai%26aufirst%3DT.%26aulast%3DNagato%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DKomabayashi%26aufirst%3DY.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DKishibe%26aufirst%3DK.%26aulast%3DOhkuri%26aufirst%3DT.%26aulast%3DTakahara%26aufirst%3DM.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DHarabuchi%26aufirst%3DY.%26atitle%3DCCL17%2520and%2520CCL22%252FCCR4%2520Signaling%2520is%2520a%2520Strong%2520Candidate%2520for%2520Novel%2520Targeted%2520Therapy%2520Against%2520Nasal%2520Natural%2520Killer%252FT-Cell%2520Lymphoma%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2015%26volume%3D64%26spage%3D697%26epage%3D705%26doi%3D10.1007%2Fs00262-015-1675-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wreggett, K. A.</span></span> <span> </span><span class="NLM_article-title">An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G Protein-Coupled Receptors CCR4 and CCR5</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">855</span>, <span class="refDoi"> DOI: 10.1124/mol.107.039321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1124%2Fmol.107.039321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=18042736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1egsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=855&author=G.+Andrewsauthor=C.+Jonesauthor=K.+A.+Wreggett&title=An+Intracellular+Allosteric+Site+for+a+Specific+Class+of+Antagonists+of+the+CC+Chemokine+G+Protein-Coupled+Receptors+CCR4+and+CCR5&doi=10.1124%2Fmol.107.039321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5</span></div><div class="casAuthors">Andrews, Glen; Jones, Carolyn; Wreggett, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A novel mechanism for antagonism of the human chemokine receptors CCR4 and CCR5 has been discovered with a series of small-mol. compds. that seems to interact with an allosteric, intracellular site on the receptor.  The existence of this site is supported by a series of observations: (1) intracellular access of these antagonists is required for their activity; (2) specific, saturable binding of a radiolabeled antagonist requires the presence of CCR4; and (3) through engineering receptor chimeras by reciprocal transfer of C-terminal domains between CCR4 and CCR5, compd. binding and the selective structure-activity relationships for antagonism of these receptors seem to be assocd. with the integrity of that intracellular region.  Published antagonists from other chem. series do not seem to bind to the novel site, and their interaction with either CCR4 or CCR5 is not affected by alteration of the C-terminal domain.  The precise location of the proposed binding site remains to be detd., but the known close assocn. of the C-terminal domain, including helix 8, as a proposed intracellular region that interacts with transduction proteins (e.g., G proteins and β-arrestin) suggests that this could be a generic allosteric site for chemokine receptors and perhaps more broadly for class A G protein-coupled receptors.  The existence of such a site that can be targeted for drug discovery has implications for screening assays for receptor antagonists, which would need, therefore, to consider compd. properties for access to this intracellular site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAPVG6Nu0Wf7Vg90H21EOLACvtfcHk0ljkuicINT6_PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1egsLw%253D&md5=f3624c421bac61365f63ea1389dffea0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.039321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.039321%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DWreggett%26aufirst%3DK.%2BA.%26atitle%3DAn%2520Intracellular%2520Allosteric%2520Site%2520for%2520a%2520Specific%2520Class%2520of%2520Antagonists%2520of%2520the%2520CC%2520Chemokine%2520G%2520Protein-Coupled%2520Receptors%2520CCR4%2520and%2520CCR5%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D855%26doi%3D10.1124%2Fmol.107.039321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalesso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span> <span> </span><span class="NLM_article-title">Antagonism of Human CC-Chemokine Receptor 4 Can Be Achieved Through Three Distinct Binding Sites on the Receptor</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e00019</span> <span class="refDoi"> DOI: 10.1002/prp2.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1002%2Fprp2.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25505571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yntr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&author=R.+J.+Slackauthor=L.+J.+Russellauthor=N.+P.+Bartonauthor=C.+Westonauthor=G.+Nalessoauthor=S.-A.+Thompsonauthor=M.+Allenauthor=Y.+H.+Chenauthor=A.+Barnesauthor=S.+T.+Hodgsonauthor=D.+A.+Hall&title=Antagonism+of+Human+CC-Chemokine+Receptor+4+Can+Be+Achieved+Through+Three+Distinct+Binding+Sites+on+the+Receptor&doi=10.1002%2Fprp2.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor</span></div><div class="casAuthors">Slack, Robert J.; Russell, Linda J.; Barton, Nick P.; Weston, Cathryn; Nalesso, Giovanna; Thompson, Sally-Anne; Allen, Morven; Chen, Yu Hua; Barnes, Ashley; Hodgson, Simon T.; Hall, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology Research & Perspectives</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e00019/1-e00019/25</span>CODEN:
                <span class="NLM_cas:coden">PRPHCA</span>;
        ISSN:<span class="NLM_cas:issn">2052-1707</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Chemokine receptor antagonists appear to access two distinct binding sites on different members of this receptor family.  One class of CCR4 antagonists has been suggested to bind to a site accessible from the cytoplasm while a second class did not bind to this site.  In this report, we demonstrate that antagonists representing a variety of structural classes bind to two distinct allosteric sites on CCR4.  The effects of pairs of low-mol. wt. and/or chemokine CCR4 antagonists were evaluated on CCL17- and CCL22-induced responses of human CCR4+ T cells.  This provided an initial grouping of the antagonists into sets which appeared to bind to distinct binding sites.  Binding studies were then performed with radioligands from each set to confirm these groupings.  Some novel receptor theory was developed to allow the interpretation of the effects of the antagonist combinations.  The theory indicates that, generally, the concn.-ratio of a pair of competing allosteric modulators is maximally the sum of their individual effects while that of two modulators acting at different sites is likely to be greater than their sum.  The low-mol. wt. antagonists could be grouped into two sets on the basis of the functional and binding expts.  The antagonistic chemokines formed a third set whose behavior was consistent with that of simple competitive antagonists.  These studies indicate that there are two allosteric regulatory sites on CCR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj9cDmC7ops7Vg90H21EOLACvtfcHk0ljkuicINT6_PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yntr3O&md5=d3c75616ffba6b6644c8755fcff21e5c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fprp2.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.19%26sid%3Dliteratum%253Aachs%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DRussell%26aufirst%3DL.%2BJ.%26aulast%3DBarton%26aufirst%3DN.%2BP.%26aulast%3DWeston%26aufirst%3DC.%26aulast%3DNalesso%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DS.-A.%26aulast%3DAllen%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DBarnes%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DHall%26aufirst%3DD.%2BA.%26atitle%3DAntagonism%2520of%2520Human%2520CC-Chemokine%2520Receptor%25204%2520Can%2520Be%2520Achieved%2520Through%2520Three%2520Distinct%2520Binding%2520Sites%2520on%2520the%2520Receptor%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2013%26volume%3D1%26doi%3D10.1002%2Fprp2.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ajram, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swieboda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousnier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Internalization of the Chemokine Receptor CCR4 Can Be Evoked by Orthosteric and Allosteric Receptor Antagonists</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>729</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.ejphar.2014.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=24534492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1CrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=729&publication_year=2014&pages=75-85&author=L.+Ajramauthor=M.+Beggauthor=R.+Slackauthor=J.+Cryanauthor=D.+Hallauthor=S.+Hodgsonauthor=A.+Fordauthor=A.+Barnesauthor=D.+Swiebodaauthor=A.+Mousnierauthor=R.+Solari&title=Internalization+of+the+Chemokine+Receptor+CCR4+Can+Be+Evoked+by+Orthosteric+and+Allosteric+Receptor+Antagonists&doi=10.1016%2Fj.ejphar.2014.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists</span></div><div class="casAuthors">Ajram, Laura; Begg, Malcolm; Slack, Robert; Cryan, Jenni; Hall, David; Hodgson, Simon; Ford, Alison; Barnes, Ashley; Swieboda, Dawid; Mousnier, Aurelie; Solari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">729</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The chemokine receptor CCR4 has at least two natural agonist ligands, MDC (CCL22) and TARC (CCL17) which bind to the same orthosteric site with a similar affinity.  Both ligands are known to evoke chemotaxis of CCR4-bearing T cells and also elicit CCR4 receptor internalization.  A series of small mol. allosteric antagonists have been described which displace the agonist ligand, and inhibit chemotaxis.  The aim of this study was to det. which cellular coupling pathways are involved in internalization, and if antagonists binding to the CCR4 receptor could themselves evoke receptor internalization.  CCL22 binding coupled CCR4 efficiently to β-arrestin and stimulated GTPγS binding however CCL17 did not couple to β-arrestin and only partially stimulated GTPγS binding.  CCL22 potently induced internalization of almost all cell surface CCR4, while CCL17 showed only weak effects.  We describe four small mol. antagonists that were demonstrated to bind to two distinct allosteric sites on the CCR4 receptor, and while both classes inhibited agonist ligand binding and chemotaxis, one of the allosteric sites also evoked receptor internalization.  Furthermore, we also characterize an N-terminally truncated version of CCL22 which acts as a competitive antagonist at the orthosteric site, and surprisingly also evokes receptor internalization without demonstrating any agonist activity.  Collectively this study demonstrates that orthosteric and allosteric antagonists of the CCR4 receptor are capable of evoking receptor internalization, providing a novel strategy for drug discovery against this class of target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cp_MmkWDlrVg90H21EOLACvtfcHk0lg64hyMbbvktA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1CrsrY%253D&md5=2d48b60057b1a037979e02f0a4fe95b4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DAjram%26aufirst%3DL.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DSlack%26aufirst%3DR.%26aulast%3DCryan%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DFord%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DA.%26aulast%3DSwieboda%26aufirst%3DD.%26aulast%3DMousnier%26aufirst%3DA.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DInternalization%2520of%2520the%2520Chemokine%2520Receptor%2520CCR4%2520Can%2520Be%2520Evoked%2520by%2520Orthosteric%2520and%2520Allosteric%2520Receptor%2520Antagonists%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D729%26spage%3D75%26epage%3D85%26doi%3D10.1016%2Fj.ejphar.2014.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerville, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span> <span> </span><span class="NLM_article-title">Core Exploration in Optimization of Chemokine Receptor CCR4 Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.10.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.bmcl.2006.10.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=17098428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFaguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=679-682&author=A.+V.+Purandareauthor=H.+Wanauthor=J.+E.+Somervilleauthor=C.+Burkeauthor=W.+Vaccaroauthor=X.+Yangauthor=K.+W.+McIntyreauthor=M.+A.+Poss&title=Core+Exploration+in+Optimization+of+Chemokine+Receptor+CCR4+Antagonists&doi=10.1016%2Fj.bmcl.2006.10.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Core exploration in optimization of chemokine receptor CCR4 antagonists</span></div><div class="casAuthors">Purandare, Ashok V.; Wan, Honghe; Somerville, John E.; Burke, Christine; Vaccaro, Wayne; Yang, XiaoXia; McIntyre, Kim W.; Poss, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">679-682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design, synthesis, and SAR studies of 'core' variations led to identification of novel, selective, and potent small mol. antagonist (I) of the CC chemokine receptor-4 (CCR4) with improved in vitro activity and liability profile.  Compd. I was efficacious in a murine allergic inflammation model (ED50 ∼ 10 mg/kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCc-Oj8IV7u7Vg90H21EOLACvtfcHk0lg64hyMbbvktA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFaguw%253D%253D&md5=604537d7fd88fe913ef078ab1602ea02</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.10.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.10.091%26sid%3Dliteratum%253Aachs%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSomerville%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DC.%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26atitle%3DCore%2520Exploration%2520in%2520Optimization%2520of%2520Chemokine%2520Receptor%2520CCR4%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D679%26epage%3D682%26doi%3D10.1016%2Fj.bmcl.2006.10.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent CCR4 antagonists: Synthesis and Structure–Activity Relationship Study of 2,4-Diaminoquinazolines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">7021</span>– <span class="NLM_lpage">7032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.05.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.bmc.2008.05.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=18539035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVKqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=7021-7032&author=K.+Yokoyamaauthor=N.+Ishikawaauthor=S.+Igarashiauthor=N.+Kawanoauthor=K.+Hattoriauthor=T.+Miyazakiauthor=S.-I.+Oginoauthor=Y.+Matsumotoauthor=M.+Takeuchiauthor=M.+Ohta&title=Discovery+of+potent+CCR4+antagonists%3A+Synthesis+and+Structure%E2%80%93Activity+Relationship+Study+of+2%2C4-Diaminoquinazolines&doi=10.1016%2Fj.bmc.2008.05.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines</span></div><div class="casAuthors">Yokoyama, Kazuhiro; Ishikawa, Noriko; Igarashi, Susumu; Kawano, Noriyuki; Hattori, Kazuyuki; Miyazaki, Takahiro; Ogino, Shin-ichi; Matsumoto, Yuzo; Takeuchi, Makoto; Ohta, Mitsuaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7021-7032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of the corporate compd. libraries.  Subsequent compd. optimization elucidated the structure-activity relationships and led the identification of 2-(1,4'-bipiperidine-1'-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4-amine (I), which showed potent inhibition in the [35S]GTPγS-binding assay (IC50 = 18 nM).  This compd. also inhibited the chemotaxis of human and mouse CCR4-expressing cells (IC50 = 140 nM, 39 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrdUZMdi8qc7Vg90H21EOLACvtfcHk0lg64hyMbbvktA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVKqt7w%253D&md5=bf4e5fb2b015a4635a824f9d311a07b3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.05.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.05.036%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DN.%26aulast%3DIgarashi%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DOgino%26aufirst%3DS.-I.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520potent%2520CCR4%2520antagonists%253A%2520Synthesis%2520and%2520Structure%25E2%2580%2593Activity%2520Relationship%2520Study%2520of%25202%252C4-Diaminoquinazolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D7021%26epage%3D7032%26doi%3D10.1016%2Fj.bmc.2008.05.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuribayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span> <span> </span><span class="NLM_article-title">RS-1748, a Novel CC Chemokine Receptor 4 Antagonist, Inhibits Ovalbumin-Induced Airway Inflammation in Guinea Pigs</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1248/bpb.33.1067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1248%2Fbpb.33.1067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=20522980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslynsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=1067-1069&author=Y.+Nakagamiauthor=Y.+Kawaseauthor=K.+Yonekuboauthor=E.+Nosakaauthor=M.+Etoriauthor=S.+Takahashiauthor=N.+Takagiauthor=T.+Fukudaauthor=T.+Kuribayashiauthor=F.+Naraauthor=M.+Yamashita&title=RS-1748%2C+a+Novel+CC+Chemokine+Receptor+4+Antagonist%2C+Inhibits+Ovalbumin-Induced+Airway+Inflammation+in+Guinea+Pigs&doi=10.1248%2Fbpb.33.1067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs</span></div><div class="casAuthors">Nakagami, Yasuhiro; Kawase, Yumi; Yonekubo, Kazuki; Nosaka, Emi; Etori, Maki; Takahashi, Sakiko; Takagi, Nana; Fukuda, Takeshi; Kuribayashi, Takeshi; Nara, Futoshi; Yamashita, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1067-1069</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">CC chemokine receptor 4 (CCR4) is generally recognized as a preferential marker for T helper 2 cells, and we have previously reported morpholine-deriv. CCR4 antagonists, RS-1154 and RS-1269.  Here, we investigate the pharmacol. profiles of a novel pyrimidine-deriv. CCR4 antagonist, 2-{4-[2-(diethylamino)-ethoxy]phenyl}-N-(2,4-difluorobenzyl)-5-fluoropyrimidin-4-amine (RS-1748), which showed potency to inhibit the bindings of [125I]CCL17 and [35S]GTPγS to human CCR4-expressing Chinese hamster ovary (CHO) cells with IC50 values of 59.9 nM and 18.4 nM, resp.  Furthermore, RS-1748 inhibited ovalbumin-induced airway inflammation in guinea pigs at a dose of 10 mg/kg.  These results indicate that RS-1748 would be a promising lead compd. for developing a therapeutic agent against asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKappxf9t5rVg90H21EOLACvtfcHk0ljjiC6vlawPUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslynsLY%253D&md5=f859158d9f471329d0235c58c02b844f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1248%2Fbpb.33.1067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.33.1067%26sid%3Dliteratum%253Aachs%26aulast%3DNakagami%26aufirst%3DY.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DYonekubo%26aufirst%3DK.%26aulast%3DNosaka%26aufirst%3DE.%26aulast%3DEtori%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DKuribayashi%26aufirst%3DT.%26aulast%3DNara%26aufirst%3DF.%26aulast%3DYamashita%26aufirst%3DM.%26atitle%3DRS-1748%252C%2520a%2520Novel%2520CC%2520Chemokine%2520Receptor%25204%2520Antagonist%252C%2520Inhibits%2520Ovalbumin-Induced%2520Airway%2520Inflammation%2520in%2520Guinea%2520Pigs%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2010%26volume%3D33%26spage%3D1067%26epage%3D1069%26doi%3D10.1248%2Fbpb.33.1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketcham, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biannic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M. H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diokno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbarz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassner, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pookot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shunatona, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talay, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustrow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zibinsky, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking Into the Tumor Microenvironment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6190</span>– <span class="NLM_lpage">6213</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00506</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00506" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2gsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6190-6213&author=J.+J.+Jacksonauthor=J.+M.+Ketchamauthor=A.+Younaiauthor=B.+Abrahamauthor=B.+Biannicauthor=H.+P.+Beckauthor=M.+H.+T.+Buiauthor=D.+Chianauthor=G.+Cutlerauthor=R.+Dioknoauthor=D.+X.+Huauthor=S.+Jacobsonauthor=E.+Karbarzauthor=P.+D.+Kassnerauthor=L.+Marshallauthor=J.+McKinnellauthor=C.+Melezaauthor=A.+Okalauthor=D.+Pookotauthor=M.+K.+Reillyauthor=O.+Roblesauthor=H.+P.+Shunatonaauthor=O.+Talayauthor=J.+R.+Walkerauthor=A.+Wadsworthauthor=D.+J.+Wustrowauthor=M.+Zibinsky&title=Discovery+of+a+Potent+and+Selective+CCR4+Antagonist+That+Inhibits+Treg+Trafficking+Into+the+Tumor+Microenvironment&doi=10.1021%2Facs.jmedchem.9b00506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment</span></div><div class="casAuthors">Jackson, Jeffrey J.; Ketcham, John M.; Younai, Ashkaan; Abraham, Betty; Biannic, Berenger; Beck, Hilary P.; Bui, Minna H. T.; Chian, David; Cutler, Gene; Diokno, Raymond; Hu, Dennis X.; Jacobson, Scott; Karbarz, Emily; Kassner, Paul D.; Marshall, Lisa; McKinnell, Jenny; Meleza, Cesar; Okal, Abood; Pookot, Deepa; Reilly, Maureen K.; Robles, Omar; Shunatona, Hunter P.; Talay, Oezcan; Walker, James R.; Wadsworth, Angela; Wustrow, David J.; Zibinsky, Mikhail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6190-6213</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recruitment of suppressive CD4+ FOXP3+ regulatory T cells (Treg) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncol. (IO) agents.  Human Treg express CCR4 and can be recruited to the TME through the CC chemokine ligands CCL17 and CCL22.  In some cancers, Treg accumulation correlates with poor patient prognosis.  Preclin. data suggests that preventing the recruitment of Treg and increasing the population of activated effector T cells (Teff) in the TME can potentiate antitumor immune responses.  We developed a novel series of potent, orally bioavailable small mol. antagonists of CCR4.  From this series, several compds. exhibited high potency in distinct functional assays in addn. to good in vitro and in vivo ADME properties.  The design, synthesis, and SAR of this series and confirmation of its in vivo activity are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgTBXSH2wYsrVg90H21EOLACvtfcHk0ljjiC6vlawPUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2gsbjI&md5=35c213a85a6252b7ed629ad694764a55</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00506%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DJ.%2BJ.%26aulast%3DKetcham%26aufirst%3DJ.%2BM.%26aulast%3DYounai%26aufirst%3DA.%26aulast%3DAbraham%26aufirst%3DB.%26aulast%3DBiannic%26aufirst%3DB.%26aulast%3DBeck%26aufirst%3DH.%2BP.%26aulast%3DBui%26aufirst%3DM.%2BH.%2BT.%26aulast%3DChian%26aufirst%3DD.%26aulast%3DCutler%26aufirst%3DG.%26aulast%3DDiokno%26aufirst%3DR.%26aulast%3DHu%26aufirst%3DD.%2BX.%26aulast%3DJacobson%26aufirst%3DS.%26aulast%3DKarbarz%26aufirst%3DE.%26aulast%3DKassner%26aufirst%3DP.%2BD.%26aulast%3DMarshall%26aufirst%3DL.%26aulast%3DMcKinnell%26aufirst%3DJ.%26aulast%3DMeleza%26aufirst%3DC.%26aulast%3DOkal%26aufirst%3DA.%26aulast%3DPookot%26aufirst%3DD.%26aulast%3DReilly%26aufirst%3DM.%2BK.%26aulast%3DRobles%26aufirst%3DO.%26aulast%3DShunatona%26aufirst%3DH.%2BP.%26aulast%3DTalay%26aufirst%3DO.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DWadsworth%26aufirst%3DA.%26aulast%3DWustrow%26aufirst%3DD.%2BJ.%26aulast%3DZibinsky%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520CCR4%2520Antagonist%2520That%2520Inhibits%2520Treg%2520Trafficking%2520Into%2520the%2520Tumor%2520Microenvironment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6190%26epage%3D6213%26doi%3D10.1021%2Facs.jmedchem.9b00506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Procopiou, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumeaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, Y. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morriss, K. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Needham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sollis, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staton, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–Activity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1960</span>, <span class="refDoi"> DOI: 10.1021/jm301572h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301572h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisF2js7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1946-1960&author=P.+A.+Procopiouauthor=J.+W.+Barrettauthor=N.+P.+Bartonauthor=M.+Beggauthor=D.+Claphamauthor=R.+C.+B.+Copleyauthor=A.+J.+Fordauthor=R.+H.+Gravesauthor=D.+A.+Hallauthor=A.+P.+Hancockauthor=A.+P.+Hillauthor=H.+Hobbsauthor=S.+T.+Hodgsonauthor=C.+Jumeauxauthor=Y.+M.+L.+Lacroixauthor=A.+H.+Miahauthor=K.+M.+L.+Morrissauthor=D.+Needhamauthor=E.+B.+Sheriffauthor=R.+J.+Slackauthor=C.+E.+Smithauthor=S.+L.+Sollisauthor=H.+Staton&title=Synthesis+and+Structure%E2%80%93Activity+Relationships+of+Indazole+Arylsulfonamides+as+Allosteric+CC-Chemokine+Receptor+4+%28CCR4%29+Antagonists&doi=10.1021%2Fjm301572h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists</span></div><div class="casAuthors">Procopiou, Panayiotis A.; Barrett, John W.; Barton, Nicholas P.; Begg, Malcolm; Clapham, David; Copley, Royston C. B.; Ford, Alison J.; Graves, Rebecca H.; Hall, David A.; Hancock, Ashley P.; Hill, Alan P.; Hobbs, Heather; Hodgson, Simon T.; Jumeaux, Coline; Lacroix, Yannick M. L.; Miah, Afjal H.; Morriss, Karen M. L.; Needham, Deborah; Sheriff, Emma B.; Slack, Robert J.; Smith, Claire E.; Sollis, Steven L.; Staton, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of indazole arylsulfonamides were synthesized and examd. as human CCR4 antagonists.  Methoxy- or hydroxyl- contg. groups were the more potent indazole C4 substituents.  Only small groups were tolerated at C5, C6, or C7, with the C6 analogs being preferred.  The most potent N3-substituent was 5-chlorothiophene-2-sulfonamide.  N1 meta-substituted benzyl groups possessing an α-amino-3-[(methylamino)acyl]- group were the most potent N1-substituents.  Strongly basic amino groups had low oral absorption in vivo.  Less basic analogs, such as morpholines, had good oral absorption; however, they also had high clearance.  The most potent compd. with high absorption in two species was analog I (GSK2239633A), which was selected for further development.  Aryl sulfonamide antagonists bind to CCR4 at an intracellular allosteric site denoted site II.  X-ray diffraction studies on two indazole sulfonamide fragments suggested the presence of an important intramol. interaction in the active conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGy9j0UZnY77Vg90H21EOLACvtfcHk0ljiQ32mYRfdiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisF2js7k%253D&md5=db6f996af7b0498c9c0196da94005bc2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm301572h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301572h%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DJ.%2BW.%26aulast%3DBarton%26aufirst%3DN.%2BP.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DClapham%26aufirst%3DD.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGraves%26aufirst%3DR.%2BH.%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DHancock%26aufirst%3DA.%2BP.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DHobbs%26aufirst%3DH.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DJumeaux%26aufirst%3DC.%26aulast%3DLacroix%26aufirst%3DY.%2BM.%2BL.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DMorriss%26aufirst%3DK.%2BM.%2BL.%26aulast%3DNeedham%26aufirst%3DD.%26aulast%3DSheriff%26aufirst%3DE.%2BB.%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26aulast%3DSollis%26aufirst%3DS.%2BL.%26aulast%3DStaton%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%2520Indazole%2520Arylsulfonamides%2520as%2520Allosteric%2520CC-Chemokine%2520Receptor%25204%2520%2528CCR4%2529%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1946%26epage%3D1960%26doi%3D10.1021%2Fjm301572h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuberson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teobald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=981-986&author=N.+Kindonauthor=G.+Andrewsauthor=A.+Baxterauthor=D.+Cheshireauthor=P.+Hemsleyauthor=T.+Johnsonauthor=Y.-Z.+Liuauthor=D.+McGinnityauthor=M.+McHaleauthor=A.+Meteauthor=J.+Reubersonauthor=B.+Robertsauthor=J.+Steeleauthor=B.+Teobaldauthor=J.+Unittauthor=D.+Vaughanauthor=I.+Waltersauthor=M.+J.+Stocks&title=Discovery+of+AZD-2098+and+AZD-1678%2C+Two+Potent+and+Bioavailable+CCR4+Receptor+Antagonists&doi=10.1021%2Facsmedchemlett.7b00315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists</span></div><div class="casAuthors">Kindon, Nicholas; Andrews, Glen; Baxter, Andrew; Cheshire, David; Hemsley, Paul; Johnson, Timothy; Liu, Yu-Zhen; McGinnity, Dermot; McHale, Mark; Mete, Antonio; Reuberson, James; Roberts, Bryan; Steele, John; Teobald, Barry; Unitt, John; Vaughan, Deborah; Walters, Iain; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">981-986</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 was identified as a hit in a CCR4 receptor antagonist high-throughput screen (HTS) of a subset of the AstraZeneca compd. bank.  As a hit with a lead-like profile, it was an excellent starting point for a CCR4 receptor antagonist program and enabled the rapid progression through the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR4 receptor antagonist candidate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolEsVkipAX2LVg90H21EOLACvtfcHk0ljiQ32mYRfdiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7vI&md5=8ede7ef766e88de9191b0df8ec7938a4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00315%26sid%3Dliteratum%253Aachs%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DBaxter%26aufirst%3DA.%26aulast%3DCheshire%26aufirst%3DD.%26aulast%3DHemsley%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.-Z.%26aulast%3DMcGinnity%26aufirst%3DD.%26aulast%3DMcHale%26aufirst%3DM.%26aulast%3DMete%26aufirst%3DA.%26aulast%3DReuberson%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSteele%26aufirst%3DJ.%26aulast%3DTeobald%26aufirst%3DB.%26aulast%3DUnitt%26aufirst%3DJ.%26aulast%3DVaughan%26aufirst%3DD.%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DDiscovery%2520of%2520AZD-2098%2520and%2520AZD-1678%252C%2520Two%2520Potent%2520and%2520Bioavailable%2520CCR4%2520Receptor%2520Antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D981%26epage%3D986%26doi%3D10.1021%2Facsmedchemlett.7b00315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of CCR4 Antagonists</span>. <i>Progress in Respiratory Research</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1159/000320815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1159%2F000320815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=161-165&author=D.+Hallauthor=A.+Fordauthor=S.+Hodgson&title=Therapeutic+Potential+of+CCR4+Antagonists&doi=10.1159%2F000320815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of CCR4 antagonists</span></div><div class="casAuthors">Hall, David; Ford, Alison; Hodgson, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Respiratory Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-165</span>CODEN:
                <span class="NLM_cas:coden">PRRRAE</span>;
        ISSN:<span class="NLM_cas:issn">1422-2140</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  CCR4 is a CC-chemokine receptor which is expressed on a no. of T-cell subsets.  Inhibition of this receptor is of potential interest as a target in allergic diseases due to its selective expression on Th2 but not Th1 cells and hence the potential to selectively inhibit the recruitment of Th2 cells to sites of allergic inflammation while leaving other immune responses unaffected.  CCR4 is also expressed on regulatory T cells and this has led to the hypothesis that CCR4 blockade or a CCR4-directed cytotoxic antibody may be effective in treating certain cancers.  In this article we review the clin. and preclin. literature around the role of CCR4 in allergic disease and briefly discuss the progress which has been made in identifying selective small-mol. antagonists at CCR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwDW_qnPwIcbVg90H21EOLACvtfcHk0ljiQ32mYRfdiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVKiug%253D%253D&md5=a96417abce82e8be411705dcf37a7ac9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1159%2F000320815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000320815%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DD.%26aulast%3DFord%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%26atitle%3DTherapeutic%2520Potential%2520of%2520CCR4%2520Antagonists%26jtitle%3DProgress%2520in%2520Respiratory%2520Research%26date%3D2010%26volume%3D39%26spage%3D161%26epage%3D165%26doi%3D10.1159%2F000320815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horuk, R.</span></span> <span> </span><span class="NLM_article-title">Recent Progress in the Development of Antagonists to the Chemokine Receptors CCR3 and CCR4</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1517/17460441.2014.897324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1517%2F17460441.2014.897324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=24641500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFClt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=467-483&author=J.+E.+Peaseauthor=R.+Horuk&title=Recent+Progress+in+the+Development+of+Antagonists+to+the+Chemokine+Receptors+CCR3+and+CCR4&doi=10.1517%2F17460441.2014.897324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4</span></div><div class="casAuthors">Pease, James Edward; Horuk, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">467-483</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The chemokine receptors CCR3 and CCR4 have been shown to be important therapeutic targets for the treatment of a variety of diseases.  Although only two chemokine receptor inhibitors have been approved so far, there are numerous compds. that are in various stages of development.  Areas covered: In this review article, the authors provide an update on the progress made in the identification of antagonists against the chemokine receptors CCR3 and CCR4 from 2009 to the present.  The rationale of writing this review article is to cover the most important approaches to identifying antagonists to these two receptors, which could prove to be useful therapeutics in treating proinflammatory diseases.  Expert opinion: Pharmaceutical companies have expended a considerable amt. of money and effort to identify potent inhibitors of CCR3 and CCR4 for the treatment of asthma and atopic diseases.  Although a variety of compds. have been described and several have progressed into the clinic, none have so far made it as approved drugs.  There are, however, novel approaches such as mogamulizumab, a monoclonal antibody to CCR4 currently is in clin. trials for cancer and ASM8, an antisense nucleotide to CCR3, which is in Phase II clin. trials for asthma that might still prove to be successful new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXmZrBcC5PbLVg90H21EOLACvtfcHk0ljid9-9qlXJMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFClt7o%253D&md5=d77cb820f88320311ed1c09f15f7a800</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.897324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.897324%26sid%3Dliteratum%253Aachs%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DRecent%2520Progress%2520in%2520the%2520Development%2520of%2520Antagonists%2520to%2520the%2520Chemokine%2520Receptors%2520CCR3%2520and%2520CCR4%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D467%26epage%3D483%26doi%3D10.1517%2F17460441.2014.897324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerahee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Marle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2239633, a CC-Chemokine Receptor 4 Antagonist, in Healthy Male Subjects: Results from an Open-Label and from a Randomised Study</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">14</span>, <span class="refDoi"> DOI: 10.1186/2050-6511-14-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1186%2F2050-6511-14-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=23448278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=14&author=A.+Cahnauthor=S.+Hodgsonauthor=R.+Wilsonauthor=J.+Robertsonauthor=J.+Watsonauthor=M.+Beeraheeauthor=S.+C.+Hughesauthor=G.+Youngauthor=R.+Gravesauthor=D.+Hallauthor=S.+van+Marleauthor=R.+Solari&title=Safety%2C+Tolerability%2C+Pharmacokinetics+and+Pharmacodynamics+of+GSK2239633%2C+a+CC-Chemokine+Receptor+4+Antagonist%2C+in+Healthy+Male+Subjects%3A+Results+from+an+Open-Label+and+from+a+Randomised+Study&doi=10.1186%2F2050-6511-14-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study</span></div><div class="casAuthors">Cahn, Anthony; Hodgson, Simon; Wilson, Robert; Robertson, Jonathan; Watson, Joanna; Beerahee, Misba; Hughes, Steve C.; Young, Graeme; Graves, Rebecca; Hall, David; van Marle, Sjoerd; Solari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The CC-chemokine receptor 4 (CCR4) is thought potentially to play a crit. role in asthma pathogenesis due to its ability to recruit type 2 T-helper lymphocytes to the inflamed airways.  Therefore, CCR4 provides an excellent target for anti-inflammatory therapy.  Methods: The safety, tolerability, pharmacokinetics and pharmacodynamics of the CCR4 antagonist GSK2239633, N-(3-((3-(5-chlorothiophene-2-sulfonamido)-4-methoxy-1H-indazol-1-yl)methyl)benzyl)-2-hydroxy-2-methylpropanamide, were examd. in healthy males.  Two studies were performed: 1) an open-label, study in which six subjects received a single i.v. infusion of [14C]-GSK2239633 100 μg (10 kBq) (NCT01086462), and 2) a randomised, double-blind, placebo-controlled, cross-over, ascending dose study in which 24 subjects received single oral doses of GSK2239633 150-1500 mg (NCT01371812).  Results: Following i.v. dosing, plasma GSK2239633 displayed rapid, bi-phasic distribution and slow terminal elimination (t1/2:13.5 h), suggesting that GSK2239633 was a low to moderate clearance drug.  Following oral dosing, blood levels of GSK2239633 reached Cmax rapidly (median tmax:1.0-1.5 h).  Estd. GSK2239633 bioavailability was low with a max. value detd. of only 16%.  Food increased GSK2239633 systemic exposure (as assessed by AUC and Cmax).  Increases in AUC and Cmax were less than dose proportional.  Adverse events were reported by three subjects (50%) following i.v. administration, and by 19 subjects (79%) following oral administration; most (46/47; 98%) events were mild/moderate in intensity.  GSK2239633 1500 mg inhibited thymus- and activation-regulated chemokine-induced (TARC) actin polymn. reaching a mean CCR4 occupancy of 74%.  Conclusion: In conclusion, GSK2239633 was well-tolerated and capable of inhibiting TARC from activating the CCR4 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRGQ7kxHbu_LVg90H21EOLACvtfcHk0ljid9-9qlXJMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWisro%253D&md5=c087afba982a7a6ad0f14bee7f8bafb9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2F2050-6511-14-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2050-6511-14-14%26sid%3Dliteratum%253Aachs%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DJ.%26aulast%3DBeerahee%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DS.%2BC.%26aulast%3DYoung%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DD.%26aulast%3Dvan%2BMarle%26aufirst%3DS.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DSafety%252C%2520Tolerability%252C%2520Pharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520GSK2239633%252C%2520a%2520CC-Chemokine%2520Receptor%25204%2520Antagonist%252C%2520in%2520Healthy%2520Male%2520Subjects%253A%2520Results%2520from%2520an%2520Open-Label%2520and%2520from%2520a%2520Randomised%2520Study%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D14%26spage%3D14%26doi%3D10.1186%2F2050-6511-14-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Immuno-Oncology Therapeutic Agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.12.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.bmcl.2017.12.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=29326017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlKltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=319-329&author=P.+L.+Toogood&title=Small+Molecule+Immuno-Oncology+Therapeutic+Agents&doi=10.1016%2Fj.bmcl.2017.12.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule immuno-oncology therapeutic agents</span></div><div class="casAuthors">Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Treatment of cancer by activation of an antitumor immune response is now a widely practiced and well-accepted approach to therapy.  However, despite dramatic responses in some patients, the high proportion of unresponsive patients points to a considerable unmet medical need.  Although antibody therapies have led the way, small mol. immuno-oncol. agents are close behind.  This perspective provides an overview of some of the many small mol. approaches being explored.  It encompasses small mol. modulators of validated targets such as programed cell death 1 (PD-1) as well as novel approaches still to be proven clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqabNsLZRrBPbVg90H21EOLACvtfcHk0ljid9-9qlXJMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlKltQ%253D%253D&md5=2457f116552bf50e7134fea28d914524</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.12.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.12.044%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DSmall%2520Molecule%2520Immuno-Oncology%2520Therapeutic%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D319%26epage%3D329%26doi%3D10.1016%2Fj.bmcl.2017.12.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span> </span><span class="NLM_article-title">FDA Approves Treatment for Two Rare Types of non-Hodgkin
Lymphoma</span>. <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm</a> (accessed April 4, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+Treatment+for+Two+Rare+Types+of+non-Hodgkin%0ALymphoma.+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm616176.htm+%28accessed+April+4%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520Treatment%2520for%2520Two%2520Rare%2520Types%2520of%2520non-Hodgkin%250ALymphoma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">Stevens–Johnson Syndrome Associated with Mogamulizumab Treatment of Adult T-Cell Leukemia/Lymphoma</span>. <i>Cancer Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1111/cas.12116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1111%2Fcas.12116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=23360455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVCjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=647-650&author=T.+Ishidaauthor=A.+Itoauthor=F.+Satoauthor=S.+Kusumotoauthor=S.+Iidaauthor=H.+Inagakiauthor=A.+Moritaauthor=S.+Akinagaauthor=R.+Ueda&title=Stevens%E2%80%93Johnson+Syndrome+Associated+with+Mogamulizumab+Treatment+of+Adult+T-Cell+Leukemia%2FLymphoma&doi=10.1111%2Fcas.12116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma</span></div><div class="casAuthors">Ishida, Takashi; Ito, Asahi; Sato, Fumihiko; Kusumoto, Shigeru; Iida, Shinsuke; Inagaki, Hiroshi; Morita, Akimichi; Akinaga, Shiro; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">647-650</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We report an adult T-cell leukemia/lymphoma patient suffering from Stevens-Johnson Syndrome (SJS) during mogamulizumab (humanized anti-CCR4 monoclonal antibody) treatment.  There was a durable significant redn. of the CD4+CD25highFOXP3+ regulatory T (Treg) cell subset in the patient's PBMC, and the affected inflamed skin almost completely lacked FOXP3-pos. cells.  This implies an assocn. between redn. of the Treg subset by mogamulizimab and occurrence of SJS.  The present case should contribute not only to our understanding of human pathol. resulting from therapeutic depletion of Treg cells, but also alert us to the possibility of immune-related severe adverse events such as SJS when using mogamulizumab.  We are currently conducting a clin. trial of mogamulizumab for CCR4-neg. solid cancers (UMIN000010050), specifically aiming to deplete Treg cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKZ1pzzErzKbVg90H21EOLACvtfcHk0lj51Ok1God_0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVCjsrs%253D&md5=e2050c18ed4be88401547ddede792606</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fcas.12116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12116%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DF.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DStevens%25E2%2580%2593Johnson%2520Syndrome%2520Associated%2520with%2520Mogamulizumab%2520Treatment%2520of%2520Adult%2520T-Cell%2520Leukemia%252FLymphoma%26jtitle%3DCancer%2520Science%26date%3D2013%26volume%3D104%26spage%3D647%26epage%3D650%26doi%3D10.1111%2Fcas.12116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saulite, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoetzenecker, W.</span></span> <span> </span><span class="NLM_article-title">Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab</span>. <i>Current Problems in Dermatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1159/000478079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1159%2F000478079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=29131039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A280%3ADC%252BC1M3gsFCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=70-81&author=I.+Sauliteauthor=E.+Guenovaauthor=W.+Hoetzenecker&title=Adverse+Reactions+of+Antibody-Therapy+for+Primary+Cutaneous+Lymphomas%3A+Rituximab%2C+Brentuximab+Vedotin%2C+Alemtuzumab%2C+and+Mogamulizumab&doi=10.1159%2F000478079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab</span></div><div class="casAuthors">Saulite I; Guenova E; Hoetzenecker W</div><div class="citationInfo"><span class="NLM_cas:title">Current problems in dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of advanced PCLs is limited and rarely reaches complete remission despite aggressive treatment modalities, such as polychemotherapy with various adverse effects.  However, several monoclonal antibodies drug agents in patients with advanced primary cutaneous lymphomas demonstrate promising efficacy and manageable safety profiles.  The monoclonal antibodies drug agents have favourable tolerability compared with multi-agent cytotoxic chemotherapy.  However, adverse effects manifest with a broad clinical spectrum, hence the markers of targeted therapies are not limited to tumour cells but found on tumour cells and also on benign T and/or B cells.  Moreover, the safety profile and direct causal association of drug and adverse effects should be interpreted with caution because many of the patients in clinical studies have received multiple treatments.  Here, we focus on the safety profile of mAbs therapies that have recently been approved or are currently under preclinical or clinical investigation for CBCLs (rituximab) and CTCLs (brentuximab, mogamulizumab, and alemtuzumab).  Further studies to define clinical safety profile in the patient cohort with cutaneous lymphomas are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7GsfUuEYOZDToTC3aBaesfW6udTcc2eYE0LtaNZMUcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3gsFCrtg%253D%253D&md5=7dca3c477b4b4b32af104d8c97727f49</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1159%2F000478079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000478079%26sid%3Dliteratum%253Aachs%26aulast%3DSaulite%26aufirst%3DI.%26aulast%3DGuenova%26aufirst%3DE.%26aulast%3DHoetzenecker%26aufirst%3DW.%26atitle%3DAdverse%2520Reactions%2520of%2520Antibody-Therapy%2520for%2520Primary%2520Cutaneous%2520Lymphomas%253A%2520Rituximab%252C%2520Brentuximab%2520Vedotin%252C%2520Alemtuzumab%252C%2520and%2520Mogamulizumab%26jtitle%3DCurrent%2520Problems%2520in%2520Dermatology%26date%3D2018%26volume%3D53%26spage%3D70%26epage%3D81%26doi%3D10.1159%2F000478079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, L.</span>; <span class="NLM_string-name">Marubayashi, S.</span>; <span class="NLM_string-name">Jorapur, A.</span>; <span class="NLM_string-name">Jacobsen, S.</span>; <span class="NLM_string-name">Zibinsky, M.</span>; <span class="NLM_string-name">Robles, O.</span>; <span class="NLM_string-name">Hu, D.</span>; <span class="NLM_string-name">Jackson, J.</span>; <span class="NLM_string-name">Pookat, D.</span>; <span class="NLM_string-name">Sanchez, J.</span>; <span class="NLM_string-name">Brovarney, M.</span>; <span class="NLM_string-name">Wadsworth, A.</span>; <span class="NLM_string-name">Chian, D.</span>; <span class="NLM_string-name">Wustrow, D.</span>; <span class="NLM_string-name">Kassner, P.</span>; <span class="NLM_string-name">Cutler, G.</span>; <span class="NLM_string-name">Wong, B.</span>; <span class="NLM_string-name">Brockstedt, D.</span>; <span class="NLM_string-name">Talay, O.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Marshall%2C+L.%3B+Marubayashi%2C+S.%3B+Jorapur%2C+A.%3B+Jacobsen%2C+S.%3B+Zibinsky%2C+M.%3B+Robles%2C+O.%3B+Hu%2C+D.%3B+Jackson%2C+J.%3B+Pookat%2C+D.%3B+Sanchez%2C+J.%3B+Brovarney%2C+M.%3B+Wadsworth%2C+A.%3B+Chian%2C+D.%3B+Wustrow%2C+D.%3B+Kassner%2C+P.%3B+Cutler%2C+G.%3B+Wong%2C+B.%3B+Brockstedt%2C+D.%3B+Talay%2C+O.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DL." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadhe, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-H.</span></span> <span> </span><span class="NLM_article-title">Insights Into the Binding Modes of CC Chemokine Receptor 4 (CCR4) Inhibitors: A Combined Approach Involving Homology Modelling, Docking, and Molecular Dynamics Simulation Studies</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1039/C4MB00568F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1039%2FC4MB00568F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25474265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2gsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=618-634&author=C.+G.+Gadheauthor=M.-H.+Kim&title=Insights+Into+the+Binding+Modes+of+CC+Chemokine+Receptor+4+%28CCR4%29+Inhibitors%3A+A+Combined+Approach+Involving+Homology+Modelling%2C+Docking%2C+and+Molecular+Dynamics+Simulation+Studies&doi=10.1039%2FC4MB00568F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the binding modes of CC chemokine receptor 4 (CCR4) inhibitors: a combined approach involving homology modelling, docking, and molecular dynamics simulation studies</span></div><div class="casAuthors">Gadhe, Changdev G.; Kim, Mi-hyun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">618-634</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">CC chemokine receptor 4 (CCR4), a G protein-coupled receptor (GPCR), plays a vital role in the progression of asthma, T-cell lymphoma, inflammation, and Alzheimer's disease.  To date, the structure of CCR4 has not been detd.  Therefore, the nature of the interactions between inhibitors and CCR4 is not well known.  In this study, we used CCR5 as a template to model the structure of CCR4.  Docking studies were performed for four naphthalene-sulfonamide derivs. and crucial ligand-protein interactions were analyzed.  Mol. dynamics (MD) simulations of these complexes (100 ns each) were carried out to gain insights into the interactions between ligands and CCR4.  MD simulations revealed that the residues identified by the docking were displaced and new residues were inserted near the ligands.  Results of a principal component anal. (PCA) suggested that CCR4 unfolds at the extracellular site surrounding the ligands.  Our simulations identified crucial residues involved in CCR4 antagonism, which were supported by previous mutational studies.  Addnl., we identified Ser3.29, Leu3.33, Ser5.39, Phe6.47, Ile7.35, Thr7.38, Thr7.40, and Ala7.42 as residues that play crucial roles in CCR4 antagonism.  Mutational studies will help elucidate the significance of these residues in CCR4 antagonism.  An understanding of ligand-CCR4 interactions might aid in the design of novel CCR4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRMUcXVRcYzrVg90H21EOLACvtfcHk0lj51Ok1God_0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2gsLbN&md5=bdcbc124d76dd7e2b5c12deef983efef</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1039%2FC4MB00568F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MB00568F%26sid%3Dliteratum%253Aachs%26aulast%3DGadhe%26aufirst%3DC.%2BG.%26aulast%3DKim%26aufirst%3DM.-H.%26atitle%3DInsights%2520Into%2520the%2520Binding%2520Modes%2520of%2520CC%2520Chemokine%2520Receptor%25204%2520%2528CCR4%2529%2520Inhibitors%253A%2520A%2520Combined%2520Approach%2520Involving%2520Homology%2520Modelling%252C%2520Docking%252C%2520and%2520Molecular%2520Dynamics%2520Simulation%2520Studies%26jtitle%3DMol.%2520BioSyst.%26date%3D2015%26volume%3D11%26spage%3D618%26epage%3D634%26doi%3D10.1039%2FC4MB00568F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominitzki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neurath, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span> <span> </span><span class="NLM_article-title">In Vitro Generation of CD4+CD25+ Regulatory Cells From Murin Naive T Cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1794</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1038%2Fnprot.2007.258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=17641646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1789-1794&author=M.+C.+Fantiniauthor=S.+Dominitzkiauthor=A.+Rizzoauthor=M.+F.+Neurathauthor=C.+Becker&title=In+Vitro+Generation+of+CD4%2BCD25%2B+Regulatory+Cells+From+Murin+Naive+T+Cells&doi=10.1038%2Fnprot.2007.258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro generation of CD4+CD25+ regulatory cells from murine naive T cells</span></div><div class="casAuthors">Fantini, Massimo C.; Dominitzki, Sabine; Rizzo, Angelo; Neurath, Markus F.; Becker, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1789-1794</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CD4+CD25+ regulatory T cells (Tregs) are crucial for the maintenance of immunol. tolerance.  Recent data indicate that Tregs not only develop in the thymus during ontogeny but can also differentiate from naive T cells in the periphery.  The following protocol describes a method by which Tregs are generated in vitro by stimulation of naive T cells in the presence of transforming growth factor β (Ti-Tregs).  In vitro-induced regulatory T cells express markers of conventional Treg such as CD25 and the genetic program committing transcription factor FoxP3.  Functionally the in vitro-generated Ti-Tregs suppress T-cell activation and proliferation while in vivo these cells have been proven to control inflammation in different animal models, suggesting a potential use of these cells for immunotherapy.  The protocol can be completed within 5 days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3F3KjV9Klt7Vg90H21EOLACvtfcHk0lgqBO6wUVqulQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahur7F&md5=98e484cedf0f4ee16dddf269040c2550</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.258%26sid%3Dliteratum%253Aachs%26aulast%3DFantini%26aufirst%3DM.%2BC.%26aulast%3DDominitzki%26aufirst%3DS.%26aulast%3DRizzo%26aufirst%3DA.%26aulast%3DNeurath%26aufirst%3DM.%2BF.%26aulast%3DBecker%26aufirst%3DC.%26atitle%3DIn%2520Vitro%2520Generation%2520of%2520CD4%252BCD25%252B%2520Regulatory%2520Cells%2520From%2520Murin%2520Naive%2520T%2520Cells%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D1789%26epage%3D1794%26doi%3D10.1038%2Fnprot.2007.258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. B.</span></span> <span> </span><span class="NLM_article-title">Generation and Function of Induced Regulatory T Cells</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2013.00152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.3389%2Ffimmu.2013.00152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=23355837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eisLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1-13&author=E.+G.+Schmittauthor=C.+B.+Williams&title=Generation+and+Function+of+Induced+Regulatory+T+Cells&doi=10.3389%2Ffimmu.2013.00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and function of induced regulatoryT cells</span></div><div class="casAuthors">Schmitt, Erica G.; Williams, Calvin B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">CD4+ CD25+ Foxp3+ regulatory T (Treg) cells are essential to the balance between proand anti-inflammatory responses.There are two major subsets ofTreg cells, "natural" Treg (nTreg) cells that develop in the thymus, and "induced" Treg (iTreg) cells that arise in the periphery from CD4+ Foxp3- conventional T cells and can be generated in vitro.  Previous work has established that both subsets are required for immunol. tolerance.  Addnl., in vitro-derived iTreg cells can reestablish tolerance in situations where Treg cells are decreased or defective.  This review will focus on iTreg cells, drawing comparisons to nTreg cells when possible.We discuss the mol. mechanisms of iTreg cell induction, both in vivo and in vitro, reviewthe Foxp3-dependent and -independent transcriptional landscape of iTreg cells, and examine the proposed suppressive mechanisms utilized by each Treg cell subset.  We also compare the T cell receptor repertoire of the Treg cell subsets, discuss inflammatory conditions where iTreg cells are generated or have been used for treatment, and address the issue of iTreg cell stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYYLe4jXKCMLVg90H21EOLACvtfcHk0lgqBO6wUVqulQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eisLrJ&md5=ad1cc139b8da8608b7cf6bd413cace1a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2013.00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2013.00152%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DE.%2BG.%26aulast%3DWilliams%26aufirst%3DC.%2BB.%26atitle%3DGeneration%2520and%2520Function%2520of%2520Induced%2520Regulatory%2520T%2520Cells%26jtitle%3DFront.%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D1%26epage%3D13%26doi%3D10.3389%2Ffimmu.2013.00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="note"><p class="first last">Compound <b>38</b> is referred to as <b>CCR4–351</b> in ref <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haseeb  Mughal</span>, <span class="hlFld-ContribAuthor ">Michal  Szostak</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the synthesis and reactivity of azetidines: strain-driven character of the four-membered heterocycle. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (15)
                                     , 3274-3286. <a href="https://doi.org/10.1039/D1OB00061F" title="DOI URL">https://doi.org/10.1039/D1OB00061F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00061F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00061F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bsynthesis%252Band%252Breactivity%252Bof%252Bazetidines%25253A%252Bstrain-driven%252Bcharacter%252Bof%252Bthe%252Bfour-membered%252Bheterocycle%26aulast%3DMughal%26aufirst%3DHaseeb%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D15%26spage%3D3274%26epage%3D3286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justine  Cinier</span>, <span class="hlFld-ContribAuthor ">Margaux  Hubert</span>, <span class="hlFld-ContribAuthor ">Laurie  Besson</span>, <span class="hlFld-ContribAuthor ">Anthony  Di Roio</span>, <span class="hlFld-ContribAuthor ">Céline  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Vincent  Lombardi</span>, <span class="hlFld-ContribAuthor ">Christophe  Caux</span>, <span class="hlFld-ContribAuthor ">Christine  Ménétrier-Caux</span>. </span><span class="cited-content_cbyCitation_article-title">Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (8)
                                     , 1850. <a href="https://doi.org/10.3390/cancers13081850" title="DOI URL">https://doi.org/10.3390/cancers13081850</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13081850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13081850%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DRecruitment%252Band%252BExpansion%252Bof%252BTregs%252BCells%252Bin%252Bthe%252BTumor%252BEnvironment%2525E2%252580%252594How%252Bto%252BTarget%252BThem%25253F%26aulast%3DCinier%26aufirst%3DJustine%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D8%26spage%3D1850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Quan  Jiang</span>, <span class="hlFld-ContribAuthor ">Zi-Xian  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Zhong</span>, <span class="hlFld-ContribAuthor ">Lu-Jun  Shen</span>, <span class="hlFld-ContribAuthor ">Xue  Han</span>, <span class="hlFld-ContribAuthor ">Xuxiazi  Zou</span>, <span class="hlFld-ContribAuthor ">Xin-Yi  Liu</span>, <span class="hlFld-ContribAuthor ">Yi-Nan  Deng</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Gui-Hua  Chen</span>, <span class="hlFld-ContribAuthor ">Wuguo  Deng</span>, <span class="hlFld-ContribAuthor ">Jin-Hua  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data. </span><span class="cited-content_cbyCitation_journal-name">OncoImmunology</span><span> <strong>2021,</strong> <em>10 </em>
                                    (1)
                                     , 1908010. <a href="https://doi.org/10.1080/2162402X.2021.1908010" title="DOI URL">https://doi.org/10.1080/2162402X.2021.1908010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/2162402X.2021.1908010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F2162402X.2021.1908010%26sid%3Dliteratum%253Aachs%26jtitle%3DOncoImmunology%26atitle%3DInvestigating%252BMechanisms%252Bof%252BResponse%252Bor%252BResistance%252Bto%252BImmune%252BCheckpoint%252BInhibitors%252Bby%252BAnalyzing%252BCell-Cell%252BCommunications%252Bin%252BTumors%252BBefore%252Band%252BAfter%252BProgrammed%252BCell%252BDeath-1%252B%252528PD-1%252529%252BTargeted%252BTherapy%25253A%252BAn%252BIntegrative%252BAnalysis%252BUsing%252BSingle-cell%252BRNA%252Band%252BBulk-RNA%252BSequencing%252BData%26aulast%3DJiang%26aufirst%3DYi-Quan%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D1%26spage%3D1908010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative class I and class II CCR4 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Pharmacophore map of previously reported CCR4 antagonists. (B) Current RAPT pharmacophore model. (C) Design of novel piperidinyl-azetidine series using a pharmacophore map for class I CCR4 antagonists: topological and spatial orientation of the basic nitrogen is crucial for maintaining potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>16</b> and Activities of the Single Diastereomers <b>17</b> and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethenesulfonyl fluoride, DCM; (b) MeOH, NH<sub>4</sub>OH, 70 °C; (c) 4 N HCl in dioxane, DCM; (d) (<i>R</i>)-6-chloro-1-(1-(2,4-dichlorophenyl)ethyl)-3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyrazine, DMSO, <i>N</i>,<i>N</i>-diisopropylethylamine, 80 °C, 4 h; (d) separation of diastereomers on chiral HPLC.</p></p></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Selectivity of CCR4 antagonist <b>38</b> at 500 nM against a panel of human chemokine receptors in a β-arrestin recruitment assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Treatment with Compound <b>38</b> reduces T<sub>reg</sub> migration into the tumor. (A) Schematic outline of treatment and tumor model that is used in this study. (B) Number of GFP<sup>+</sup> T<sub>reg</sub> in the tumor. For statistical analysis, the two-tailed <i>t</i> test was used.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacy of compound <b>38</b> in a Pan02-OVA model with a 50 mg/kg PO QD dosing regimen. See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">Supporting Information</a> for details. For statistical analysis, the two-tailed <i>t</i> test was used.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Antitumor efficacy of compound <b>38</b> in a CT26 model with a 50 mg/kg PO QD dosing regimen. See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf" class="ext-link">Supporting Information</a> for details. For statistical analysis, the two-tailed <i>t</i> test was used.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>7</b>–<b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-(azetidin-3-yl)piperidine or 1-(azetidin-3-yl)-<i>N</i>,<i>N</i>-dimethylmethanamine, <i>N</i>,<i>N</i>-diisopropylethylamine, DMSO, 80 °C, 12 h; (b) ethyl glyoxylate or acetaldehyde, NaBH(OAc)<sub>3</sub>, 1,2-DCE, rt; (c) HCl, 1,4-dioxane<sub>,</sub>DCM, rt; (d) <i>N</i>,<i>N</i>-diisopropylethylamine, <b>15a</b>, DMF, 80 °C, 12 h.</p></p></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>19</b>, <b>20</b>, and <b>28</b>–<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaHB(OAC)<sub>3</sub>, 1,2-DCE, rt; (b) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O, EtOH, rt;(c) RSO<sub>2</sub>Cl or RCOCl, DCM, <i>N</i>,<i>N</i>-diisopropylethylamine; (d) HCl, 1,4-dioxane, DCM, rt; (e) <b>15a</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C; (f) separation of diastereomers by Chiral HPLC or SFC.</p><p class="last"><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on the maximum single diastereomer recovery.</p></p></figure><figure data-id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>21</b>, <b>24</b>, <b>25</b>, <b>27</b>, and <b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <span class="smallcaps smallerCapital">l</span>-(+)-mandelic acid, MTBE, 60 °C, 40%; (b) Michael acceptor, DCM, rt; (c) HCl, 1,4-dioxane, DCM, rt; (d) <b>15a</b> or <b>15b</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C.</p><p><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on maximum single diastereomer recovery.</p><p class="last"><span class="fn-label"><sup>c</sup></span>Compound was made from racemic amine and diastereomers were separated by chiral HPLC or SFC.</p></p></figure><figure data-id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0011.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Piperidinyl-Azetidine CCR4 Antagonist <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl acrylate, DMF, 50 °C, 3 h; (b) LiBH<sub>4</sub>, THF, MeOH, 50 °C, 24 h; (c) HCl, 1,4-dioxane, DCM, rt; (d) <b>15a</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C; (e) separation of diastereomers by chiral HPLC using OZ-H, 20% ethanol/80% heptanes with 0.1% diethylamine.</p><p class="last"><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on the maximum single diastereomer recovery.</p></p></figure><figure data-id="sch6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0012.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>23</b>, <b>26</b>, <b>31</b>, <b>37</b>–<b>39</b>, and <b>40</b>–<b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <span class="smallcaps smallerCapital">l</span>-(+)-mandelic acid, MTBE, 60 °C, 40%; (b) aldehyde, NaHB(OAc)<sub>3</sub>, 1,2-DCE, rt; (c) HCl, 1,4-dioxane, DCM, rt; (d) <b>15</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C; (e) LiOH, MeOH, water, rt; (f) MeNH<sub>2</sub> or Me<sub>2</sub>NH, T<sub>3</sub>P, EtOAc.</p><p><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on the maximum single diastereomer recovery.</p><p><span class="fn-label"><sup>c</sup></span>The compound was made from racemic amine, and diastereomers were separated by chiral HPLC or SFC.</p><p><span class="fn-label"><sup>d</sup></span>Yield is shown for methyl ester, which was hydrolyzed using LiOH in MeOH/water with 90% yield to afford <b>23</b>.</p><p class="last"><span class="fn-label"><sup>e</sup></span>This compound was prepared using both racemic amine <b>11</b> and enantioenriched (<i>R</i>)-<b>11</b>, confirming stereochemistry of the product.</p></p></figure><figure data-id="sch7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0013.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Piperidinyl-Azetidine CCR4 Antagonists <b>22</b>, <b>32</b>, <b>34</b>, and <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <span class="smallcaps smallerCapital">l</span>-(+)-mandelic acid, MTBE, 60 °C, 40%; (b) R<sub>1</sub>CH<sub>2</sub>X (X = Br or I), acetonitrile or 1,4-dioxane, potassium or sodium carbonate, 75–90 °C, 12 h; (c) HCl, 1,4-dioxane, DCM, rt; (d) <b>15a</b> or <b>15b</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DMF, 80 °C.</p><p><span class="fn-label"><sup>b</sup></span>Yield for the last two steps based on the maximum single diastereomer recovery.</p><p class="last"><span class="fn-label"><sup>c</sup></span>The compound was made from racemic amine, and diastereomers were separated by chiral HPLC or SFC.</p></p></figure><figure data-id="sch8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/medium/jm0c00988_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0014.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compound <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00988/20200806/images/large/jm0c00988_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00988&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <span class="smallcaps smallerCapital">l</span>-(+)-mandelic acid, MTBE, 60 °C, 40%; (b) NaBH(OAc)<sub>3</sub>, 1,2-DCE, 22 °C, 98%; (c) HCl, 1,4-dioxane, DCM 22 °C, 99%; (d) <b>15b</b>, <i>N</i>,<i>N</i>-diisopropylethylamine, DCM, 22 °C, 83%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i143">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67450" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67450" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span>; <span class="NLM_string-name">Jaffee, E.</span>; <span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Immune Evasion by Tumors</span>. In  <i>Advances in Immunology</i>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">United States</span>, <span class="NLM_year">2006</span>; Vol.  <span class="NLM_volume">90</span>, pp  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">81</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=51-81&author=C.+G.+Drake&author=E.+Jaffee&author=D.+M.+Pardoll&title=Advances+in+Immunology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DC.%2BG.%26atitle%3DMechanisms%2520of%2520Immune%2520Evasion%2520by%2520Tumors%26btitle%3DAdvances%2520in%2520Immunology%26pub%3DAcademic%2520Press%26date%3D2006%26volume%3D90%26spage%3D51%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hadrup, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thor Straten, P.</span></span> <span> </span><span class="NLM_article-title">Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment</span>. <i>Cancer Microenviron.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1007/s12307-012-0127-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1007%2Fs12307-012-0127-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=23242673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOlur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=123-133&author=S.+Hadrupauthor=M.+Doniaauthor=P.+Thor+Straten&title=Effector+CD4+and+CD8+T+Cells+and+Their+Role+in+the+Tumor+Microenvironment&doi=10.1007%2Fs12307-012-0127-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment</span></div><div class="casAuthors">Hadrup, Sine; Donia, Marco; thor Straten, Per</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Microenvironment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-133</span>CODEN:
                <span class="NLM_cas:coden">CMAICW</span>;
        ISSN:<span class="NLM_cas:issn">1875-2284</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  T cells in tumors-the so-called tumor infiltrating lymphocytes (TIL) have been studied intensively over the past years.  Compelling evidence point to a clin. relevance for high nos. of T cells at the tumor site with CD8 memory T cells as a key denominator for overall survival (OS) in patients with colo-rectal cancer (CRC), and also for others solid cancers.  These data goes hand in hand with studies of clonality of TIL showing the T cells among TIL are expanded clonally, and also that tumor specific T cells of CD4 as well as CD8 type are enriched at the tumor site.  The tumor microenvironment is hostile to T cell function e.g., due to expression of enzymes that depletes the amino acids tryptophan and arginine, high concn. of tumor secreted lactate, and presence innate cells or regulatory T cells both with suppressive activity.  Analyses of the specificity of TILs in melanoma demonstrate that quite few known antigens are in fact recognized by these cultures underscoring patient unique and/or mutated antigens may represent important target for recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO_PUIt1Wyz7Vg90H21EOLACvtfcHk0lja558H-vTAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOlur%252FL&md5=eab48cec4355dedc34341179927989d4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs12307-012-0127-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12307-012-0127-6%26sid%3Dliteratum%253Aachs%26aulast%3DHadrup%26aufirst%3DS.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DThor%2BStraten%26aufirst%3DP.%26atitle%3DEffector%2520CD4%2520and%2520CD8%2520T%2520Cells%2520and%2520Their%2520Role%2520in%2520the%2520Tumor%2520Microenvironment%26jtitle%3DCancer%2520Microenviron.%26date%3D2013%26volume%3D6%26spage%3D123%26epage%3D133%26doi%3D10.1007%2Fs12307-012-0127-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Cancer Immunotherapy: Harnessing the Immune System to Battle Cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3335</span>– <span class="NLM_lpage">3337</span>, <span class="refDoi"> DOI: 10.1172/JCI83871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1172%2FJCI83871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=26325031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A280%3ADC%252BC287otVersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3335-3337&author=Y.+Yang&title=Cancer+Immunotherapy%3A+Harnessing+the+Immune+System+to+Battle+Cancer&doi=10.1172%2FJCI83871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy: harnessing the immune system to battle cancer</span></div><div class="casAuthors">Yang Yiping</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3335-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immunotherapy.  These successes also underscore the importance of understanding basic tumor immunology for successful clinical translation in treating patients with cancer.  The Reviews in this Review Series focus on current developments in cancer immunotherapy, highlight recent advances in our understanding of basic aspects of tumor immunology, and suggest how these insights can lead to the development of new immunotherapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCDsEQcCnxNc25P7XSLhESfW6udTcc2eaG0XkOXDpm8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287otVersw%253D%253D&md5=5a53437eb397adb28804ede24b04c8cf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1172%2FJCI83871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI83871%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26atitle%3DCancer%2520Immunotherapy%253A%2520Harnessing%2520the%2520Immune%2520System%2520to%2520Battle%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D3335%26epage%3D3337%26doi%3D10.1172%2FJCI83871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu-Lieskovan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">707</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.cell.2017.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=28187290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1ygtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=707-723&author=P.+Sharmaauthor=S.+Hu-Lieskovanauthor=J.+A.+Wargoauthor=A.+Ribas&title=Primary%2C+Adaptive%2C+and+Acquired+Resistance+to+Cancer+Immunotherapy&doi=10.1016%2Fj.cell.2017.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy</span></div><div class="casAuthors">Sharma, Padmanee; Hu-Lieskovan, Siwen; Wargo, Jennifer A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">707-723</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies.  Broadening the clin. applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy.  The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion.  As the mol. mechanisms of resistance to immunotherapy are elucidated, actionable strategies to prevent or treat them may be derived to improve clin. outcomes for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcdZs4zsnQGrVg90H21EOLACvtfcHk0lja558H-vTAag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1ygtb4%253D&md5=5a2d0ec3d2d0d438f2e9ede5053ed1aa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DHu-Lieskovan%26aufirst%3DS.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DPrimary%252C%2520Adaptive%252C%2520and%2520Acquired%2520Resistance%2520to%2520Cancer%2520Immunotherapy%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D707%26epage%3D723%26doi%3D10.1016%2Fj.cell.2017.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdemon-Hogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conejo-Garcia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryczek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span> <span> </span><span class="NLM_article-title">Specific Recruitment of Regulatory T cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1038/nm1093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1038%2Fnm1093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=15322536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=942-949&author=T.+J.+Curielauthor=G.+Coukosauthor=L.+Zouauthor=X.+Alvarezauthor=P.+Chengauthor=P.+Mottramauthor=M.+Evdemon-Hoganauthor=J.+R.+Conejo-Garciaauthor=L.+Zhangauthor=M.+Burowauthor=Y.+Zhuauthor=S.+Weiauthor=I.+Kryczekauthor=B.+Danielauthor=A.+Gordonauthor=L.+Myersauthor=A.+Lacknerauthor=M.+L.+Disisauthor=K.+L.+Knutsonauthor=L.+Chenauthor=W.+Zou&title=Specific+Recruitment+of+Regulatory+T+cells+in+Ovarian+Carcinoma+Fosters+Immune+Privilege+and+Predicts+Reduced+Survival&doi=10.1038%2Fnm1093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span></div><div class="casAuthors">Curiel, Tyler J.; Coukos, George; Zou, Linhua; Alvarez, Xavier; Cheng, Pui; Mottram, Peter; Evdemon-Hogan, Melina; Conejo-Garcia, Jose R.; Zhang, Lin; Burow, Matthew; Zhu, Yun; Wei, Shuang; Kryczek, Ilona; Daniel, Ben; Gordon, Alan; Myers, Leann; Lackner, Andrew; Disis, Mary L.; Knutson, Keith L.; Chen, Lieping; Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">942-949</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Regulatory T (Treg) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells.  Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-assocd. antigen-reactive lymphocytes mediated by Treg cells; however, definitive evidence that Treg cells have an immunopathol. role in human cancer is lacking.  Here the authors show, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor Treg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo.  The authors also show that tumor Treg cells are assocd. with a high death hazard and reduced survival.  Human Treg cells preferentially move to and accumulate in tumors and ascites, but rarely enter draining lymph nodes in later cancer stages.  Tumor cells and microenvironmental macrophages produce the chemokine CCL22, which mediates trafficking of Treg cells to the tumor.  This specific recruitment of Treg cells represents a mechanism by which tumors may foster immune privilege.  Thus, blocking Treg cell migration or function may help to defeat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUuPjm7zZim7Vg90H21EOLACvtfcHk0lj3pMMuBmWG0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D&md5=eaf598e6096d6e92381c1b26f4b2fe91</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm1093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1093%26sid%3Dliteratum%253Aachs%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DAlvarez%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DP.%26aulast%3DMottram%26aufirst%3DP.%26aulast%3DEvdemon-Hogan%26aufirst%3DM.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBurow%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DKryczek%26aufirst%3DI.%26aulast%3DDaniel%26aufirst%3DB.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DMyers%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DA.%26aulast%3DDisis%26aufirst%3DM.%2BL.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DW.%26atitle%3DSpecific%2520Recruitment%2520of%2520Regulatory%2520T%2520cells%2520in%2520Ovarian%2520Carcinoma%2520Fosters%2520Immune%2520Privilege%2520and%2520Predicts%2520Reduced%2520Survival%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D942%26epage%3D949%26doi%3D10.1038%2Fnm1093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treilleux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendriss-Vermare, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachelot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard-Leon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arfi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biota, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffin, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durand, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqual, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray-Coquard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puisieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménétrier-Caux, C.</span></span> <span> </span><span class="NLM_article-title">Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2000</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1158%2F0008-5472.CAN-08-2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=19244125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFSrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=2000&author=M.+Gobertauthor=I.+Treilleuxauthor=N.+Bendriss-Vermareauthor=T.+Bachelotauthor=S.+Goddard-Leonauthor=V.+Arfiauthor=C.+Biotaauthor=A.+C.+Doffinauthor=I.+Durandauthor=D.+Oliveauthor=S.+Perezauthor=N.+Pasqualauthor=C.+Faureauthor=I.+Ray-Coquardauthor=A.+Puisieuxauthor=C.+Cauxauthor=J.-Y.+Blayauthor=C.+M%C3%A9n%C3%A9trier-Caux&title=Regulatory+T+Cells+Recruited+through+CCL22%2FCCR4+Are+Selectively+Activated+in+Lymphoid+Infiltrates+Surrounding+Primary+Breast+Tumors+and+Lead+to+an+Adverse+Clinical+Outcome&doi=10.1158%2F0008-5472.CAN-08-2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome</span></div><div class="casAuthors">Gobert, Michael; Treilleux, Isabelle; Bendriss-Vermare, Nathalie; Bachelot, Thomas; Goddard-Leon, Sophie; Arfi, Vanessa; Biota, Cathy; Doffin, Anne Claire; Durand, Isabelle; Olive, Daniel; Perez, Solene; Pasqual, Nicolas; Faure, Christelle; Ray-Coquard, Isabelle; Puisieux, Alain; Caux, Christophe; Blay, Jean-Yves; Menetrier-Caux, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immunohistochem. anal. of FOXP3 in primary breast tumors showed that a high no. of tumor-infiltrating regulatory T cells (Ti-Treg) within lymphoid infiltrates surrounding the tumor was predictive of relapse and death, in contrast to those present within the tumor bed.  Ex vivo anal. showed that these tumor-infiltrating FOXP3+ T cells are typical Treg based on their CD4+CD25highCD127lowFOXP3+ phenotype, their anergic state on in vitro stimulation, and their suppressive functions.  These Ti-Treg could be selectively recruited through CCR4 as illustrated by (a) selective blood Treg CCR4 expression and migration to CCR4 ligands, (b) CCR4 down-regulation on Ti-Treg, and (c) correlation between Ti-Treg in lymphoid infiltrates and intratumoral CCL22 expression.  Importantly, in contrast to other T cells, Ti-Treg are selectively activated locally and proliferate in situ, showing T-cell receptor engagement and suggesting specific recognition of tumor-assocd. antigens (TAA).  Immunohistochem. stainings for ICOS, Ki67, and DC-LAMP show that Ti-Treg were close to mature DC-LAMP+ dendritic cells (DC) in lymphoid infiltrates but not in tumor bed and were activated and proliferating.  Furthermore, proximity between Ti-Treg, CD3+, and CD8+ T cells was documented within lymphoid infiltrates.  Altogether, these results show that Treg are selectively recruited within lymphoid infiltrates and activated by mature DC likely through TAA presentation, resulting in the prevention of effector T-cell activation, immune escape, and ultimately tumor progression.  This study sheds new light on Treg physiol. and validates CCR4/CCL22 and ICOS as therapeutic targets in breast tumors, which represent a major health problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqhKbsz9ynO7Vg90H21EOLACvtfcHk0lhtYbaU-PW8kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFSrtbg%253D&md5=452bc4cee9c3cba90cfce6cf6dd4994d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-2360%26sid%3Dliteratum%253Aachs%26aulast%3DGobert%26aufirst%3DM.%26aulast%3DTreilleux%26aufirst%3DI.%26aulast%3DBendriss-Vermare%26aufirst%3DN.%26aulast%3DBachelot%26aufirst%3DT.%26aulast%3DGoddard-Leon%26aufirst%3DS.%26aulast%3DArfi%26aufirst%3DV.%26aulast%3DBiota%26aufirst%3DC.%26aulast%3DDoffin%26aufirst%3DA.%2BC.%26aulast%3DDurand%26aufirst%3DI.%26aulast%3DOlive%26aufirst%3DD.%26aulast%3DPerez%26aufirst%3DS.%26aulast%3DPasqual%26aufirst%3DN.%26aulast%3DFaure%26aufirst%3DC.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DM%25C3%25A9n%25C3%25A9trier-Caux%26aufirst%3DC.%26atitle%3DRegulatory%2520T%2520Cells%2520Recruited%2520through%2520CCL22%252FCCR4%2520Are%2520Selectively%2520Activated%2520in%2520Lymphoid%2520Infiltrates%2520Surrounding%2520Primary%2520Breast%2520Tumors%2520and%2520Lead%2520to%2520an%2520Adverse%2520Clinical%2520Outcome%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D2000%26doi%3D10.1158%2F0008-5472.CAN-08-2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Betts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Shanawany, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scurr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallimore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godkin, A.</span></span> <span> </span><span class="NLM_article-title">Suppression of Tumour-Specific CD4+ T Cells by Regulatory T Cells is Associated with Progression of Human Colorectal Cancer</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1171</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2011-300970</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1136%2Fgutjnl-2011-300970" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=22207629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kks7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=1163-1171&author=G.+Bettsauthor=E.+Jonesauthor=S.+Junaidauthor=T.+El-Shanawanyauthor=M.+Scurrauthor=P.+Mizenauthor=M.+Kumarauthor=S.+Jonesauthor=B.+Reesauthor=G.+Williamsauthor=A.+Gallimoreauthor=A.+Godkin&title=Suppression+of+Tumour-Specific+CD4%2B+T+Cells+by+Regulatory+T+Cells+is+Associated+with+Progression+of+Human+Colorectal+Cancer&doi=10.1136%2Fgutjnl-2011-300970"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer</span></div><div class="casAuthors">Betts, Gareth; Jones, Emma; Junaid, Syed; El-Shanawany, Tariq; Scurr, Martin; Mizen, Paul; Kumar, Mayur; Jones, Sion; Rees, Brian; Williams, Geraint; Gallimore, Awen; Godkin, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1163-1171</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background There is indirect evidence that T cell responses can control the metastatic spread of colorectal cancer (CRC).  However, an enrichment of CD4+Foxp3+ regulatory T cells (Tregs) has also been documented.  Objective To evaluate whether CRC promotes Treg activity and how this influences anti-tumor immune responses and disease progression.  Methods A longitudinal study of Treg activity on a cohort of patients was performed before and after tumor resection.  Specific CD4+ T cell responses were also measured to the tumor assocd. antigens carcinoembryonic antigen (CEA) and 5T4.  Results Tregs from 62 preoperative CRC patients expressed a highly significant increase in levels of Foxp3 compared to healthy age-matched controls (p=0.007), which returned to normal after surgery (p=0.0075).  CD4+ T cell responses to one or both of the tumor assocd. antigens, CEA and 5T4, were obsd. in approx. two-thirds of patients and one third of these responses were suppressed by Tregs.  Strikingly, in all patients with tumor recurrence at 12 mo, significant preoperative suppression was obsd. of tumor-specific (p=0.003) but not control CD4+ T cell responses.  Conclusion These findings demonstrate that the presence of CRC drives the activity of Tregs and accompanying suppression of CD4+ T cell responses to tumor-assocd. antigens.  Suppression is assocd. with recurrence of tumor at 12 mo, implying that Tregs contribute to disease progression.  These findings offer a rationale for the manipulation of Tregs for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR3mvhw4Z1rrVg90H21EOLACvtfcHk0lhtYbaU-PW8kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kks7jM&md5=3ccff67cce65c23da40d1f8da2765397</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2011-300970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2011-300970%26sid%3Dliteratum%253Aachs%26aulast%3DBetts%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DJunaid%26aufirst%3DS.%26aulast%3DEl-Shanawany%26aufirst%3DT.%26aulast%3DScurr%26aufirst%3DM.%26aulast%3DMizen%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DRees%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DGallimore%26aufirst%3DA.%26aulast%3DGodkin%26aufirst%3DA.%26atitle%3DSuppression%2520of%2520Tumour-Specific%2520CD4%252B%2520T%2520Cells%2520by%2520Regulatory%2520T%2520Cells%2520is%2520Associated%2520with%2520Progression%2520of%2520Human%2520Colorectal%2520Cancer%26jtitle%3DGut%26date%3D2012%26volume%3D61%26spage%3D1163%26epage%3D1171%26doi%3D10.1136%2Fgutjnl-2011-300970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">An Increased Abundance of Tumor-Infiltrating Regulatory T Cells Is Correlated with the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e91551</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0091551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1371%2Fjournal.pone.0091551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=24637664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVWntb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=Y.+Tangauthor=X.+Xuauthor=S.+Guoauthor=C.+Zhangauthor=Y.+Tangauthor=Y.+Tianauthor=B.+Niauthor=B.+Luauthor=H.+Wang&title=An+Increased+Abundance+of+Tumor-Infiltrating+Regulatory+T+Cells+Is+Correlated+with+the+Progression+and+Prognosis+of+Pancreatic+Ductal+Adenocarcinoma&doi=10.1371%2Fjournal.pone.0091551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma</span></div><div class="casAuthors">Tang, Yichen; Xu, Xuejun; Guo, Shixiang; Zhang, Chaobin; Tang, Yan; Tian, Yi; Ni, Bing; Lu, Binfeng; Wang, Huaizhi</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e91551/1-e91551/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">CD4+CD25+Foxp3+ regulatory T cells (Tregs) can inhibit cytotoxic responses.  Though several studies have analyzed Treg frequency in the peripheral blood mononuclear cells (PBMCs) of pancreatic ductal adenocarcinoma (PDA) patients using flow cytometry (FCM), few studies have examd. how intratumoral Tregs might contribute to immunosuppression in the tumor microenvironment.  Thus, the potential role of intratumoral Tregs in PDA patients remains to be elucidated.  In this study, we found that the percentages of Tregs, CD4+ T cells and CD8+ T cells were all increased significantly in tumor tissue compared to control pancreatic tissue, as assessed via FCM, whereas the percentages of these cell types in PBMCs did not differ between PDA patients and healthy volunteers.  The percentages of CD8+ T cells in tumors were significantly lower than in PDA patient PBMCs.  In addn., the relative nos. of CD4+CD25+Foxp3+ Tregs and CD8+ T cells were neg. correlated in the tissue of PDA patients, and the abundance of Tregs was significantly correlated with tumor differentiation.  Addnl., Foxp3+ T cells were obsd. more frequently in juxtatumoral stroma (immediately adjacent to the tumor epithelial cells).  Patients showing an increased prevalence of Foxp3+ T cells had a poorer prognosis, which was an independent factor for patient survival.  These results suggest that Tregs may promote PDA progression by inhibiting the antitumor immunity of CD8+ T cells at local intratumoral sites.  Moreover, a high proportion of Tregs in tumor tissues may reflect suppressed antitumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOhRQW2-sWLLVg90H21EOLACvtfcHk0li9PXv5L3J3kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVWntb%252FL&md5=8577403b41758396004556664fbc7ad9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0091551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0091551%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DAn%2520Increased%2520Abundance%2520of%2520Tumor-Infiltrating%2520Regulatory%2520T%2520Cells%2520Is%2520Correlated%2520with%2520the%2520Progression%2520and%2520Prognosis%2520of%2520Pancreatic%2520Ductal%2520Adenocarcinoma%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0091551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracci, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsuang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemels, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsey, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrensch, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiencke, J. K.</span></span> <span> </span><span class="NLM_article-title">Serum Macrophage-Derived Chemokine/CCL22 Levels are Associated with Glioma Risk, CD4 T Cell Lymphopenia and Survival Time</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">826</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1002/ijc.29441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1002%2Fijc.29441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25604093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVajtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=826-836&author=M.+Zhouauthor=P.+M.+Bracciauthor=L.+S.+McCoyauthor=G.+Hsuangauthor=J.+L.+Wiemelsauthor=T.+Riceauthor=S.+Zhengauthor=K.+T.+Kelseyauthor=M.+R.+Wrenschauthor=J.+K.+Wiencke&title=Serum+Macrophage-Derived+Chemokine%2FCCL22+Levels+are+Associated+with+Glioma+Risk%2C+CD4+T+Cell+Lymphopenia+and+Survival+Time&doi=10.1002%2Fijc.29441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time</span></div><div class="casAuthors">Zhou, Mi; Bracci, Paige M.; McCoy, Lucie S.; Hsuang, George; Wiemels, Joseph L.; Rice, Terri; Zheng, Shichun; Kelsey, Karl T.; Wrensch, Margaret R.; Wiencke, John K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">826-836</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Defects in antigen presenting cell function have been implicated in glioma immunosuppression.  We measured peripheral CCL22, a dendritic cell/macrophage derived T cell trafficking chemokine, in sera from 1,208 glioma cases and 976 controls to assess whether it might provide a biomarker of glioma risk, survival and immune dysfunction.  Cluster models were used to examine the relationship between CCL22 and glioma risk.  Patient survival was assessed using Cox regression models.  We also examd. the relationship between CCL22 levels and CD4 cell counts, as well as allergy history and IgE levels.  CCL22 levels were significantly lower among glioma cases compared with controls (Mean ± SEM: 1.23 ± 0.03 ng/mL in cases vs. 1.60 ± 0.03 ng/mL in controls, p < 0.0001) and this difference remained significant even after controlling for other covariates in the cluster models (highest quartile vs. lowest Odds Ratio = 0.21, p < 0.0001).  CD4 cell counts were pos. correlated with CCL22 in glioma cases (Spearman r2 = 0.51, p < 0.01) and were significantly lower in cases compared with controls.  Higher CCL22 levels were assocd. with longer survival in all cases combined and in GBM cases (hazard ratioallcases = 0.81; 95% CI: 0.72-0.91, p = 0.0003).  CCL22 levels were not assocd. with IgE level or self-reported allergies.  Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histol., grade and IDH mutation status.  CCL22 should be considered a marker of immune status with potential prognostic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7bCfHIddb-LVg90H21EOLACvtfcHk0li9PXv5L3J3kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVajtb4%253D&md5=8ea50f9c73cca78b7c6f250a302cc7af</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fijc.29441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29441%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DBracci%26aufirst%3DP.%2BM.%26aulast%3DMcCoy%26aufirst%3DL.%2BS.%26aulast%3DHsuang%26aufirst%3DG.%26aulast%3DWiemels%26aufirst%3DJ.%2BL.%26aulast%3DRice%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DKelsey%26aufirst%3DK.%2BT.%26aulast%3DWrensch%26aufirst%3DM.%2BR.%26aulast%3DWiencke%26aufirst%3DJ.%2BK.%26atitle%3DSerum%2520Macrophage-Derived%2520Chemokine%252FCCL22%2520Levels%2520are%2520Associated%2520with%2520Glioma%2520Risk%252C%2520CD4%2520T%2520Cell%2520Lymphopenia%2520and%2520Survival%2520Time%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D826%26epage%3D836%26doi%3D10.1002%2Fijc.29441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ihara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujikawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motohashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span> <span> </span><span class="NLM_article-title">CD45RA-Foxp3high Regulatory T Cells Have a Negative Impact on the Clinical Outcome of Head and Neck Squamous Cell Carcinoma</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1275</span>– <span class="NLM_lpage">1285</span>, <span class="refDoi"> DOI: 10.1007/s00262-017-2021-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1007%2Fs00262-017-2021-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=28551813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovFChs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1275-1285&author=F.+Iharaauthor=D.+Sakuraiauthor=A.+Horinakaauthor=Y.+Makitaauthor=A.+Fujikawaauthor=T.+Sakuraiauthor=K.+Yamasakiauthor=N.+Kuniiauthor=S.+Motohashiauthor=T.+Nakayamaauthor=Y.+Okamoto&title=CD45RA-Foxp3high+Regulatory+T+Cells+Have+a+Negative+Impact+on+the+Clinical+Outcome+of+Head+and+Neck+Squamous+Cell+Carcinoma&doi=10.1007%2Fs00262-017-2021-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">CD45RA-Foxp3high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma</span></div><div class="casAuthors">Ihara, Fumie; Sakurai, Daiju; Horinaka, Atsushi; Makita, Yuji; Fujikawa, Akira; Sakurai, Toshioki; Yamasaki, Kazuki; Kunii, Naoki; Motohashi, Shinichiro; Nakayama, Toshinori; Okamoto, Yoshitaka</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1275-1285</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A recent study reported Tregs could be divided into functional subsets based on the expression of CD45RA and Foxp3.  Method: The frequency of circulating Treg subsets was analyzed in patients with HNSCC and compared with the frequency in patients with benign tumors.  The assocn. of Treg subsets with the frequency of lymphocyte subsets, status of progression, clin. course, and prognosis were also examd.  Results: The frequency of CD4+Foxp3+ Tregs was comparable between HNSCC patients and age-matched benign tumor patients; however, CD45RA-Foxp3high Tregs were significantly increased in HNSCC patients, in particular those with advanced stage tumors.  The high frequency of CD45RA-Foxp3high Tregs correlated with a poor prognosis and the low frequency of CD45RA-Foxp3high Tregs before treatment showed a better clin. outcome, even in patients with advanced stage tumors.  CD45RA-Foxp3high Treg nos. were decreased after intensive treatments; however, Treg nos. recovered in the early stages of recurrent cases, even before the clin. manifestation.  Conclusion: CD45RA-Foxp3high Tregs are assocd. with the clin. course of HNSCC and might be a new target for treatment and an early marker of tumor recurrence in HNSCC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5iaIxQuliSrVg90H21EOLACvtfcHk0li9PXv5L3J3kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovFChs70%253D&md5=2709893b5ed3506fafe07a1ddd1f38de</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00262-017-2021-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-017-2021-z%26sid%3Dliteratum%253Aachs%26aulast%3DIhara%26aufirst%3DF.%26aulast%3DSakurai%26aufirst%3DD.%26aulast%3DHorinaka%26aufirst%3DA.%26aulast%3DMakita%26aufirst%3DY.%26aulast%3DFujikawa%26aufirst%3DA.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DYamasaki%26aufirst%3DK.%26aulast%3DKunii%26aufirst%3DN.%26aulast%3DMotohashi%26aufirst%3DS.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DY.%26atitle%3DCD45RA-Foxp3high%2520Regulatory%2520T%2520Cells%2520Have%2520a%2520Negative%2520Impact%2520on%2520the%2520Clinical%2520Outcome%2520of%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2017%26volume%3D66%26spage%3D1275%26epage%3D1285%26doi%3D10.1007%2Fs00262-017-2021-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakaguchi, S.</span></span> <span> </span><span class="NLM_article-title">Induction of Tumor Immunity by Removing CD25+ and CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">5211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10553041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADyaK1MXntlKktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=1999&pages=5211&author=J.+Shimizuauthor=S.+Yamazakiauthor=S.+Sakaguchi&title=Induction+of+Tumor+Immunity+by+Removing+CD25%2B+and+CD4%2B+T+Cells%3A+A+Common+Basis+Between+Tumor+Immunity+and+Autoimmunity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity</span></div><div class="casAuthors">Shimizu, Jun; Yamazaki, Sayuri; Sakaguchi, Shimon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5211-5218</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">This study shows that removal of a T cell subpopulation can evoke effective tumor immunity in otherwise non-responding animals.  Elimination of CD25-expressing T cells, which constitute 5-10% of peripheral CD4+ T cells in normal naive mice, elicited potent immune responses to syngeneic tumors in vivo and eradicated them.  The responses were mediated by tumor-specific CD8+ CTLs and tumor-nonspecific CD4-8- cytotoxic cells akin to NK cells.  Furthermore, in vitro culture of CD25+4+ T cell-depleted splenic cell suspensions prepd. from tumor-unsensitized normal mice led to spontaneous generation of similar CD4-8- cytotoxic cells capable of killing a broad spectrum of tumors; reconstitution of CD25+4+ T cells inhibited the generation.  In this culture, self-reactive CD25-4+ T cells responding to self peptides/class II MHC complexes on APCs spontaneously proliferated upon removal of CD25+4+ T cells, secreting large amts. of IL-2.  The IL-2 thus produced appeared to be responsible for the generation of CD4-8- NK cells as lymphokine-activated killer cells, because direct addn. of an equiv. amt. of IL-2 to the culture of CD4-8- cells generated similar lymphokine-activated killer/NK cells, whereas coculture of normal CD4-8- cells with CD25-4+ T cells from IL-2-deficient mice did not.  Thus, removal of immunoregulatory CD25+4+ T cells can abrogate immunol. unresponsiveness to syngeneic tumors in vivo and in vitro, leading to spontaneous development of tumor-specific effector cells as well as tumor-nonspecific ones.  This novel way of evoking tumor immunity would help to devise effective immunotherapy for cancer in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo1kVJ1ReNzrVg90H21EOLACvtfcHk0liINfR0lMp7fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntlKktbw%253D&md5=5fb4e8865ea721166eb4c6599ab08e0a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DJ.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DSakaguchi%26aufirst%3DS.%26atitle%3DInduction%2520of%2520Tumor%2520Immunity%2520by%2520Removing%2520CD25%252B%2520and%2520CD4%252B%2520T%2520Cells%253A%2520A%2520Common%2520Basis%2520Between%2520Tumor%2520Immunity%2520and%2520Autoimmunity%26jtitle%3DJ.%2520Immunol.%26date%3D1999%26volume%3D163%26spage%3D5211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassett, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Macedo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin-Breneman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broaddus, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenwald, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haydu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glitza, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vence, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wistuba, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaria, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overwijk, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blando, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span> <span> </span><span class="NLM_article-title">Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">827</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1158%2F2159-8290.CD-15-1545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=27301722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12mtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=827&author=P.-L.+Chenauthor=W.+Rohauthor=A.+Reubenauthor=Z.+A.+Cooperauthor=C.+N.+Spencerauthor=P.+A.+Prietoauthor=J.+P.+Millerauthor=R.+L.+Bassettauthor=V.+Gopalakrishnanauthor=K.+Waniauthor=M.+P.+De+Macedoauthor=J.+L.+Austin-Brenemanauthor=H.+Jiangauthor=Q.+Changauthor=S.+M.+Reddyauthor=W.-S.+Chenauthor=M.+T.+Tetzlaffauthor=R.+J.+Broaddusauthor=M.+A.+Daviesauthor=J.+E.+Gershenwaldauthor=L.+Hayduauthor=A.+J.+Lazarauthor=S.+P.+Patelauthor=P.+Hwuauthor=W.-J.+Hwuauthor=A.+Diabauthor=I.+C.+Glitzaauthor=S.+E.+Woodmanauthor=L.+M.+Venceauthor=I.+I.+Wistubaauthor=R.+N.+Amariaauthor=L.+N.+Kwongauthor=V.+Prietoauthor=R.+E.+Davisauthor=W.+Maauthor=W.+W.+Overwijkauthor=A.+H.+Sharpeauthor=J.+Huauthor=P.+A.+Futrealauthor=J.+Blandoauthor=P.+Sharmaauthor=J.+P.+Allisonauthor=L.+Chinauthor=J.+A.+Wargo&title=Analysis+of+Immune+Signatures+in+Longitudinal+Tumor+Samples+Yields+Insight+into+Biomarkers+of+Response+and+Mechanisms+of+Resistance+to+Immune+Checkpoint+Blockade&doi=10.1158%2F2159-8290.CD-15-1545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade</span></div><div class="casAuthors">Chen, Pei-Ling; Roh, Whijae; Reuben, Alexandre; Cooper, Zachary A.; Spencer, Christine N.; Prieto, Peter A.; Miller, John P.; Bassett, Roland L.; Gopalakrishnan, Vancheswaran; Wani, Khalida; Petaccia De Macedo, Mariana; Austin-Breneman, Jacob L.; Jiang, Hong; Chang, Qing; Reddy, Sangeetha M.; Chen, Wei-Shen; Tetzlaff, Michael T.; Broaddus, Russell J.; Davies, Michael A.; Gershenwald, Jeffrey E.; Haydu, Lauren; Lazar, Alexander J.; Patel, Sapna P.; Hwu, Patrick; Hwu, Wen-Jen; Diab, Adi; Glitza, Isabella C.; Woodman, Scott E.; Vence, Luis M.; Wistuba, Ignacio I.; Amaria, Rodabe N.; Kwong, Lawrence N.; Prieto, Victor; Davis, R. Eric; Ma, Wencai; Overwijk, Willem W.; Sharpe, Arlene H.; Hu, Jianhua; Futreal, P. Andrew; Blando, Jorge; Sharma, Padmanee; Allison, James P.; Chin, Lynda; Wargo, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">827-837</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal.  Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and other cancers, but robust biomarkers have not been identified.  We studied a cohort of patients with metastatic melanoma initially treated with cytotoxic T-lymphocyte-assocd. antigen-4 (CTLA4) blockade (n = 53) followed by programmed death-1 (PD-1) blockade at progression (n = 46), and analyzed immune signatures in longitudinal tissue samples collected at multiple time points during therapy.  In this study, we demonstrate that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade.  Importantly, potential mechanisms of therapeutic resistance to immune checkpoint blockade were also identified.  Significance: These studies demonstrate that adaptive immune signatures in early on-treatment tumor biopsies are predictive of response to checkpoint blockade and yield insight into mechanisms of therapeutic resistance.  These concepts have far-reaching implications in this age of precision medicine and should be explored in immune checkpoint blockade treatment across cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4yheFcpbQs7Vg90H21EOLACvtfcHk0liINfR0lMp7fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12mtbbP&md5=e8cae5ccf55f9fe4f217044708c1cb32</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1545%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.-L.%26aulast%3DRoh%26aufirst%3DW.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DSpencer%26aufirst%3DC.%2BN.%26aulast%3DPrieto%26aufirst%3DP.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BP.%26aulast%3DBassett%26aufirst%3DR.%2BL.%26aulast%3DGopalakrishnan%26aufirst%3DV.%26aulast%3DWani%26aufirst%3DK.%26aulast%3DDe%2BMacedo%26aufirst%3DM.%2BP.%26aulast%3DAustin-Breneman%26aufirst%3DJ.%2BL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DReddy%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DW.-S.%26aulast%3DTetzlaff%26aufirst%3DM.%2BT.%26aulast%3DBroaddus%26aufirst%3DR.%2BJ.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DHaydu%26aufirst%3DL.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DS.%2BP.%26aulast%3DHwu%26aufirst%3DP.%26aulast%3DHwu%26aufirst%3DW.-J.%26aulast%3DDiab%26aufirst%3DA.%26aulast%3DGlitza%26aufirst%3DI.%2BC.%26aulast%3DWoodman%26aufirst%3DS.%2BE.%26aulast%3DVence%26aufirst%3DL.%2BM.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DAmaria%26aufirst%3DR.%2BN.%26aulast%3DKwong%26aufirst%3DL.%2BN.%26aulast%3DPrieto%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DOverwijk%26aufirst%3DW.%2BW.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26aulast%3DBlando%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26atitle%3DAnalysis%2520of%2520Immune%2520Signatures%2520in%2520Longitudinal%2520Tumor%2520Samples%2520Yields%2520Insight%2520into%2520Biomarkers%2520of%2520Response%2520and%2520Mechanisms%2520of%2520Resistance%2520to%2520Immune%2520Checkpoint%2520Blockade%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D827%26doi%3D10.1158%2F2159-8290.CD-15-1545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berlato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioppa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montfort, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jangani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulbe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemann, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powles, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quezada, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkwill, F. R.</span></span> <span> </span><span class="NLM_article-title">A CCR4 Antagonist Reverses the Tumor-Promoting Microenvironment of Renal Cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1172/JCI82976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1172%2FJCI82976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=28134623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A280%3ADC%252BC1c3gsVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=801-813&author=C.+Berlatoauthor=M.+N.+Khanauthor=T.+Schioppaauthor=R.+Thompsonauthor=E.+Maniatiauthor=A.+Montfortauthor=M.+Janganiauthor=M.+Canosaauthor=H.+Kulbeauthor=U.+B.+Hagemannauthor=A.+R.+Duncanauthor=L.+Fletcherauthor=R.+W.+Wilkinsonauthor=T.+Powlesauthor=S.+A.+Quezadaauthor=F.+R.+Balkwill&title=A+CCR4+Antagonist+Reverses+the+Tumor-Promoting+Microenvironment+of+Renal+Cancer&doi=10.1172%2FJCI82976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer</span></div><div class="casAuthors">Berlato Chiara; Khan Moddasar N; Schioppa Tiziana; Thompson Richard; Maniati Eleni; Montfort Anne; Jangani Maryam; Canosa Monica; Kulbe Hagen; Hagemann Urs B; Duncan Alexander R; Fletcher Laura; Wilkinson Robert W; Powles Thomas; Quezada Sergio A; Balkwill Frances R</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">801-813</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Elevated expression of the chemokine receptor CCR4 in tumors is associated with poor prognosis in several cancers.  Here, we have determined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed abnormal levels of CCR4 ligands in RCC patient plasma.  An antagonistic anti-CCR4 antibody had antitumor activity in the RENCA mouse model of RCC.  CCR4 inhibition did not reduce the proportion of infiltrating leukocytes in the tumor microenvironment but altered the phenotype of myeloid cells, increased NK cell and Th1 cytokine levels, and reduced immature myeloid cell infiltrate and blood chemokine levels.  In spite of prominent changes in the myeloid compartment, the anti-CCR4 antibody did not affect RENCA tumors in T cell-deficient mice, and treatment with an anti-class II MHC antibody abrogated its antitumor activity.  We concluded that the effects of the anti-CCR4 antibody required the adaptive immune system and CD4+ T cells.  Moreover, CCL17-induced IFN-γ production was reduced when Th1-polarized normal CD4+ T cells were exposed to the CCR4 ligand, evidencing the involvement of CCR4 in Th1/Th2 regulation.  The anti-CCR4 antibody, alone or in combination with other immune modulators, is a potential treatment approach to human solid cancers with high levels of CCR4-expressing tumor-infiltrating leukocytes and abnormal plasma CCR4 ligand levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoQFKAF-OvBn6CEoQgWY10fW6udTcc2eZR76ftQc_NPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3gsVGnsA%253D%253D&md5=031641076ef19ed1e1ca081e2ac069b8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1172%2FJCI82976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI82976%26sid%3Dliteratum%253Aachs%26aulast%3DBerlato%26aufirst%3DC.%26aulast%3DKhan%26aufirst%3DM.%2BN.%26aulast%3DSchioppa%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DR.%26aulast%3DManiati%26aufirst%3DE.%26aulast%3DMontfort%26aufirst%3DA.%26aulast%3DJangani%26aufirst%3DM.%26aulast%3DCanosa%26aufirst%3DM.%26aulast%3DKulbe%26aufirst%3DH.%26aulast%3DHagemann%26aufirst%3DU.%2BB.%26aulast%3DDuncan%26aufirst%3DA.%2BR.%26aulast%3DFletcher%26aufirst%3DL.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DPowles%26aufirst%3DT.%26aulast%3DQuezada%26aufirst%3DS.%2BA.%26aulast%3DBalkwill%26aufirst%3DF.%2BR.%26atitle%3DA%2520CCR4%2520Antagonist%2520Reverses%2520the%2520Tumor-Promoting%2520Microenvironment%2520of%2520Renal%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D801%26epage%3D813%26doi%3D10.1172%2FJCI82976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">CCR4 as a Novel Molecular Target for Immunotherapy of Cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2006.00307.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1111%2Fj.1349-7006.2006.00307.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=16952304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFemtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=1139-1146&author=T.+Ishidaauthor=R.+Ueda&title=CCR4+as+a+Novel+Molecular+Target+for+Immunotherapy+of+Cancer&doi=10.1111%2Fj.1349-7006.2006.00307.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CCR4 as a novel molecular target for immunotherapy of cancer</span></div><div class="casAuthors">Ishida, Takashi; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1139-1146</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukocyte trafficking, which is critically regulated by chemokines and their receptors, shares many of the characteristics of tumor cell infiltration and metastasis.  Expression of CC chemokine receptor 4 (CCR4) by tumor cells is assocd. with skin involvement, but CCR4 also has an important role in normal and tumor immunity.  In a subset of patients with CCR4+ T-cell leukemia/lymphoma, the tumor cells themselves function as regulatory T (Treg) cells, contributing to tumor survival in the face of host antitumor immune responses.  In other types of cancers, the chemokines TARC/CCL17 and MDC/CCL22, specific ligands for CCR4 that are produced by tumor cells and the tumor microenvironment, attract CCR4+ Treg cells to the tumor, where they create a favorable environment for tumor escape from host immune responses.  A novel humanized anti-CCR4 monoclonal antibody (mAb) has been developed, the Fc region of which is defucosylated to enhance antibody-dependent cellular cytotoxicity by increasing its binding affinity to Fc receptor on effector cells.  We are now conducting a phase I clin. trial of this anti-CCR4 mAb in patients with CCR4+ T-cell leukemia/lymphoma in Japan (clin. trials gov. identifier: NCT00355472).  Anti-CCR4 mAb could be an ideal treatment modality for many different cancers, not only to directly kill the CCR4+ tumor cells, but also to overcome the suppressive effect of CCR4+ Treg cells on the host immune response to tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSaM9sSn_TJbVg90H21EOLACvtfcHk0liNsf2U8AuBZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFemtbjJ&md5=1ae7461548ceb9b10873b891551e4d9e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2006.00307.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2006.00307.x%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DCCR4%2520as%2520a%2520Novel%2520Molecular%2520Target%2520for%2520Immunotherapy%2520of%2520Cancer%26jtitle%3DCancer%2520Sci.%26date%3D2006%26volume%3D97%26spage%3D1139%26epage%3D1146%26doi%3D10.1111%2Fj.1349-7006.2006.00307.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshie, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, K.</span></span> <span> </span><span class="NLM_article-title">CCR4 and its Ligands: From Bench to Bedside</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxu079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1093%2Fintimm%2Fdxu079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25087232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFejtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=11-20&author=O.+Yoshieauthor=K.+Matsushima&title=CCR4+and+its+Ligands%3A+From+Bench+to+Bedside&doi=10.1093%2Fintimm%2Fdxu079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">CCR4 and its ligands: from bench to bedside</span></div><div class="casAuthors">Yoshie, Osamu; Matsushima, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-20</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Chemokines and chemokine receptors orchestrate cell migration and homing in the body.  Humans have at least 44 chemokines that are further classified into four subfamilies based on the N-terminal conserved cysteine motifs: CXC, CC, C and CX3C.  All the known chemokine receptors are seven transmembrane-type receptors.  Humans have 18 chemotactic and 5 atypical non-chemotactic (recycling or scavenging) receptors.  CC chemokine receptor 4 (CCR4) is the receptor for two CC chemokine ligands (CCLs)-CCL17 (also called thymus- and activation-regulated chemokine) and CCL22 (macrophage-derived chemokine).  Among the various T-cell subsets, CCR4 is predominantly expressed by Th2 cells, cutaneous lymphocyte antigen-pos. skin-homing T cells and Treg cells.  Thus, CCR4 attracts much attention for its possible clin. applications in diseases involving these T-cell subsets.  Furthermore, CCR4 is often highly expressed by mature T-cell neoplasms such as adult T-cell leukemia/lymphoma (ATL) and cutaneous T-cell lymphomas (CTCLs).  This article is a brief overview of basic and clin. research on CCR4 and its ligands, which has eventually led to the development of a humanized defucosylated anti-CCR4 antibody "Mogamulizumab" for treatment of relapsed/refractory ATL and CTCLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSHH-JLAL3JbVg90H21EOLACvtfcHk0liNsf2U8AuBZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFejtb0%253D&md5=1361a07097b9ea62f8c04f78638f5460</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxu079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxu079%26sid%3Dliteratum%253Aachs%26aulast%3DYoshie%26aufirst%3DO.%26aulast%3DMatsushima%26aufirst%3DK.%26atitle%3DCCR4%2520and%2520its%2520Ligands%253A%2520From%2520Bench%2520to%2520Bedside%26jtitle%3DInt.%2520Immunol.%26date%3D2015%26volume%3D27%26spage%3D11%26epage%3D20%26doi%3D10.1093%2Fintimm%2Fdxu079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiedemann, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knott, M. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haubner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesseler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kühnemuth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layritz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormanns, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anz, D.</span></span> <span> </span><span class="NLM_article-title">Cancer Cell-Derived IL-1α Induces CCL22 and the Recruitment of Regulatory T Cells</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1175794</span> <span class="refDoi"> DOI: 10.1080/2162402X.2016.1175794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1080%2F2162402X.2016.1175794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=27757295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSgur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=G.+M.+Wiedemannauthor=M.+M.+L.+Knottauthor=V.+K.+Vetterauthor=M.+Rappauthor=S.+Haubnerauthor=J.+Fesselerauthor=B.+K%C3%BChnemuthauthor=P.+Layritzauthor=R.+Thalerauthor=S.+Krugerauthor=S.+Ormannsauthor=D.+Mayrauthor=S.+Endresauthor=D.+Anz&title=Cancer+Cell-Derived+IL-1%CE%B1+Induces+CCL22+and+the+Recruitment+of+Regulatory+T+Cells&doi=10.1080%2F2162402X.2016.1175794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells</span></div><div class="casAuthors">Wiedemann, Gabriela Maria; Knott, Max Martin Ludwig; Vetter, Viola Katharina; Rapp, Moritz; Haubner, Sascha; Fesseler, Julia; Kuehnemuth, Benjamin; Layritz, Patrick; Thaler, Raffael; Kruger, Stephan; Ormanns, Steffen; Mayr, Doris; Endres, Stefan; Anz, David</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e1175794/1-e1175794/11</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">In cancer patients, immunosuppression through regulatory T cells (Treg) is a crucial component of tumor immune evasion and contributes to disease progression.  Tumor-infiltrating Treg in particular suppress local effector T cell responses and are assocd. with poor prognosis in tumors such as human pancreatic cancer or hepatocellular carcinoma (HCC).  The chemokine CCL22 is known to recruit Treg into the tumor tissue and many types of human tumors are known to express high levels of CCL22.  The mechanisms leading to intratumoral secretion of CCL22 are so far unknown.  We demonstrate here that intratumoral CCL22 is induced in tumor-infiltrating immune cells through cancer cell-derived interleukin-1 (IL-1α).  In pancreatic cancer and HCC, CCL22 is produced by intratumoral dendritic cells, while the cancer cells themselves do not secrete CCL22 in vitro and in vivo.  Incubation of human peripheral blood mononuclear cells (PBMC) or murine splenocytes with tumor cells or tumor cell supernatants strongly induced CCL22 secretion in vitro.  Tumor cell supernatants contained IL-1 and CCL22 induction in PBMC could be specifically prevented by the IL-1 receptor antagonist anakinra or by transfection of tumor cell lines with IL-1 siRNA, leading to a suppression of Treg migration.  In conclusion, we identify here tumor cell-derived IL-1α as a major inducer of the Treg attracting chemokine CCL22 in human cancer cells.  Therapeutic blockade of the IL-1 pathway could represent a promising strategy to inhibit tumor-induced immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpslhagMdrESbVg90H21EOLACvtfcHk0liNsf2U8AuBZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSgur7E&md5=75aaa060cfc445e8af5afe9d60018a88</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1175794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1175794%26sid%3Dliteratum%253Aachs%26aulast%3DWiedemann%26aufirst%3DG.%2BM.%26aulast%3DKnott%26aufirst%3DM.%2BM.%2BL.%26aulast%3DVetter%26aufirst%3DV.%2BK.%26aulast%3DRapp%26aufirst%3DM.%26aulast%3DHaubner%26aufirst%3DS.%26aulast%3DFesseler%26aufirst%3DJ.%26aulast%3DK%25C3%25BChnemuth%26aufirst%3DB.%26aulast%3DLayritz%26aufirst%3DP.%26aulast%3DThaler%26aufirst%3DR.%26aulast%3DKruger%26aufirst%3DS.%26aulast%3DOrmanns%26aufirst%3DS.%26aulast%3DMayr%26aufirst%3DD.%26aulast%3DEndres%26aufirst%3DS.%26aulast%3DAnz%26aufirst%3DD.%26atitle%3DCancer%2520Cell-Derived%2520IL-1%25CE%25B1%2520Induces%2520CCL22%2520and%2520the%2520Recruitment%2520of%2520Regulatory%2520T%2520Cells%26jtitle%3DOncoImmunology%26date%3D2016%26volume%3D5%26doi%3D10.1080%2F2162402X.2016.1175794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiba, S.</span></span> <span> </span><span class="NLM_article-title">Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.3389%2Ffonc.2018.00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=29410946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A280%3ADC%252BC1Mvotl2jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=3&author=T.+Fujimuraauthor=Y.+Kambayashiauthor=Y.+Fujisawaauthor=T.+Hidakaauthor=S.+Aiba&title=Tumor-Associated+Macrophages%3A+Therapeutic+Targets+for+Skin+Cancer&doi=10.3389%2Ffonc.2018.00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer</span></div><div class="casAuthors">Fujimura Taku; Kambayashi Yumi; Hidaka Takanori; Aiba Setsuya; Fujisawa Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) are significant components of the microenvironment of solid tumors in the majority of cancers.  TAMs sequentially develop from monocytes into functional macrophages.  In each differentiation stage, TAMs obtain various immunosuppressive functions to maintain the tumor microenvironment (e.g., expression of immune checkpoint molecules, production of Treg-related chemokines and cytokines, production of arginase I).  Although the main population of TAMs is immunosuppressive M2 macrophages, TAMs can be modulated into M1-type macrophages in each differential stage, leading to the suppression of tumor growth.  Because the administration of certain drugs or stromal factors can stimulate TAMs to produce specific chemokines, leading to the recruitment of various tumor-infiltrating lymphocytes, TAMs can serve as targets for cancer immunotherapy.  In this review, we discuss the differentiation, activation, and immunosuppressive function of TAMs, as well as their benefits in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd4fdOtIBLJdbHMBt0mMIXfW6udTcc2ebAwLeTMfjvpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mvotl2jsQ%253D%253D&md5=9ef4239912db99e8c706e1cbc2c11cef</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00003%26sid%3Dliteratum%253Aachs%26aulast%3DFujimura%26aufirst%3DT.%26aulast%3DKambayashi%26aufirst%3DY.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DHidaka%26aufirst%3DT.%26aulast%3DAiba%26aufirst%3DS.%26atitle%3DTumor-Associated%2520Macrophages%253A%2520Therapeutic%2520Targets%2520for%2520Skin%2520Cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26spage%3D3%26doi%3D10.3389%2Ffonc.2018.00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span> <span> </span><span class="NLM_article-title">Molecular Cloning and Characterization of Chemokine-Like Factor 1 (CKLF1), a Novel Human Cytokine with Unique Structure and Potential Chemotactic Activity</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">127</span>, <span class="refDoi"> DOI: 10.1042/0264-6021:3570127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1042%2Fbj3570127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=11415443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Ojtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2001&pages=127&author=W.+Hanauthor=Y.+Louauthor=J.+Tangauthor=Y.+Zhangauthor=Y.+Chenauthor=Y.+Liauthor=W.+Guauthor=J.+Huangauthor=L.+Guiauthor=Y.+Tangauthor=F.+Liauthor=Q.+Songauthor=C.+Diauthor=L.+Wangauthor=Q.+Shiauthor=R.+Sunauthor=D.+Xiaauthor=M.+Ruiauthor=J.+Tangauthor=D.+Ma&title=Molecular+Cloning+and+Characterization+of+Chemokine-Like+Factor+1+%28CKLF1%29%2C+a+Novel+Human+Cytokine+with+Unique+Structure+and+Potential+Chemotactic+Activity&doi=10.1042%2F0264-6021%3A3570127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity</span></div><div class="casAuthors">Han, Wenling; Lou, Yaxin; Tang, Junmin; Zhang, Yingmei; Chen, Yingyu; Li, Ying; Gu, Weifeng; Huang, Jiaqiang; Gui, Liming; Tang, Yan; Li, Feng; Song, Quansheng; Di, Chunhui; Wang, Lu; Shi, Qun; Sun, Ronghua; Xia, Donglan; Rui, Min; Tang, Jian; Ma, Dalong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Cytokines are small proteins that have an essential role in the immune and inflammatory responses.  The repertoire of cytokines is becoming diverse and expanding.  Here the authors report the identification and characterization of a novel cytokine designated as chemokine-like factor 1 (CKLF1).  The full-length cDNA of CKLF1 is 530 bp long and a single open reading frame encoding 99 amino acid residues.  CKLF1 bears no significant similarity to any other known cytokine in its amino acid sequence.  Expression of CKLF1 can be partly inhibited by interleukin 10 in PHA-stimulated U937 cells.  Recombinant CKLF1 is a potent chemoattractant for neutrophils, monocytes and lymphocytes; moreover, it can stimulate the proliferation of murine skeletal muscle cells.  These results suggest that CKLF1 might have important roles in inflammation and in the regeneration of skeletal muscle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKBchdzE5wabVg90H21EOLACvtfcHk0lhZXdVvsW8P1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Ojtbk%253D&md5=574d3966f7b27285d697d0c6953f2f60</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1042%2Fbj3570127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3570127%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DGui%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DDi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DD.%26aulast%3DRui%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DD.%26atitle%3DMolecular%2520Cloning%2520and%2520Characterization%2520of%2520Chemokine-Like%2520Factor%25201%2520%2528CKLF1%2529%252C%2520a%2520Novel%2520Human%2520Cytokine%2520with%2520Unique%2520Structure%2520and%2520Potential%2520Chemotactic%2520Activity%26jtitle%3DBiochem.%2520J.%26date%3D2001%26volume%3D357%26spage%3D127%26doi%3D10.1042%2F0264-6021%3A3570127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span> <span> </span><span class="NLM_article-title">Chemokine-Like Factor 1 is a Functional Ligand for CC Chemokine Receptor 4 (CCR4)</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">614</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2005.05.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.lfs.2005.05.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=16137713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlWqu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2006&pages=614-621&author=Y.+Wangauthor=Y.+Zhangauthor=X.+Yangauthor=W.+Hanauthor=Y.+Liuauthor=Q.+Xuauthor=R.+Zhaoauthor=C.+Diauthor=Q.+Songauthor=D.+Ma&title=Chemokine-Like+Factor+1+is+a+Functional+Ligand+for+CC+Chemokine+Receptor+4+%28CCR4%29&doi=10.1016%2Fj.lfs.2005.05.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4)</span></div><div class="casAuthors">Wang, Ying; Zhang, Yingmei; Yang, Xue; Han, Wenling; Liu, Yanan; Xu, Qianmei; Zhao, Rui; Di, Chunhui; Song, Quansheng; Ma, Dalong</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">614-621</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chemokine-like factor 1 (CKLF1) exhibits chemotactic effects on leukocytes.  Its amino acid sequence shares similarity with those of TARC/CCL17 and MDC/CCL22, the cognate ligands for CCR4.  The chemotactic effects of CKLF1 for CCR4-transfected cells could be desensitized by TARC/CCL17 and markedly inhibited by PTX.  CKLF1 induced a calcium flux in CCR4-transfected cells and fully desensitized a subsequent response to TARC/CCL17, and TARC/CCL17 could partly desensitize the response to CKLF1.  CKLF1 caused significant receptor internalization in pCCR4-EGFP transfected cells.  Taken together, CKLF1 is a novel functional ligand for CCR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAqlHhhw3zS7Vg90H21EOLACvtfcHk0lhZXdVvsW8P1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlWqu7bJ&md5=f33cc1856d52df0d6e8985ff413035f5</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2005.05.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2005.05.070%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DDi%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DD.%26atitle%3DChemokine-Like%2520Factor%25201%2520is%2520a%2520Functional%2520Ligand%2520for%2520CC%2520Chemokine%2520Receptor%25204%2520%2528CCR4%2529%26jtitle%3DLife%2520Sci.%26date%3D2006%26volume%3D78%26spage%3D614%26epage%3D621%26doi%3D10.1016%2Fj.lfs.2005.05.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinenaite, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munir Ahmad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Met, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westergaard, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klausen, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svane, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. H.</span></span> <span> </span><span class="NLM_article-title">CCL22-specific T Cells: Modulating the Immunosuppressive Tumor Microenvironment</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1238541</span> <span class="refDoi"> DOI: 10.1080/2162402X.2016.1238541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1080%2F2162402X.2016.1238541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=27999757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2msb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&author=E.+Martinenaiteauthor=S.+Munir+Ahmadauthor=M.+Hansenauthor=%C3%96.+Metauthor=M.+W.+Westergaardauthor=S.+K.+Larsenauthor=T.+W.+Klausenauthor=M.+Doniaauthor=I.+M.+Svaneauthor=M.+H.+Andersen&title=CCL22-specific+T+Cells%3A+Modulating+the+Immunosuppressive+Tumor+Microenvironment&doi=10.1080%2F2162402X.2016.1238541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment</span></div><div class="casAuthors">Martinenaite, Evelina; Munir Ahmad, Shamaila; Hansen, Morten; Met, Ozcan; Westergaard, Marie Wulff; Larsen, Stine Kiaer; Klausen, Tobias Wirenfeldt; Donia, Marco; Svane, Inge Marie; Andersen, Mads Hald</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e1238541/1-e1238541/10</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Tumor cells and tumor-infiltrating macrophages produce the chemokine CCL22, which attracts regulatory T cells (Tregs) into the tumor microenvironment, decreasing anticancer immunity.  Here, we investigated the possibility of targeting CCL22-expressing cells by activating specific T cells.  We analyzed the CCL22 protein signal sequence, identifying a human leukocyte antigen A2- (HLA-A2-) restricted peptide epitope, which we then used to stimulate peripheral blood mononuclear cells (PMBCs) to expand populations of CCL22-specific T cells in vitro.  T cells recognizing an epitope derived from the signal-peptide of CCL22 will recognize CCL22-expressing cells even though CCL22 is secreted out of the cell.  CCL22-specific T cells recognized and killed CCL22-expressing cancer cells.  Furthermore, CCL22-specific T cells lysed acute monocytic leukemia cells in a CCL22 expression-dependent manner.  Using the Enzyme-Linked ImmunoSPOT assay, we examd. peripheral blood mononuclear cells from HLA-A2+ cancer patients and healthy volunteers for reactivity against the CCL22-derived T-cell epitope.  This revealed spontaneous T-cell responses against the CCL22-derived epitope in cancer patients and in healthy donors.  Finally, we performed tetramer enrichment/depletion expts. to examine the impact of HLA-A2-restricted CCL22-specific T cells on CCL22 levels among PMBCs.  The addn. or activation of CCL22-specific T cells decreased the CCL22 level in the microenvironment.  Activating CCL22-specific T cells (e.g., by vaccination) may directly target cancer cells and tumor-assocd. macrophages, thereby modulating Treg recruitment into the tumor environment and augmenting anticancer immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9WDcRz5OxnbVg90H21EOLACvtfcHk0li7N4wi_JPvMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2msb7P&md5=543da99773be1ac52e9b600fee286639</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1238541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1238541%26sid%3Dliteratum%253Aachs%26aulast%3DMartinenaite%26aufirst%3DE.%26aulast%3DMunir%2BAhmad%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DM.%26aulast%3DMet%26aufirst%3D%25C3%2596.%26aulast%3DWestergaard%26aufirst%3DM.%2BW.%26aulast%3DLarsen%26aufirst%3DS.%2BK.%26aulast%3DKlausen%26aufirst%3DT.%2BW.%26aulast%3DDonia%26aufirst%3DM.%26aulast%3DSvane%26aufirst%3DI.%2BM.%26aulast%3DAndersen%26aufirst%3DM.%2BH.%26atitle%3DCCL22-specific%2520T%2520Cells%253A%2520Modulating%2520the%2520Immunosuppressive%2520Tumor%2520Microenvironment%26jtitle%3DOncoImmunology%26date%3D2016%26volume%3D5%26doi%3D10.1080%2F2162402X.2016.1238541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komabayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishibe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkuri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harabuchi, Y.</span></span> <span> </span><span class="NLM_article-title">CCL17 and CCL22/CCR4 Signaling is a Strong Candidate for Novel Targeted Therapy Against Nasal Natural Killer/T-Cell Lymphoma</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1007/s00262-015-1675-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1007%2Fs00262-015-1675-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25754123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkt1Omsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=697-705&author=T.+Kumaiauthor=T.+Nagatoauthor=H.+Kobayashiauthor=Y.+Komabayashiauthor=S.+Uedaauthor=K.+Kishibeauthor=T.+Ohkuriauthor=M.+Takaharaauthor=E.+Celisauthor=Y.+Harabuchi&title=CCL17+and+CCL22%2FCCR4+Signaling+is+a+Strong+Candidate+for+Novel+Targeted+Therapy+Against+Nasal+Natural+Killer%2FT-Cell+Lymphoma&doi=10.1007%2Fs00262-015-1675-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma</span></div><div class="casAuthors">Kumai, Takumi; Nagato, Toshihiro; Kobayashi, Hiroya; Komabayashi, Yuki; Ueda, Seigo; Kishibe, Kan; Ohkuri, Takayuki; Takahara, Miki; Celis, Esteban; Harabuchi, Yasuaki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">697-705</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Nasal natural killer/T-cell lymphoma (NNKTL) is assocd. with Epstein-Barr virus and has a poor prognosis because of local invasion and/or multiple dissemination.  Various chemokines play a role in tumor proliferation and invasion, and chemokine receptors including the C-C chemokine receptor 4 (CCR4) are recognized as potential targets for treating hematol. malignancies.  The aim of the present study was to det. whether specific chemokines are produced by NNKTL.  We compared chemokine expression patterns in culture supernatants of NNKTL cell lines with those of other lymphoma or leukemia cell lines using chemokine protein array and ELISA.  Chemokine (C-C motif) ligand (CCL) 17 and CCL22 were highly produced by NNKTL cell lines as compared to the other cell lines.  In addn., CCL17 and CCL22 were readily obsd. in the sera of NNKTL patients.  The levels of these chemokines were significantly higher in patients than in healthy controls.  Furthermore, we detected the expression of CCR4 (the receptor for CCL17 and CCL22) on the surface of NNKTL cell lines and in tissues of NNKTL patients.  Anti-CCR4 monoclonal antibody (mAb) efficiently induced antibody-dependent cellular cytotoxicity mediated by natural killer cells against NNKTL cell lines.  Our results suggest that CCL17 and CCL22 may be important factors in the development of NNKTL and open up the possibility of immunotherapy of this lymphoma using anti-CCR4 mAb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg0g-aCyoytLVg90H21EOLACvtfcHk0li7N4wi_JPvMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkt1Omsrk%253D&md5=8d437143dd821e1f2785236b556c1bdd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs00262-015-1675-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-015-1675-7%26sid%3Dliteratum%253Aachs%26aulast%3DKumai%26aufirst%3DT.%26aulast%3DNagato%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DKomabayashi%26aufirst%3DY.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DKishibe%26aufirst%3DK.%26aulast%3DOhkuri%26aufirst%3DT.%26aulast%3DTakahara%26aufirst%3DM.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DHarabuchi%26aufirst%3DY.%26atitle%3DCCL17%2520and%2520CCL22%252FCCR4%2520Signaling%2520is%2520a%2520Strong%2520Candidate%2520for%2520Novel%2520Targeted%2520Therapy%2520Against%2520Nasal%2520Natural%2520Killer%252FT-Cell%2520Lymphoma%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2015%26volume%3D64%26spage%3D697%26epage%3D705%26doi%3D10.1007%2Fs00262-015-1675-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wreggett, K. A.</span></span> <span> </span><span class="NLM_article-title">An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G Protein-Coupled Receptors CCR4 and CCR5</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">855</span>, <span class="refDoi"> DOI: 10.1124/mol.107.039321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1124%2Fmol.107.039321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=18042736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1egsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=855&author=G.+Andrewsauthor=C.+Jonesauthor=K.+A.+Wreggett&title=An+Intracellular+Allosteric+Site+for+a+Specific+Class+of+Antagonists+of+the+CC+Chemokine+G+Protein-Coupled+Receptors+CCR4+and+CCR5&doi=10.1124%2Fmol.107.039321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5</span></div><div class="casAuthors">Andrews, Glen; Jones, Carolyn; Wreggett, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A novel mechanism for antagonism of the human chemokine receptors CCR4 and CCR5 has been discovered with a series of small-mol. compds. that seems to interact with an allosteric, intracellular site on the receptor.  The existence of this site is supported by a series of observations: (1) intracellular access of these antagonists is required for their activity; (2) specific, saturable binding of a radiolabeled antagonist requires the presence of CCR4; and (3) through engineering receptor chimeras by reciprocal transfer of C-terminal domains between CCR4 and CCR5, compd. binding and the selective structure-activity relationships for antagonism of these receptors seem to be assocd. with the integrity of that intracellular region.  Published antagonists from other chem. series do not seem to bind to the novel site, and their interaction with either CCR4 or CCR5 is not affected by alteration of the C-terminal domain.  The precise location of the proposed binding site remains to be detd., but the known close assocn. of the C-terminal domain, including helix 8, as a proposed intracellular region that interacts with transduction proteins (e.g., G proteins and β-arrestin) suggests that this could be a generic allosteric site for chemokine receptors and perhaps more broadly for class A G protein-coupled receptors.  The existence of such a site that can be targeted for drug discovery has implications for screening assays for receptor antagonists, which would need, therefore, to consider compd. properties for access to this intracellular site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAPVG6Nu0Wf7Vg90H21EOLACvtfcHk0li7N4wi_JPvMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1egsLw%253D&md5=f3624c421bac61365f63ea1389dffea0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.039321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.039321%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DWreggett%26aufirst%3DK.%2BA.%26atitle%3DAn%2520Intracellular%2520Allosteric%2520Site%2520for%2520a%2520Specific%2520Class%2520of%2520Antagonists%2520of%2520the%2520CC%2520Chemokine%2520G%2520Protein-Coupled%2520Receptors%2520CCR4%2520and%2520CCR5%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D855%26doi%3D10.1124%2Fmol.107.039321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalesso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span> <span> </span><span class="NLM_article-title">Antagonism of Human CC-Chemokine Receptor 4 Can Be Achieved Through Three Distinct Binding Sites on the Receptor</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e00019</span> <span class="refDoi"> DOI: 10.1002/prp2.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1002%2Fprp2.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25505571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yntr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&author=R.+J.+Slackauthor=L.+J.+Russellauthor=N.+P.+Bartonauthor=C.+Westonauthor=G.+Nalessoauthor=S.-A.+Thompsonauthor=M.+Allenauthor=Y.+H.+Chenauthor=A.+Barnesauthor=S.+T.+Hodgsonauthor=D.+A.+Hall&title=Antagonism+of+Human+CC-Chemokine+Receptor+4+Can+Be+Achieved+Through+Three+Distinct+Binding+Sites+on+the+Receptor&doi=10.1002%2Fprp2.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor</span></div><div class="casAuthors">Slack, Robert J.; Russell, Linda J.; Barton, Nick P.; Weston, Cathryn; Nalesso, Giovanna; Thompson, Sally-Anne; Allen, Morven; Chen, Yu Hua; Barnes, Ashley; Hodgson, Simon T.; Hall, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology Research & Perspectives</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e00019/1-e00019/25</span>CODEN:
                <span class="NLM_cas:coden">PRPHCA</span>;
        ISSN:<span class="NLM_cas:issn">2052-1707</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Chemokine receptor antagonists appear to access two distinct binding sites on different members of this receptor family.  One class of CCR4 antagonists has been suggested to bind to a site accessible from the cytoplasm while a second class did not bind to this site.  In this report, we demonstrate that antagonists representing a variety of structural classes bind to two distinct allosteric sites on CCR4.  The effects of pairs of low-mol. wt. and/or chemokine CCR4 antagonists were evaluated on CCL17- and CCL22-induced responses of human CCR4+ T cells.  This provided an initial grouping of the antagonists into sets which appeared to bind to distinct binding sites.  Binding studies were then performed with radioligands from each set to confirm these groupings.  Some novel receptor theory was developed to allow the interpretation of the effects of the antagonist combinations.  The theory indicates that, generally, the concn.-ratio of a pair of competing allosteric modulators is maximally the sum of their individual effects while that of two modulators acting at different sites is likely to be greater than their sum.  The low-mol. wt. antagonists could be grouped into two sets on the basis of the functional and binding expts.  The antagonistic chemokines formed a third set whose behavior was consistent with that of simple competitive antagonists.  These studies indicate that there are two allosteric regulatory sites on CCR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj9cDmC7ops7Vg90H21EOLACvtfcHk0lhgssssWhNQrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yntr3O&md5=d3c75616ffba6b6644c8755fcff21e5c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fprp2.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.19%26sid%3Dliteratum%253Aachs%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DRussell%26aufirst%3DL.%2BJ.%26aulast%3DBarton%26aufirst%3DN.%2BP.%26aulast%3DWeston%26aufirst%3DC.%26aulast%3DNalesso%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DS.-A.%26aulast%3DAllen%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DBarnes%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DHall%26aufirst%3DD.%2BA.%26atitle%3DAntagonism%2520of%2520Human%2520CC-Chemokine%2520Receptor%25204%2520Can%2520Be%2520Achieved%2520Through%2520Three%2520Distinct%2520Binding%2520Sites%2520on%2520the%2520Receptor%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2013%26volume%3D1%26doi%3D10.1002%2Fprp2.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ajram, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cryan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swieboda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousnier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Internalization of the Chemokine Receptor CCR4 Can Be Evoked by Orthosteric and Allosteric Receptor Antagonists</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>729</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.ejphar.2014.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=24534492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlt1CrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=729&publication_year=2014&pages=75-85&author=L.+Ajramauthor=M.+Beggauthor=R.+Slackauthor=J.+Cryanauthor=D.+Hallauthor=S.+Hodgsonauthor=A.+Fordauthor=A.+Barnesauthor=D.+Swiebodaauthor=A.+Mousnierauthor=R.+Solari&title=Internalization+of+the+Chemokine+Receptor+CCR4+Can+Be+Evoked+by+Orthosteric+and+Allosteric+Receptor+Antagonists&doi=10.1016%2Fj.ejphar.2014.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists</span></div><div class="casAuthors">Ajram, Laura; Begg, Malcolm; Slack, Robert; Cryan, Jenni; Hall, David; Hodgson, Simon; Ford, Alison; Barnes, Ashley; Swieboda, Dawid; Mousnier, Aurelie; Solari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">729</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The chemokine receptor CCR4 has at least two natural agonist ligands, MDC (CCL22) and TARC (CCL17) which bind to the same orthosteric site with a similar affinity.  Both ligands are known to evoke chemotaxis of CCR4-bearing T cells and also elicit CCR4 receptor internalization.  A series of small mol. allosteric antagonists have been described which displace the agonist ligand, and inhibit chemotaxis.  The aim of this study was to det. which cellular coupling pathways are involved in internalization, and if antagonists binding to the CCR4 receptor could themselves evoke receptor internalization.  CCL22 binding coupled CCR4 efficiently to β-arrestin and stimulated GTPγS binding however CCL17 did not couple to β-arrestin and only partially stimulated GTPγS binding.  CCL22 potently induced internalization of almost all cell surface CCR4, while CCL17 showed only weak effects.  We describe four small mol. antagonists that were demonstrated to bind to two distinct allosteric sites on the CCR4 receptor, and while both classes inhibited agonist ligand binding and chemotaxis, one of the allosteric sites also evoked receptor internalization.  Furthermore, we also characterize an N-terminally truncated version of CCL22 which acts as a competitive antagonist at the orthosteric site, and surprisingly also evokes receptor internalization without demonstrating any agonist activity.  Collectively this study demonstrates that orthosteric and allosteric antagonists of the CCR4 receptor are capable of evoking receptor internalization, providing a novel strategy for drug discovery against this class of target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3cp_MmkWDlrVg90H21EOLACvtfcHk0lhgssssWhNQrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlt1CrsrY%253D&md5=2d48b60057b1a037979e02f0a4fe95b4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DAjram%26aufirst%3DL.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DSlack%26aufirst%3DR.%26aulast%3DCryan%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DFord%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DA.%26aulast%3DSwieboda%26aufirst%3DD.%26aulast%3DMousnier%26aufirst%3DA.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DInternalization%2520of%2520the%2520Chemokine%2520Receptor%2520CCR4%2520Can%2520Be%2520Evoked%2520by%2520Orthosteric%2520and%2520Allosteric%2520Receptor%2520Antagonists%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D729%26spage%3D75%26epage%3D85%26doi%3D10.1016%2Fj.ejphar.2014.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerville, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccaro, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span> <span> </span><span class="NLM_article-title">Core Exploration in Optimization of Chemokine Receptor CCR4 Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.10.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.bmcl.2006.10.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=17098428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFaguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=679-682&author=A.+V.+Purandareauthor=H.+Wanauthor=J.+E.+Somervilleauthor=C.+Burkeauthor=W.+Vaccaroauthor=X.+Yangauthor=K.+W.+McIntyreauthor=M.+A.+Poss&title=Core+Exploration+in+Optimization+of+Chemokine+Receptor+CCR4+Antagonists&doi=10.1016%2Fj.bmcl.2006.10.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Core exploration in optimization of chemokine receptor CCR4 antagonists</span></div><div class="casAuthors">Purandare, Ashok V.; Wan, Honghe; Somerville, John E.; Burke, Christine; Vaccaro, Wayne; Yang, XiaoXia; McIntyre, Kim W.; Poss, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">679-682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design, synthesis, and SAR studies of 'core' variations led to identification of novel, selective, and potent small mol. antagonist (I) of the CC chemokine receptor-4 (CCR4) with improved in vitro activity and liability profile.  Compd. I was efficacious in a murine allergic inflammation model (ED50 ∼ 10 mg/kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCc-Oj8IV7u7Vg90H21EOLACvtfcHk0lhgssssWhNQrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFaguw%253D%253D&md5=604537d7fd88fe913ef078ab1602ea02</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.10.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.10.091%26sid%3Dliteratum%253Aachs%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSomerville%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DC.%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26atitle%3DCore%2520Exploration%2520in%2520Optimization%2520of%2520Chemokine%2520Receptor%2520CCR4%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D679%26epage%3D682%26doi%3D10.1016%2Fj.bmcl.2006.10.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent CCR4 antagonists: Synthesis and Structure–Activity Relationship Study of 2,4-Diaminoquinazolines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">7021</span>– <span class="NLM_lpage">7032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.05.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.bmc.2008.05.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=18539035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVKqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=7021-7032&author=K.+Yokoyamaauthor=N.+Ishikawaauthor=S.+Igarashiauthor=N.+Kawanoauthor=K.+Hattoriauthor=T.+Miyazakiauthor=S.-I.+Oginoauthor=Y.+Matsumotoauthor=M.+Takeuchiauthor=M.+Ohta&title=Discovery+of+potent+CCR4+antagonists%3A+Synthesis+and+Structure%E2%80%93Activity+Relationship+Study+of+2%2C4-Diaminoquinazolines&doi=10.1016%2Fj.bmc.2008.05.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines</span></div><div class="casAuthors">Yokoyama, Kazuhiro; Ishikawa, Noriko; Igarashi, Susumu; Kawano, Noriyuki; Hattori, Kazuyuki; Miyazaki, Takahiro; Ogino, Shin-ichi; Matsumoto, Yuzo; Takeuchi, Makoto; Ohta, Mitsuaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7021-7032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of the corporate compd. libraries.  Subsequent compd. optimization elucidated the structure-activity relationships and led the identification of 2-(1,4'-bipiperidine-1'-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4-amine (I), which showed potent inhibition in the [35S]GTPγS-binding assay (IC50 = 18 nM).  This compd. also inhibited the chemotaxis of human and mouse CCR4-expressing cells (IC50 = 140 nM, 39 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrdUZMdi8qc7Vg90H21EOLACvtfcHk0liHDCHA1DuegA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVKqt7w%253D&md5=bf4e5fb2b015a4635a824f9d311a07b3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.05.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.05.036%26sid%3Dliteratum%253Aachs%26aulast%3DYokoyama%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DN.%26aulast%3DIgarashi%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DOgino%26aufirst%3DS.-I.%26aulast%3DMatsumoto%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DOhta%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520potent%2520CCR4%2520antagonists%253A%2520Synthesis%2520and%2520Structure%25E2%2580%2593Activity%2520Relationship%2520Study%2520of%25202%252C4-Diaminoquinazolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D7021%26epage%3D7032%26doi%3D10.1016%2Fj.bmc.2008.05.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuribayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span> <span> </span><span class="NLM_article-title">RS-1748, a Novel CC Chemokine Receptor 4 Antagonist, Inhibits Ovalbumin-Induced Airway Inflammation in Guinea Pigs</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1067</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1248/bpb.33.1067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1248%2Fbpb.33.1067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=20522980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslynsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=1067-1069&author=Y.+Nakagamiauthor=Y.+Kawaseauthor=K.+Yonekuboauthor=E.+Nosakaauthor=M.+Etoriauthor=S.+Takahashiauthor=N.+Takagiauthor=T.+Fukudaauthor=T.+Kuribayashiauthor=F.+Naraauthor=M.+Yamashita&title=RS-1748%2C+a+Novel+CC+Chemokine+Receptor+4+Antagonist%2C+Inhibits+Ovalbumin-Induced+Airway+Inflammation+in+Guinea+Pigs&doi=10.1248%2Fbpb.33.1067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs</span></div><div class="casAuthors">Nakagami, Yasuhiro; Kawase, Yumi; Yonekubo, Kazuki; Nosaka, Emi; Etori, Maki; Takahashi, Sakiko; Takagi, Nana; Fukuda, Takeshi; Kuribayashi, Takeshi; Nara, Futoshi; Yamashita, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1067-1069</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">CC chemokine receptor 4 (CCR4) is generally recognized as a preferential marker for T helper 2 cells, and we have previously reported morpholine-deriv. CCR4 antagonists, RS-1154 and RS-1269.  Here, we investigate the pharmacol. profiles of a novel pyrimidine-deriv. CCR4 antagonist, 2-{4-[2-(diethylamino)-ethoxy]phenyl}-N-(2,4-difluorobenzyl)-5-fluoropyrimidin-4-amine (RS-1748), which showed potency to inhibit the bindings of [125I]CCL17 and [35S]GTPγS to human CCR4-expressing Chinese hamster ovary (CHO) cells with IC50 values of 59.9 nM and 18.4 nM, resp.  Furthermore, RS-1748 inhibited ovalbumin-induced airway inflammation in guinea pigs at a dose of 10 mg/kg.  These results indicate that RS-1748 would be a promising lead compd. for developing a therapeutic agent against asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKappxf9t5rVg90H21EOLACvtfcHk0liHDCHA1DuegA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslynsLY%253D&md5=f859158d9f471329d0235c58c02b844f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1248%2Fbpb.33.1067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.33.1067%26sid%3Dliteratum%253Aachs%26aulast%3DNakagami%26aufirst%3DY.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DYonekubo%26aufirst%3DK.%26aulast%3DNosaka%26aufirst%3DE.%26aulast%3DEtori%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DTakagi%26aufirst%3DN.%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DKuribayashi%26aufirst%3DT.%26aulast%3DNara%26aufirst%3DF.%26aulast%3DYamashita%26aufirst%3DM.%26atitle%3DRS-1748%252C%2520a%2520Novel%2520CC%2520Chemokine%2520Receptor%25204%2520Antagonist%252C%2520Inhibits%2520Ovalbumin-Induced%2520Airway%2520Inflammation%2520in%2520Guinea%2520Pigs%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2010%26volume%3D33%26spage%3D1067%26epage%3D1069%26doi%3D10.1248%2Fbpb.33.1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketcham, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biannic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M. H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diokno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbarz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassner, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pookot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robles, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shunatona, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talay, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustrow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zibinsky, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking Into the Tumor Microenvironment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6190</span>– <span class="NLM_lpage">6213</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00506</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00506" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2gsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6190-6213&author=J.+J.+Jacksonauthor=J.+M.+Ketchamauthor=A.+Younaiauthor=B.+Abrahamauthor=B.+Biannicauthor=H.+P.+Beckauthor=M.+H.+T.+Buiauthor=D.+Chianauthor=G.+Cutlerauthor=R.+Dioknoauthor=D.+X.+Huauthor=S.+Jacobsonauthor=E.+Karbarzauthor=P.+D.+Kassnerauthor=L.+Marshallauthor=J.+McKinnellauthor=C.+Melezaauthor=A.+Okalauthor=D.+Pookotauthor=M.+K.+Reillyauthor=O.+Roblesauthor=H.+P.+Shunatonaauthor=O.+Talayauthor=J.+R.+Walkerauthor=A.+Wadsworthauthor=D.+J.+Wustrowauthor=M.+Zibinsky&title=Discovery+of+a+Potent+and+Selective+CCR4+Antagonist+That+Inhibits+Treg+Trafficking+Into+the+Tumor+Microenvironment&doi=10.1021%2Facs.jmedchem.9b00506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment</span></div><div class="casAuthors">Jackson, Jeffrey J.; Ketcham, John M.; Younai, Ashkaan; Abraham, Betty; Biannic, Berenger; Beck, Hilary P.; Bui, Minna H. T.; Chian, David; Cutler, Gene; Diokno, Raymond; Hu, Dennis X.; Jacobson, Scott; Karbarz, Emily; Kassner, Paul D.; Marshall, Lisa; McKinnell, Jenny; Meleza, Cesar; Okal, Abood; Pookot, Deepa; Reilly, Maureen K.; Robles, Omar; Shunatona, Hunter P.; Talay, Oezcan; Walker, James R.; Wadsworth, Angela; Wustrow, David J.; Zibinsky, Mikhail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6190-6213</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recruitment of suppressive CD4+ FOXP3+ regulatory T cells (Treg) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncol. (IO) agents.  Human Treg express CCR4 and can be recruited to the TME through the CC chemokine ligands CCL17 and CCL22.  In some cancers, Treg accumulation correlates with poor patient prognosis.  Preclin. data suggests that preventing the recruitment of Treg and increasing the population of activated effector T cells (Teff) in the TME can potentiate antitumor immune responses.  We developed a novel series of potent, orally bioavailable small mol. antagonists of CCR4.  From this series, several compds. exhibited high potency in distinct functional assays in addn. to good in vitro and in vivo ADME properties.  The design, synthesis, and SAR of this series and confirmation of its in vivo activity are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgTBXSH2wYsrVg90H21EOLACvtfcHk0liHDCHA1DuegA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2gsbjI&md5=35c213a85a6252b7ed629ad694764a55</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00506%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DJ.%2BJ.%26aulast%3DKetcham%26aufirst%3DJ.%2BM.%26aulast%3DYounai%26aufirst%3DA.%26aulast%3DAbraham%26aufirst%3DB.%26aulast%3DBiannic%26aufirst%3DB.%26aulast%3DBeck%26aufirst%3DH.%2BP.%26aulast%3DBui%26aufirst%3DM.%2BH.%2BT.%26aulast%3DChian%26aufirst%3DD.%26aulast%3DCutler%26aufirst%3DG.%26aulast%3DDiokno%26aufirst%3DR.%26aulast%3DHu%26aufirst%3DD.%2BX.%26aulast%3DJacobson%26aufirst%3DS.%26aulast%3DKarbarz%26aufirst%3DE.%26aulast%3DKassner%26aufirst%3DP.%2BD.%26aulast%3DMarshall%26aufirst%3DL.%26aulast%3DMcKinnell%26aufirst%3DJ.%26aulast%3DMeleza%26aufirst%3DC.%26aulast%3DOkal%26aufirst%3DA.%26aulast%3DPookot%26aufirst%3DD.%26aulast%3DReilly%26aufirst%3DM.%2BK.%26aulast%3DRobles%26aufirst%3DO.%26aulast%3DShunatona%26aufirst%3DH.%2BP.%26aulast%3DTalay%26aufirst%3DO.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DWadsworth%26aufirst%3DA.%26aulast%3DWustrow%26aufirst%3DD.%2BJ.%26aulast%3DZibinsky%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520CCR4%2520Antagonist%2520That%2520Inhibits%2520Treg%2520Trafficking%2520Into%2520the%2520Tumor%2520Microenvironment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6190%26epage%3D6213%26doi%3D10.1021%2Facs.jmedchem.9b00506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Procopiou, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumeaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, Y. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miah, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morriss, K. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Needham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheriff, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sollis, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staton, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–Activity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1960</span>, <span class="refDoi"> DOI: 10.1021/jm301572h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301572h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisF2js7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1946-1960&author=P.+A.+Procopiouauthor=J.+W.+Barrettauthor=N.+P.+Bartonauthor=M.+Beggauthor=D.+Claphamauthor=R.+C.+B.+Copleyauthor=A.+J.+Fordauthor=R.+H.+Gravesauthor=D.+A.+Hallauthor=A.+P.+Hancockauthor=A.+P.+Hillauthor=H.+Hobbsauthor=S.+T.+Hodgsonauthor=C.+Jumeauxauthor=Y.+M.+L.+Lacroixauthor=A.+H.+Miahauthor=K.+M.+L.+Morrissauthor=D.+Needhamauthor=E.+B.+Sheriffauthor=R.+J.+Slackauthor=C.+E.+Smithauthor=S.+L.+Sollisauthor=H.+Staton&title=Synthesis+and+Structure%E2%80%93Activity+Relationships+of+Indazole+Arylsulfonamides+as+Allosteric+CC-Chemokine+Receptor+4+%28CCR4%29+Antagonists&doi=10.1021%2Fjm301572h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists</span></div><div class="casAuthors">Procopiou, Panayiotis A.; Barrett, John W.; Barton, Nicholas P.; Begg, Malcolm; Clapham, David; Copley, Royston C. B.; Ford, Alison J.; Graves, Rebecca H.; Hall, David A.; Hancock, Ashley P.; Hill, Alan P.; Hobbs, Heather; Hodgson, Simon T.; Jumeaux, Coline; Lacroix, Yannick M. L.; Miah, Afjal H.; Morriss, Karen M. L.; Needham, Deborah; Sheriff, Emma B.; Slack, Robert J.; Smith, Claire E.; Sollis, Steven L.; Staton, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1946-1960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of indazole arylsulfonamides were synthesized and examd. as human CCR4 antagonists.  Methoxy- or hydroxyl- contg. groups were the more potent indazole C4 substituents.  Only small groups were tolerated at C5, C6, or C7, with the C6 analogs being preferred.  The most potent N3-substituent was 5-chlorothiophene-2-sulfonamide.  N1 meta-substituted benzyl groups possessing an α-amino-3-[(methylamino)acyl]- group were the most potent N1-substituents.  Strongly basic amino groups had low oral absorption in vivo.  Less basic analogs, such as morpholines, had good oral absorption; however, they also had high clearance.  The most potent compd. with high absorption in two species was analog I (GSK2239633A), which was selected for further development.  Aryl sulfonamide antagonists bind to CCR4 at an intracellular allosteric site denoted site II.  X-ray diffraction studies on two indazole sulfonamide fragments suggested the presence of an important intramol. interaction in the active conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGy9j0UZnY77Vg90H21EOLACvtfcHk0lhwlezTp8rtyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisF2js7k%253D&md5=db6f996af7b0498c9c0196da94005bc2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm301572h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301572h%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DJ.%2BW.%26aulast%3DBarton%26aufirst%3DN.%2BP.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DClapham%26aufirst%3DD.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGraves%26aufirst%3DR.%2BH.%26aulast%3DHall%26aufirst%3DD.%2BA.%26aulast%3DHancock%26aufirst%3DA.%2BP.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DHobbs%26aufirst%3DH.%26aulast%3DHodgson%26aufirst%3DS.%2BT.%26aulast%3DJumeaux%26aufirst%3DC.%26aulast%3DLacroix%26aufirst%3DY.%2BM.%2BL.%26aulast%3DMiah%26aufirst%3DA.%2BH.%26aulast%3DMorriss%26aufirst%3DK.%2BM.%2BL.%26aulast%3DNeedham%26aufirst%3DD.%26aulast%3DSheriff%26aufirst%3DE.%2BB.%26aulast%3DSlack%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26aulast%3DSollis%26aufirst%3DS.%2BL.%26aulast%3DStaton%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%2520Indazole%2520Arylsulfonamides%2520as%2520Allosteric%2520CC-Chemokine%2520Receptor%25204%2520%2528CCR4%2529%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1946%26epage%3D1960%26doi%3D10.1021%2Fjm301572h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuberson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teobald, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, M. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">986</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=981-986&author=N.+Kindonauthor=G.+Andrewsauthor=A.+Baxterauthor=D.+Cheshireauthor=P.+Hemsleyauthor=T.+Johnsonauthor=Y.-Z.+Liuauthor=D.+McGinnityauthor=M.+McHaleauthor=A.+Meteauthor=J.+Reubersonauthor=B.+Robertsauthor=J.+Steeleauthor=B.+Teobaldauthor=J.+Unittauthor=D.+Vaughanauthor=I.+Waltersauthor=M.+J.+Stocks&title=Discovery+of+AZD-2098+and+AZD-1678%2C+Two+Potent+and+Bioavailable+CCR4+Receptor+Antagonists&doi=10.1021%2Facsmedchemlett.7b00315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists</span></div><div class="casAuthors">Kindon, Nicholas; Andrews, Glen; Baxter, Andrew; Cheshire, David; Hemsley, Paul; Johnson, Timothy; Liu, Yu-Zhen; McGinnity, Dermot; McHale, Mark; Mete, Antonio; Reuberson, James; Roberts, Bryan; Steele, John; Teobald, Barry; Unitt, John; Vaughan, Deborah; Walters, Iain; Stocks, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">981-986</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 was identified as a hit in a CCR4 receptor antagonist high-throughput screen (HTS) of a subset of the AstraZeneca compd. bank.  As a hit with a lead-like profile, it was an excellent starting point for a CCR4 receptor antagonist program and enabled the rapid progression through the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR4 receptor antagonist candidate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolEsVkipAX2LVg90H21EOLACvtfcHk0lhwlezTp8rtyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7vI&md5=8ede7ef766e88de9191b0df8ec7938a4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00315%26sid%3Dliteratum%253Aachs%26aulast%3DKindon%26aufirst%3DN.%26aulast%3DAndrews%26aufirst%3DG.%26aulast%3DBaxter%26aufirst%3DA.%26aulast%3DCheshire%26aufirst%3DD.%26aulast%3DHemsley%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.-Z.%26aulast%3DMcGinnity%26aufirst%3DD.%26aulast%3DMcHale%26aufirst%3DM.%26aulast%3DMete%26aufirst%3DA.%26aulast%3DReuberson%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSteele%26aufirst%3DJ.%26aulast%3DTeobald%26aufirst%3DB.%26aulast%3DUnitt%26aufirst%3DJ.%26aulast%3DVaughan%26aufirst%3DD.%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26atitle%3DDiscovery%2520of%2520AZD-2098%2520and%2520AZD-1678%252C%2520Two%2520Potent%2520and%2520Bioavailable%2520CCR4%2520Receptor%2520Antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D981%26epage%3D986%26doi%3D10.1021%2Facsmedchemlett.7b00315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Potential of CCR4 Antagonists</span>. <i>Progress in Respiratory Research</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1159/000320815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1159%2F000320815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=161-165&author=D.+Hallauthor=A.+Fordauthor=S.+Hodgson&title=Therapeutic+Potential+of+CCR4+Antagonists&doi=10.1159%2F000320815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of CCR4 antagonists</span></div><div class="casAuthors">Hall, David; Ford, Alison; Hodgson, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Respiratory Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-165</span>CODEN:
                <span class="NLM_cas:coden">PRRRAE</span>;
        ISSN:<span class="NLM_cas:issn">1422-2140</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  CCR4 is a CC-chemokine receptor which is expressed on a no. of T-cell subsets.  Inhibition of this receptor is of potential interest as a target in allergic diseases due to its selective expression on Th2 but not Th1 cells and hence the potential to selectively inhibit the recruitment of Th2 cells to sites of allergic inflammation while leaving other immune responses unaffected.  CCR4 is also expressed on regulatory T cells and this has led to the hypothesis that CCR4 blockade or a CCR4-directed cytotoxic antibody may be effective in treating certain cancers.  In this article we review the clin. and preclin. literature around the role of CCR4 in allergic disease and briefly discuss the progress which has been made in identifying selective small-mol. antagonists at CCR4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwDW_qnPwIcbVg90H21EOLACvtfcHk0lgrSAJLyaZ-sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVKiug%253D%253D&md5=a96417abce82e8be411705dcf37a7ac9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1159%2F000320815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000320815%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DD.%26aulast%3DFord%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%26atitle%3DTherapeutic%2520Potential%2520of%2520CCR4%2520Antagonists%26jtitle%3DProgress%2520in%2520Respiratory%2520Research%26date%3D2010%26volume%3D39%26spage%3D161%26epage%3D165%26doi%3D10.1159%2F000320815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horuk, R.</span></span> <span> </span><span class="NLM_article-title">Recent Progress in the Development of Antagonists to the Chemokine Receptors CCR3 and CCR4</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1517/17460441.2014.897324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1517%2F17460441.2014.897324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=24641500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFClt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=467-483&author=J.+E.+Peaseauthor=R.+Horuk&title=Recent+Progress+in+the+Development+of+Antagonists+to+the+Chemokine+Receptors+CCR3+and+CCR4&doi=10.1517%2F17460441.2014.897324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4</span></div><div class="casAuthors">Pease, James Edward; Horuk, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">467-483</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The chemokine receptors CCR3 and CCR4 have been shown to be important therapeutic targets for the treatment of a variety of diseases.  Although only two chemokine receptor inhibitors have been approved so far, there are numerous compds. that are in various stages of development.  Areas covered: In this review article, the authors provide an update on the progress made in the identification of antagonists against the chemokine receptors CCR3 and CCR4 from 2009 to the present.  The rationale of writing this review article is to cover the most important approaches to identifying antagonists to these two receptors, which could prove to be useful therapeutics in treating proinflammatory diseases.  Expert opinion: Pharmaceutical companies have expended a considerable amt. of money and effort to identify potent inhibitors of CCR3 and CCR4 for the treatment of asthma and atopic diseases.  Although a variety of compds. have been described and several have progressed into the clinic, none have so far made it as approved drugs.  There are, however, novel approaches such as mogamulizumab, a monoclonal antibody to CCR4 currently is in clin. trials for cancer and ASM8, an antisense nucleotide to CCR3, which is in Phase II clin. trials for asthma that might still prove to be successful new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXmZrBcC5PbLVg90H21EOLACvtfcHk0lgrSAJLyaZ-sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFClt7o%253D&md5=d77cb820f88320311ed1c09f15f7a800</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.897324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.897324%26sid%3Dliteratum%253Aachs%26aulast%3DPease%26aufirst%3DJ.%2BE.%26aulast%3DHoruk%26aufirst%3DR.%26atitle%3DRecent%2520Progress%2520in%2520the%2520Development%2520of%2520Antagonists%2520to%2520the%2520Chemokine%2520Receptors%2520CCR3%2520and%2520CCR4%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D467%26epage%3D483%26doi%3D10.1517%2F17460441.2014.897324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerahee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Marle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, R.</span></span> <span> </span><span class="NLM_article-title">Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2239633, a CC-Chemokine Receptor 4 Antagonist, in Healthy Male Subjects: Results from an Open-Label and from a Randomised Study</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">14</span>, <span class="refDoi"> DOI: 10.1186/2050-6511-14-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1186%2F2050-6511-14-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=23448278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=14&author=A.+Cahnauthor=S.+Hodgsonauthor=R.+Wilsonauthor=J.+Robertsonauthor=J.+Watsonauthor=M.+Beeraheeauthor=S.+C.+Hughesauthor=G.+Youngauthor=R.+Gravesauthor=D.+Hallauthor=S.+van+Marleauthor=R.+Solari&title=Safety%2C+Tolerability%2C+Pharmacokinetics+and+Pharmacodynamics+of+GSK2239633%2C+a+CC-Chemokine+Receptor+4+Antagonist%2C+in+Healthy+Male+Subjects%3A+Results+from+an+Open-Label+and+from+a+Randomised+Study&doi=10.1186%2F2050-6511-14-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study</span></div><div class="casAuthors">Cahn, Anthony; Hodgson, Simon; Wilson, Robert; Robertson, Jonathan; Watson, Joanna; Beerahee, Misba; Hughes, Steve C.; Young, Graeme; Graves, Rebecca; Hall, David; van Marle, Sjoerd; Solari, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The CC-chemokine receptor 4 (CCR4) is thought potentially to play a crit. role in asthma pathogenesis due to its ability to recruit type 2 T-helper lymphocytes to the inflamed airways.  Therefore, CCR4 provides an excellent target for anti-inflammatory therapy.  Methods: The safety, tolerability, pharmacokinetics and pharmacodynamics of the CCR4 antagonist GSK2239633, N-(3-((3-(5-chlorothiophene-2-sulfonamido)-4-methoxy-1H-indazol-1-yl)methyl)benzyl)-2-hydroxy-2-methylpropanamide, were examd. in healthy males.  Two studies were performed: 1) an open-label, study in which six subjects received a single i.v. infusion of [14C]-GSK2239633 100 μg (10 kBq) (NCT01086462), and 2) a randomised, double-blind, placebo-controlled, cross-over, ascending dose study in which 24 subjects received single oral doses of GSK2239633 150-1500 mg (NCT01371812).  Results: Following i.v. dosing, plasma GSK2239633 displayed rapid, bi-phasic distribution and slow terminal elimination (t1/2:13.5 h), suggesting that GSK2239633 was a low to moderate clearance drug.  Following oral dosing, blood levels of GSK2239633 reached Cmax rapidly (median tmax:1.0-1.5 h).  Estd. GSK2239633 bioavailability was low with a max. value detd. of only 16%.  Food increased GSK2239633 systemic exposure (as assessed by AUC and Cmax).  Increases in AUC and Cmax were less than dose proportional.  Adverse events were reported by three subjects (50%) following i.v. administration, and by 19 subjects (79%) following oral administration; most (46/47; 98%) events were mild/moderate in intensity.  GSK2239633 1500 mg inhibited thymus- and activation-regulated chemokine-induced (TARC) actin polymn. reaching a mean CCR4 occupancy of 74%.  Conclusion: In conclusion, GSK2239633 was well-tolerated and capable of inhibiting TARC from activating the CCR4 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRGQ7kxHbu_LVg90H21EOLACvtfcHk0lgrSAJLyaZ-sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWisro%253D&md5=c087afba982a7a6ad0f14bee7f8bafb9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2F2050-6511-14-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2050-6511-14-14%26sid%3Dliteratum%253Aachs%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DJ.%26aulast%3DBeerahee%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DS.%2BC.%26aulast%3DYoung%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DR.%26aulast%3DHall%26aufirst%3DD.%26aulast%3Dvan%2BMarle%26aufirst%3DS.%26aulast%3DSolari%26aufirst%3DR.%26atitle%3DSafety%252C%2520Tolerability%252C%2520Pharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520GSK2239633%252C%2520a%2520CC-Chemokine%2520Receptor%25204%2520Antagonist%252C%2520in%2520Healthy%2520Male%2520Subjects%253A%2520Results%2520from%2520an%2520Open-Label%2520and%2520from%2520a%2520Randomised%2520Study%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D14%26spage%3D14%26doi%3D10.1186%2F2050-6511-14-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Immuno-Oncology Therapeutic Agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.12.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1016%2Fj.bmcl.2017.12.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=29326017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlKltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=319-329&author=P.+L.+Toogood&title=Small+Molecule+Immuno-Oncology+Therapeutic+Agents&doi=10.1016%2Fj.bmcl.2017.12.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule immuno-oncology therapeutic agents</span></div><div class="casAuthors">Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Treatment of cancer by activation of an antitumor immune response is now a widely practiced and well-accepted approach to therapy.  However, despite dramatic responses in some patients, the high proportion of unresponsive patients points to a considerable unmet medical need.  Although antibody therapies have led the way, small mol. immuno-oncol. agents are close behind.  This perspective provides an overview of some of the many small mol. approaches being explored.  It encompasses small mol. modulators of validated targets such as programed cell death 1 (PD-1) as well as novel approaches still to be proven clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqabNsLZRrBPbVg90H21EOLACvtfcHk0ljx-Z1lPTfglw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlKltQ%253D%253D&md5=2457f116552bf50e7134fea28d914524</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.12.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.12.044%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DSmall%2520Molecule%2520Immuno-Oncology%2520Therapeutic%2520Agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D319%26epage%3D329%26doi%3D10.1016%2Fj.bmcl.2017.12.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span> </span><span class="NLM_article-title">FDA Approves Treatment for Two Rare Types of non-Hodgkin
Lymphoma</span>. <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm</a> (accessed April 4, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+Treatment+for+Two+Rare+Types+of+non-Hodgkin%0ALymphoma.+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm616176.htm+%28accessed+April+4%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520Treatment%2520for%2520Two%2520Rare%2520Types%2520of%2520non-Hodgkin%250ALymphoma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">Stevens–Johnson Syndrome Associated with Mogamulizumab Treatment of Adult T-Cell Leukemia/Lymphoma</span>. <i>Cancer Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1111/cas.12116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1111%2Fcas.12116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=23360455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVCjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=647-650&author=T.+Ishidaauthor=A.+Itoauthor=F.+Satoauthor=S.+Kusumotoauthor=S.+Iidaauthor=H.+Inagakiauthor=A.+Moritaauthor=S.+Akinagaauthor=R.+Ueda&title=Stevens%E2%80%93Johnson+Syndrome+Associated+with+Mogamulizumab+Treatment+of+Adult+T-Cell+Leukemia%2FLymphoma&doi=10.1111%2Fcas.12116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma</span></div><div class="casAuthors">Ishida, Takashi; Ito, Asahi; Sato, Fumihiko; Kusumoto, Shigeru; Iida, Shinsuke; Inagaki, Hiroshi; Morita, Akimichi; Akinaga, Shiro; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">647-650</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We report an adult T-cell leukemia/lymphoma patient suffering from Stevens-Johnson Syndrome (SJS) during mogamulizumab (humanized anti-CCR4 monoclonal antibody) treatment.  There was a durable significant redn. of the CD4+CD25highFOXP3+ regulatory T (Treg) cell subset in the patient's PBMC, and the affected inflamed skin almost completely lacked FOXP3-pos. cells.  This implies an assocn. between redn. of the Treg subset by mogamulizimab and occurrence of SJS.  The present case should contribute not only to our understanding of human pathol. resulting from therapeutic depletion of Treg cells, but also alert us to the possibility of immune-related severe adverse events such as SJS when using mogamulizumab.  We are currently conducting a clin. trial of mogamulizumab for CCR4-neg. solid cancers (UMIN000010050), specifically aiming to deplete Treg cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKZ1pzzErzKbVg90H21EOLACvtfcHk0ljx-Z1lPTfglw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVCjsrs%253D&md5=e2050c18ed4be88401547ddede792606</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fcas.12116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12116%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DF.%26aulast%3DKusumoto%26aufirst%3DS.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DInagaki%26aufirst%3DH.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DStevens%25E2%2580%2593Johnson%2520Syndrome%2520Associated%2520with%2520Mogamulizumab%2520Treatment%2520of%2520Adult%2520T-Cell%2520Leukemia%252FLymphoma%26jtitle%3DCancer%2520Science%26date%3D2013%26volume%3D104%26spage%3D647%26epage%3D650%26doi%3D10.1111%2Fcas.12116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saulite, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoetzenecker, W.</span></span> <span> </span><span class="NLM_article-title">Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab</span>. <i>Current Problems in Dermatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1159/000478079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1159%2F000478079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=29131039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A280%3ADC%252BC1M3gsFCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=70-81&author=I.+Sauliteauthor=E.+Guenovaauthor=W.+Hoetzenecker&title=Adverse+Reactions+of+Antibody-Therapy+for+Primary+Cutaneous+Lymphomas%3A+Rituximab%2C+Brentuximab+Vedotin%2C+Alemtuzumab%2C+and+Mogamulizumab&doi=10.1159%2F000478079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab</span></div><div class="casAuthors">Saulite I; Guenova E; Hoetzenecker W</div><div class="citationInfo"><span class="NLM_cas:title">Current problems in dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of advanced PCLs is limited and rarely reaches complete remission despite aggressive treatment modalities, such as polychemotherapy with various adverse effects.  However, several monoclonal antibodies drug agents in patients with advanced primary cutaneous lymphomas demonstrate promising efficacy and manageable safety profiles.  The monoclonal antibodies drug agents have favourable tolerability compared with multi-agent cytotoxic chemotherapy.  However, adverse effects manifest with a broad clinical spectrum, hence the markers of targeted therapies are not limited to tumour cells but found on tumour cells and also on benign T and/or B cells.  Moreover, the safety profile and direct causal association of drug and adverse effects should be interpreted with caution because many of the patients in clinical studies have received multiple treatments.  Here, we focus on the safety profile of mAbs therapies that have recently been approved or are currently under preclinical or clinical investigation for CBCLs (rituximab) and CTCLs (brentuximab, mogamulizumab, and alemtuzumab).  Further studies to define clinical safety profile in the patient cohort with cutaneous lymphomas are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7GsfUuEYOZDToTC3aBaesfW6udTcc2eYvMCkZ5XmDXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3gsFCrtg%253D%253D&md5=7dca3c477b4b4b32af104d8c97727f49</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1159%2F000478079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000478079%26sid%3Dliteratum%253Aachs%26aulast%3DSaulite%26aufirst%3DI.%26aulast%3DGuenova%26aufirst%3DE.%26aulast%3DHoetzenecker%26aufirst%3DW.%26atitle%3DAdverse%2520Reactions%2520of%2520Antibody-Therapy%2520for%2520Primary%2520Cutaneous%2520Lymphomas%253A%2520Rituximab%252C%2520Brentuximab%2520Vedotin%252C%2520Alemtuzumab%252C%2520and%2520Mogamulizumab%26jtitle%3DCurrent%2520Problems%2520in%2520Dermatology%26date%3D2018%26volume%3D53%26spage%3D70%26epage%3D81%26doi%3D10.1159%2F000478079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, L.</span>; <span class="NLM_string-name">Marubayashi, S.</span>; <span class="NLM_string-name">Jorapur, A.</span>; <span class="NLM_string-name">Jacobsen, S.</span>; <span class="NLM_string-name">Zibinsky, M.</span>; <span class="NLM_string-name">Robles, O.</span>; <span class="NLM_string-name">Hu, D.</span>; <span class="NLM_string-name">Jackson, J.</span>; <span class="NLM_string-name">Pookat, D.</span>; <span class="NLM_string-name">Sanchez, J.</span>; <span class="NLM_string-name">Brovarney, M.</span>; <span class="NLM_string-name">Wadsworth, A.</span>; <span class="NLM_string-name">Chian, D.</span>; <span class="NLM_string-name">Wustrow, D.</span>; <span class="NLM_string-name">Kassner, P.</span>; <span class="NLM_string-name">Cutler, G.</span>; <span class="NLM_string-name">Wong, B.</span>; <span class="NLM_string-name">Brockstedt, D.</span>; <span class="NLM_string-name">Talay, O.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Marshall%2C+L.%3B+Marubayashi%2C+S.%3B+Jorapur%2C+A.%3B+Jacobsen%2C+S.%3B+Zibinsky%2C+M.%3B+Robles%2C+O.%3B+Hu%2C+D.%3B+Jackson%2C+J.%3B+Pookat%2C+D.%3B+Sanchez%2C+J.%3B+Brovarney%2C+M.%3B+Wadsworth%2C+A.%3B+Chian%2C+D.%3B+Wustrow%2C+D.%3B+Kassner%2C+P.%3B+Cutler%2C+G.%3B+Wong%2C+B.%3B+Brockstedt%2C+D.%3B+Talay%2C+O.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DL." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadhe, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.-H.</span></span> <span> </span><span class="NLM_article-title">Insights Into the Binding Modes of CC Chemokine Receptor 4 (CCR4) Inhibitors: A Combined Approach Involving Homology Modelling, Docking, and Molecular Dynamics Simulation Studies</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1039/C4MB00568F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1039%2FC4MB00568F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=25474265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2gsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=618-634&author=C.+G.+Gadheauthor=M.-H.+Kim&title=Insights+Into+the+Binding+Modes+of+CC+Chemokine+Receptor+4+%28CCR4%29+Inhibitors%3A+A+Combined+Approach+Involving+Homology+Modelling%2C+Docking%2C+and+Molecular+Dynamics+Simulation+Studies&doi=10.1039%2FC4MB00568F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the binding modes of CC chemokine receptor 4 (CCR4) inhibitors: a combined approach involving homology modelling, docking, and molecular dynamics simulation studies</span></div><div class="casAuthors">Gadhe, Changdev G.; Kim, Mi-hyun</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">618-634</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-2051</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">CC chemokine receptor 4 (CCR4), a G protein-coupled receptor (GPCR), plays a vital role in the progression of asthma, T-cell lymphoma, inflammation, and Alzheimer's disease.  To date, the structure of CCR4 has not been detd.  Therefore, the nature of the interactions between inhibitors and CCR4 is not well known.  In this study, we used CCR5 as a template to model the structure of CCR4.  Docking studies were performed for four naphthalene-sulfonamide derivs. and crucial ligand-protein interactions were analyzed.  Mol. dynamics (MD) simulations of these complexes (100 ns each) were carried out to gain insights into the interactions between ligands and CCR4.  MD simulations revealed that the residues identified by the docking were displaced and new residues were inserted near the ligands.  Results of a principal component anal. (PCA) suggested that CCR4 unfolds at the extracellular site surrounding the ligands.  Our simulations identified crucial residues involved in CCR4 antagonism, which were supported by previous mutational studies.  Addnl., we identified Ser3.29, Leu3.33, Ser5.39, Phe6.47, Ile7.35, Thr7.38, Thr7.40, and Ala7.42 as residues that play crucial roles in CCR4 antagonism.  Mutational studies will help elucidate the significance of these residues in CCR4 antagonism.  An understanding of ligand-CCR4 interactions might aid in the design of novel CCR4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRMUcXVRcYzrVg90H21EOLACvtfcHk0lhS01Oveyw2rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2gsLbN&md5=bdcbc124d76dd7e2b5c12deef983efef</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1039%2FC4MB00568F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MB00568F%26sid%3Dliteratum%253Aachs%26aulast%3DGadhe%26aufirst%3DC.%2BG.%26aulast%3DKim%26aufirst%3DM.-H.%26atitle%3DInsights%2520Into%2520the%2520Binding%2520Modes%2520of%2520CC%2520Chemokine%2520Receptor%25204%2520%2528CCR4%2529%2520Inhibitors%253A%2520A%2520Combined%2520Approach%2520Involving%2520Homology%2520Modelling%252C%2520Docking%252C%2520and%2520Molecular%2520Dynamics%2520Simulation%2520Studies%26jtitle%3DMol.%2520BioSyst.%26date%3D2015%26volume%3D11%26spage%3D618%26epage%3D634%26doi%3D10.1039%2FC4MB00568F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fantini, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominitzki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neurath, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span> <span> </span><span class="NLM_article-title">In Vitro Generation of CD4+CD25+ Regulatory Cells From Murin Naive T Cells</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1794</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.1038%2Fnprot.2007.258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=17641646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahur7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1789-1794&author=M.+C.+Fantiniauthor=S.+Dominitzkiauthor=A.+Rizzoauthor=M.+F.+Neurathauthor=C.+Becker&title=In+Vitro+Generation+of+CD4%2BCD25%2B+Regulatory+Cells+From+Murin+Naive+T+Cells&doi=10.1038%2Fnprot.2007.258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro generation of CD4+CD25+ regulatory cells from murine naive T cells</span></div><div class="casAuthors">Fantini, Massimo C.; Dominitzki, Sabine; Rizzo, Angelo; Neurath, Markus F.; Becker, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1789-1794</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">CD4+CD25+ regulatory T cells (Tregs) are crucial for the maintenance of immunol. tolerance.  Recent data indicate that Tregs not only develop in the thymus during ontogeny but can also differentiate from naive T cells in the periphery.  The following protocol describes a method by which Tregs are generated in vitro by stimulation of naive T cells in the presence of transforming growth factor β (Ti-Tregs).  In vitro-induced regulatory T cells express markers of conventional Treg such as CD25 and the genetic program committing transcription factor FoxP3.  Functionally the in vitro-generated Ti-Tregs suppress T-cell activation and proliferation while in vivo these cells have been proven to control inflammation in different animal models, suggesting a potential use of these cells for immunotherapy.  The protocol can be completed within 5 days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3F3KjV9Klt7Vg90H21EOLACvtfcHk0lhS01Oveyw2rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahur7F&md5=98e484cedf0f4ee16dddf269040c2550</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.258%26sid%3Dliteratum%253Aachs%26aulast%3DFantini%26aufirst%3DM.%2BC.%26aulast%3DDominitzki%26aufirst%3DS.%26aulast%3DRizzo%26aufirst%3DA.%26aulast%3DNeurath%26aufirst%3DM.%2BF.%26aulast%3DBecker%26aufirst%3DC.%26atitle%3DIn%2520Vitro%2520Generation%2520of%2520CD4%252BCD25%252B%2520Regulatory%2520Cells%2520From%2520Murin%2520Naive%2520T%2520Cells%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D1789%26epage%3D1794%26doi%3D10.1038%2Fnprot.2007.258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. B.</span></span> <span> </span><span class="NLM_article-title">Generation and Function of Induced Regulatory T Cells</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2013.00152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=10.3389%2Ffimmu.2013.00152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=23355837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eisLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1-13&author=E.+G.+Schmittauthor=C.+B.+Williams&title=Generation+and+Function+of+Induced+Regulatory+T+Cells&doi=10.3389%2Ffimmu.2013.00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Generation and function of induced regulatoryT cells</span></div><div class="casAuthors">Schmitt, Erica G.; Williams, Calvin B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">CD4+ CD25+ Foxp3+ regulatory T (Treg) cells are essential to the balance between proand anti-inflammatory responses.There are two major subsets ofTreg cells, "natural" Treg (nTreg) cells that develop in the thymus, and "induced" Treg (iTreg) cells that arise in the periphery from CD4+ Foxp3- conventional T cells and can be generated in vitro.  Previous work has established that both subsets are required for immunol. tolerance.  Addnl., in vitro-derived iTreg cells can reestablish tolerance in situations where Treg cells are decreased or defective.  This review will focus on iTreg cells, drawing comparisons to nTreg cells when possible.We discuss the mol. mechanisms of iTreg cell induction, both in vivo and in vitro, reviewthe Foxp3-dependent and -independent transcriptional landscape of iTreg cells, and examine the proposed suppressive mechanisms utilized by each Treg cell subset.  We also compare the T cell receptor repertoire of the Treg cell subsets, discuss inflammatory conditions where iTreg cells are generated or have been used for treatment, and address the issue of iTreg cell stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYYLe4jXKCMLVg90H21EOLACvtfcHk0lhS01Oveyw2rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eisLrJ&md5=ad1cc139b8da8608b7cf6bd413cace1a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2013.00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2013.00152%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DE.%2BG.%26aulast%3DWilliams%26aufirst%3DC.%2BB.%26atitle%3DGeneration%2520and%2520Function%2520of%2520Induced%2520Regulatory%2520T%2520Cells%26jtitle%3DFront.%2520Immunol.%26date%3D2013%26volume%3D4%26spage%3D1%26epage%3D13%26doi%3D10.3389%2Ffimmu.2013.00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="note"><p class="first last">Compound <b>38</b> is referred to as <b>CCR4–351</b> in ref <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i140"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00988">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_05370"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00988?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00988</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Assay conditions; hepatocyte stability assay; <i>in vitro</i> CYP450 assay; <i>in vivo</i> pharmacology studies, X-ray structure of the synthetic intermediate of <b>38</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_002.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_001.pdf">jm0c00988_si_001.pdf (699.81 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00988/suppl_file/jm0c00988_si_002.xlsx">jm0c00988_si_002.xlsx (17.84 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00988&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00988%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00988" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799ca34ab153d30","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
